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ABSTRACT
In addition to its canonical role in aminoacylation, threonyl-tRNA synthetase
(TARS) possesses pro-angiogenic activity that is susceptible to the TARS-specific
antibiotic borrelidin. However, the therapeutic benefit of borrelidin is offset by its strong
toxicity to living cells. The removal of a single methylene group from the parent
borrelidin generates BC194, a modified compound with significantly reduced toxicity but
comparable anti-angiogenic potential. Biochemical analyses revealed that the difference
in toxicities was due to borrelidin’s stimulation of amino acid starvation at ten-fold lower
concentrations than BC194. However, both compounds were found to inhibit in vitro and
in vivo models of angiogenesis at sub-toxic concentrations, suggesting a similar
mechanism that is distinct from the toxic responses. Crystal structures of TARS in
complex with each compound indicated that the decreased contacts in the BC194
structure may render it more susceptible to competition with the canonical substrates and
permit sufficient aminoacylation activity over a wider concentration of inhibitor.
Conversely, both borrelidin and BC194 induce identical conformational changes in
TARS, providing a rationale for their comparable effects on angiogenesis. The
mechanisms of TARS and borrelidin-based compounds on angiogenesis were
subsequently tested using zebrafish and cell-based models. These data revealed ectopic
branching, non-functional vessels, and increased cell-cell contracts following BC194treatment or knockdown of TARS expression, suggesting a role for the enzyme in the
maturation and guidance of nascent vasculature. Using various TARS constructs this
function was found to be dependent on two interactions or activities associated with the
TARS enzyme that are distinct from its canonical aminoacylation activity. Furthermore,
observations that TARS may influence VEGF expression and purinergic signaling
suggest the possibility for a receptor-mediated response. Taken together, the results
presented here demonstrate a clear role for TARS in angiogenesis, independent of its
primary function in translation. Although the exact molecular mechanisms through which
TARS and borrelidin regulate this activity remain to be determined, these data provide a
foundation for future investigations of TARS’s function in vascular biology and its use as
a target for angiogenesis-based therapy.
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CHAPTER 1: INTRODUCTION

1.1 Functions of Aminoacyl-tRNA Synthetases
1.1.1 Aminoacyl-tRNA synthetases translate the genetic code
The aminoacyl-tRNA synthetases (ARSs) are a family of enzymes responsible for
the covalent attachment of amino acids to their corresponding tRNA through a process
known as aminoacylation. They were first discovered in 1954 by their activation of
amino acids with AMP and subsequently found to transfer the amino acid to its
corresponding tRNA molecule (1,2). ARSs are thought to be among the first proteins to
evolve and their ubiquitous distribution throughout all cellular life can be ascribed to
their critical roles in translation (3,4). In order to ensure translational fidelity each amino
acid is associated with a specific ARS. These enzymes are highly discriminatory of the
amino acids and tRNA molecules used as substrates. Despite their profound structural
differences, all ARS catalyze the core aminoacylation reaction through a two-step
mechanism described below:

1) AA + ATP  AA~AMP + PPi
2) AA-AMP + tRNAAA  AA-tRNAAA + AMP

The first step, or adenylation, activates the amino acid (AA) through condensation
with ATP to form an enzyme-bound adenylate intermediate (AA-AMP) along with the
release of inorganic pyrophosphate (PPi). Subsequently, the activated amino acid is

1

transferred to the 2’- or 3’-hydroxyl of the terminal adenosine on the acceptor arm of the
tRNA molecule, releasing charged-tRNA and AMP as products.
The ARSs can be subdivided into two, evolutionarily distinct classes, referred to
as Class I or Class II, each containing about half the available species. In general, the
ARS for each AA/tRNA pairing fall into one of the two categories, with the notable
exception of lysyl-tRNA synthetase (KARS) which has varieties associated with either
class. These classifications were originally categorized on the basis of conserved
sequence and tertiary structure motifs but have expanded to include substrate binding and
quaternary structure as well. Class I ARSs are mostly monomeric and characterized by a
Rossman dinucleotide binding domain and consensus HIGH and KMSKS sequences.
Conversely, Class II ARSs are multimeric, ususually homodimers, and defined by a
conserved fold of antiparallel β-strands and three complex sequence motifs. These
structural differences also contribute to varying biochemical properties between the two
classes. The Rossman fold of Class I enzymes binds ATP in an extended conformation in
contrast to the bent conformation adopted in Class II. Additionally, amino acids are
transferred to the 2’-hydroxyl of terminal adenosine moiety in tRNA in Class I ARS
while Class II varieties transfer to the 3’-hydroxyl group (with the exception of the Class
II phenylalanyl-tRNA synthetase (FARS) which also uses the 2’-hydroxyl) (5,6).

1.1.2 Maintenance of aminoacylation fidelity
High fidelity translation is an essential component for life as misincorporation of
amino acids can be detrimental to cell survival. Consequently, errors in translation are
rare under normal circumstances, occurring at a rate of 1 for every 103 or 104 translated
2

codons (7,8). A major contributing factor to this fidelity is ARS substrate specificity for
both amino acids and cognate tRNA. Discrimination between tRNA molecules is
achieved through mutually exclusive interactions with specific tRNA bases, referred to as
identity elements, and the respective ARS (reviewed in (9)). Errors in tRNA specificity
are quite rare under normal circumstances, with some reports suggesting a 1 in 107
misidentification events, and likely represent a minor factor in overall translation error
rate (10). Conversely, specific binding of the much smaller amino acid provides a greater
challenge.
Using structurally or chemically restrictive active sites most ARSs are able to
distinguish their target amino acid from the majority of others within the cell. However,
the close physiochemical properties of certain amino acids makes it nearly impossible for
complete discrimination without further processing. In example, several pairs of amino
acids differ only by a single methyl group, such as threonine and serine, valine and
isoleucine, or alanine and glycine. The smaller molecule of each of these pairs should be
able to fit into the binding pocket available to the other with only a modest reduction of
binding affinity. Specifically, the loss of hydrophobic interactions from a methyl group is
estimated to decrease binding affinity by 14.2 kJ/mol on average, which would reduce
discrimination, at best, to 1 in 200 (11). Therefore, to obtain the discrimination actually
observed for ARSs, secondary editing functions would have to evolve to reduce the
misincorporation of false cognate amino acids.
Editing by ARSs is often described through the use of the classical “doublesieve” model proposed by Fersht and Dingwall in 1979 (12). In this mechanism, the
active site of the ARS functions as the “course-sieve” by permitting the binding and
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catalysis of the cognate and near-cognate amino acids but precluding interactions with
most others through steric or incompatible chemical contributions (such as the steric
occlusion of leucine observed with isoleucyl-tRNA synthetase (IARS) (13)). The
subsequent and specific hydrolysis of false cognate products or intermediates relative to
the intended amino acid then constitutes the “fine-sieve”. These “fine-sieve” processes
can be further divided into one of two categories, termed pre-transfer or post-transfer
editing, based on when the editing event occurs in the reaction scheme. While some
ARSs show a preference for one of these methods, others will switch between the two
under certain conditions, indicating the possibility of redundant fidelity mechanisms (1416). In pre-transfer editing aminoacyl-adenylates generated from reactions with false
cognates are hydrolyzed prior to transfer onto awaiting tRNA molecules as is
demonstrated in the editing of homocysteine by methionyl-tRNA synthetase (MARS)
(17). Cleavage of the adenylate intermediate in these situations appears to be kinetically
driven and occurs under conditions of reduced aminoacylation activity (14,16).
In contrast, post-transfer editing involves the cleavage of false cognates from
tRNA subsequent to the aminoacyl-transfer reaction. Unlike pre-transfer editing, this
reaction occurs within an active site separate from the one involved in aminoacylation. In
Class I ARSs this site is composed of a conserved CP-1 domain associated with the
invariant Rossman fold (6). In contrast, Class II ARSs do not share a common editing
domain structure (18-20). Following aminoacylation, the charged-tRNAs are immediately
transferred to a second active site dedicated to editing. Transfer RNA charged with the
cognate amino acid lack the physiochemical properties required for binding to this site
and are subsequently released. False cognates, however, are readily admissible and
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cleaved, generating uncharged-tRNA and free amino acid. Features that facilitate this
discrimination can utilize the false cognates’ chemical properties, like the Zn2+ atom in
alanyl-tRNA synthetase (AARS) which coordinates serine’s hydroxyl group, or size, as
demonstrated by steric occlusion of isoleucine but not valine, by IARS’s editing site
(13,21).
The importance of these editing activities is emphasized by the detrimental effects
associated with their loss or dysfunction. In cell culture, the increased burden of
mistranslation can lead to the activation of cellular stress responses and apoptosis (22).
Conversely, the effects in whole organisms are more complicated. Editing disrupting
mutations in AARS have been associated with the accumulation of misfolded proteins in
mice, which leads to the loss of Purkinje cells (23). In contrast, while mutations in human
ARSs have been associated with diseases, none have been specifically linked to editing
domain mutations. In example, the peripheral neuropathy Charcot Marie Tooth syndrome
has been associated with mutations in several ARSs. However, these mutations seem to
be unrelated to the aminoacylation and editing functions of the proteins (24). Instead
these effects appear to be related to yet unknown noncanonical functions of these ARSs.
Interestingly, the field of ARS secondary functions has expanded rapidly in recent times
and have been associated with a variety of different processes, one of which serves as the
basis for this work.

1.2 Aminoacyl-tRNA synthetases as regulators of angiogenesis
In addition to their canonical functions in aminoacylation, a growing body of
evidence has identified several secondary activities associated with ARSs. Among the
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earlier reported non-translational functions were effects on RNA splicing. Mitochondrial
varieties of tyrosyl-tRNA synthetase (YARS) and leucyl-tRNA synthetase (LARS)
possess splice factor-like activities and assist in the excision of group I introns (25,26).
Transcriptional and translational regulatory properties have also been identified in ARSs
through association with transcription factors or the binding of tRNA-like structures
within mRNA promoter regions (27,28). Furthermore, ARSs in higher-order eukaryotes
have evolved roles in both internal and external cellular signaling responses, including
apoptosis and inflammation (29,30).

1.2.1 Aminoacyl-tRNA synthetases as nutrient sensors
As catalysts for the aminoacylation reaction, ARS are sensitive to intracellular
concentrations of amino acids and ATP. This feature opens opportunities for ARSs to be
used as nutritional and energy sensors within the cell. One of the best examples of this
concept was observed in recent investigations of LARS, in which the synthetase
regulated the activities of the mammalian target of rapamycin (mTOR) signaling
pathway. The mTOR pathway serves to transduce a variety of internal and external
signaling events into the regulation of translation, cell growth, metabolism and autophagy
(reviewed in (31)). Notably, mTOR is required for the initiation of translation in
eukaryotic cells by phosphorylating 4E-BP1 and preventing its inhibition of eIF-4E’s
interaction with the 5’- cap of mRNA (32). These responses are primarily mediated by
two multi-protein complexes termed mTOR complexes 1 (mTORC1) and 2 (mTORC2).
Of particular interest, the functions of mTORC1 are highly responsive to cellular nutrient
levels, specifically amino acids. High concentrations of amino acids facilitate the
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association of the complex to the lysosomal membrane through activation of the Rag
family GTPases (33,34). This translocation permits mTORC1 to interact with its primary
activator, Rheb, which is attached to the lysosome membrane, thereby initiating
downstream signaling events (35). Interestingly, mTORC1 activation is particularly
sensitive to the essential amino acid leucine (36). Subsequent investigations revealed that
the mechanism through which leucine regulates mTORC1 was dependent on LARS
(37,38). When leucine is plentiful, LARS activates the GTPase activity of the mTOR
regulating protein RagD. Activated RagD joins with the mTORC1 and stimulates its
relocation to the lysosomal membrane. Conversely, leucine depletion deactivates mTOR,
which arrests translation and restores amino acid homeostasis through the degradation of
cellular proteins.
In addition to their roles as protein building blocks some amino acids are required
as precursors in other biosynthetic pathways. In particular, glutamine is an important
component in nitrogen metabolism and a major source of malic acid used in NADPH
synthesis (39,40). Likely owing to its intimate role in basic metabolic pathways, high
levels of glutamine contributes to anti-apoptotic signaling in cells (30,41,42). One of
these mechanisms involves the glutamine-dependent association of glutaminyl-tRNA
synthetase (QARS) and the apoptosis signal-regulating kinase 1 (ASK-1). ASK-1 is
activated in response to FAS-ligand signaling and oxidative stress, which eventually
leads to apoptosis through the c-jun N-terminal kinase (JNK) associated pathways
(43,44). High levels of glutamine, however, can attenuate this effect by encouraging the
binding of QARS to ASK1 and inhibiting its pro-apoptotic signaling. Interestingly, this
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QARS-ASK1 interaction requires the binding of glutamine to the QARS active site and
emphasizes the role of the ARS as a nutrient sensor (30).
Similar to LARS and QARS, tryptophanyl-tRNA synthetase (WARS) also
possesses non-canonical signaling functions sensitive to the levels of its cognate amino
acid. This effect is dependent on the conformation of an N-terminal WHEP domain.
These helix-turn-helix domains are exclusive to ARSs and are named for tryptophanyl
(W), histidyl (H), and glutamlyl-prolyl (EP) ARSs in which they are found. When the
active site of WARS is occupied by its canonical substrates, the WHEP domain closes
over it like a cap. However, when this active site is unoccupied (apo-WARS), this
domain is unstructured and remains available for mediating protein-protein interactions.
Since WARS is a functional homo-dimer this allows for two separate WHEP interactions.
Specifically, the exposed WHEP domains of apo-WARS dimers form the central
component of a complex with the poly-(ADP-ribose) polymerase 1 (PARP1) and DNAdependent protein kinases (DNA-PKcs) following stimulation by interferon γ (IFNγ).
Formation of this complex encourages the poly-ADP ribosylation of DNA-PKcs and
activates its kinase activity against p53. As such, WARS appears to possess a function in
the regulation of p53 activity (45). Previously, IFNγ has been shown to activate p53dependent pathways involved in cellular senescence and apoptosis, suggesting that
WARS’s association with p53 may also be another nutritional stress response (46,47).
However, the full extent of this signaling remains to be determined.
In addition to activating responses related to senescence and apoptosis, amino
acid concentrations can be linked to other signaling events as well. For all ARSs, the
deprivation of amino acids can activate the general control nonderepressible 2 (GCN2)
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amino acid starvation and ER-stress pathways through the accumulation of uncharged
tRNA molecules (a pathway that will be discussed in Chapter 3 at greater detail) (48). Of
particular interest is the dysregulation of mTOR signaling or induction of ER-stress by
nutrient deprivation that has been observed to influence the expression of vascular
endothelial growth factor A (VEGFA, originally vascular permeability factor) through
the regulation of the hypoxia-inducible factor α (HIFα) transcription factor (see Appendix
I for more details on HIFα signaling) (49,50). Since VEGFA is a key signaling molecule
in the regulation of angiogenesis (see below), these observations provide an indirect
mechanism for ARS-regulation of angiogenesis. More relevant to this dissertation,
however, is the observation of direct angiogenic regulation by specific ARSs.

1.2.2 Basics of angiogenic signaling pathways
Angiogenesis, or the growth of new blood vessels from preexisting ones, is a
multifaceted process governed by the balance of pro-angiogenic and quiescent signals.
The factors mediating these effects consist of various extracellular matrix (ECM)
components, soluble growth factors, cell-cell adhesion proteins, and associated receptors
(reviewed in (51,52)). Under normal conditions vessels maintain a quiescent state
through the release of angiopoetin-1 and other survival signals from mural cells (53).
However, the spatially and temporally regulated expression of other factors can tip the
balance positively or negatively with respect to proliferation, migration, and maturation
of nascent vasculature. Many of these factors, such as fibroblast growth factor (FGF) and
platelet-derived growth factor (PDGF), are functionally redundant and associated with a
variety of biological functions (53). Conversely, VEGFA and its corresponding receptor
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VEGFR2 (also referred to as the kinase insert domain receptor (KDR) or fetal liver
kinase 1 (Flk1)) are indispensable for the process of angiogenesis and are highly specific
to endothelial cell signaling (54). VEGFA is released from tissues in response to hypoxia,
inflammation, or wound healing and activates VEGFR2’s receptor tyrosine kinase
activity in endothelial cells. Consequently, proliferation, migration, and survival are
enhanced by the activation of downstream signaling targets, including ERK1/2, p38MAPK, and AKT (55). While these various kinases may elicit overlapping effects, their
differences allow for the fine tuning of the angiogenesis process by favoring specific
responses, such as migration or proliferation.
To date, angiogenesis-associated activities have been observed in tyrosyl-tRNA
synthetase (YARS), tryptophanyl-tRNA synthetase (WARS), seryl-tRNA synthetase
(SARS), glutamyl-prolyl-tRNA synthetase (EPRS) and one closely associated protein,
aminoacyl-tRNA synthetase interacting multifunctional protein 1 (AIMP1, also known as
p43) (Table 1). Similar to growth factors, YARS, WARS, and AIMP1 function
extracellularly and are thought to be secreted. Once outside the cell, receptor interactions
vary with each ARS and elicit different responses related to inflammation, proliferation,
migration, and cell-cell contacts. Alternatively, SARS and EPRS regulate angiogenesis
intracellularly through interactions with DNA and mRNA associated with the
transcription and translation of VEGF and other angiogenic genes (56,57). While this
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Table 1. Angiogenesis-associated activities of aminoacyl-tRNA synthetases
Aminoacyl-tRNA synthetases (ARSs) are subdivided based on whether they elicit angiogenesisbased responses outside the cell, inside the cell, or are ARS-associated proteins. Effects on
angiogenesis are reported as “Pro” for pro-angiogenic responses (i.e., stimulate new blood vessel
growth), “static” for angiostatic responses (i.e., inhibit new blood vessel growth), and “Anti” for
anti-angiogenic responses (i.e., reduce current number of vessels). Abbreviations used in
Table 1: AIMP1 - Aminoacyl-tRNA synthetase interacting multifunctional protein 1; ARS –
Aminoacyl-tRNA synthetases; EC – Endothelial cell; ELR – Glutamate-leucine-arginine
sequence motif; EMAP II – Endothelial monocyte activating polypeptide II; EPRS –
glutamyl-prolyl-tRNA synthetase; GAIT – Interferon--activated inhibitor of translation; IFN
– Interferon-; MSC – Multi-synthetase complex; NLS – Nuclear localization signal; SARS –
Seryl-tRNA synthetase; WARS – Tryptophanyl-tRNA synthetase; WHEP-domain – a unique
domain named or its association with tryptophanyl-, histidyl-, and glutamyl-prolyl-tRNA
synthetases; YARS – tyrosyl-tRNA synthetase.
ARS or
Associated
Factor

Location of
Angiogenic
Function

YARS

Extracellular

WARS

Extracellular

SARS

Nucleus

EPRS

Cytoplasm

Effect on
Angiogenesis

Associated
Domains

Details

Externally Acting ARS
Secreted and cleaved into N and C
ELR motif, cytokine fragments; N-terminal ELR
Pro
EMAP IIstimulates angiogenesis; C-terminus may
like (58,59) possess EMAP II-like signaling (5860,63)
Secreted and WHEP-domain removed
WHEP
by secretion or alternative splicing; loss
Static
domain
of WHEP-domain allows for
(70)
interactions with E-cadherin (67-70)
Internally Acting ARS
Directed to nucleus by NLS; Binds to
NLS
Static
vegfaa promoter and disrupts cMyc
(56,74,78)
induction of vegfaa mRNA. (56,74,78)
IFNγ stimulates the release of EPRS
Three
from the MSC and its association with
WHEP
Static
the GAIT complex; complex binds to
domains
variety
of mechanisms
mRNA 3' elements
and inhibits
(73)
translation (57,73,81-85)

complicates our understanding of ARS secondary function, it also opens up opportunities
ARS Associated Factors
Released from MSC in response to
for the development of drugs targeting
specific aspectsapoptotic
of angiogenesis.
Therefore,
Pro
signals; secreted
as full-length
(low conc.)
EMAP II
AIMP1 or EMAP II; stimulates
AIMP1
Extracellular
further
progress
in this field would
Anti improve our
(86) knowledge
angiogensis
of mammalian
at low concentrations
physiology
but
(high conc.)
induces EC apoptosis at high
and provide new therapeutic targets for vascular-basedconcentrations
therapies. (86-91,95-97)
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1.3 Angiogenic signaling by extra-cellular ARSs
The process of angiogenesis requires the collaborative effort of numerous cells and
cell-types. Coordination of their activities relies heavily on the secretion of various
chemokines and growth factors to disseminate information throughout the local
microenvironment. The balance of these factors determines the overall stimulatory or
inhibitory nature of the signals (53). Two of the angiogenesis-associated ARSs, YARS
and WARS, utilize a similar mechanism in which the enzymes are secreted from the cell
in response to certain stimuli to engage in autocrine and paracrine type signaling (Figure
1).

1.3.1 Tyrosyl-tRNA Synthetase
The angiogenic properties of YARS are mediated by pro-inflammatory features
that were incorporated into the protein during the evolution of higher eukaryotes. Early
sequencing of YARS revealed an appended C- terminal domain in eukaryotes that shares
40% homology with endothelial monocyte activating polypeptide II (EMAP II), a procytokine that is released from cells in response to apoptotic signals (58). Under similar
conditions, YARS is secreted into the extracellular space. While no signaling activity is
observed for the full length protein, cleavage by extracellular polymorphonuclear
leukocyte (PMN) elastase generates two separate fragments: an N-terminal catalytic
domain fragment, termed “mini-YARS”, and a C-terminal EMAP II-like domain. Similar
to EMAP II, the C-terminal domain promotes chemotaxis in immune cells and stimulates
the release of tumor necrosis factor-α (TNFα) and tissue factor cytokines. While no direct
connection between angiogenesis and the YARS C-terminal domain has been reported,
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EMAP II itself originates from an ARS associated protein with ties to angiogenesis and
will be discussed in greater detail below. Interestingly, exposure to the mini-YARS
fragment also elicits chemotactic responses in leukocytes similar to α-chemokines (CysX-Cys (CXC)-chemokines), suggesting that it possesses cytokine activity as well (59).
Therefore, the rest of this section will focus on the mini-YARS fragment.
Like other members of the CXC-chemokine family, mini-YARS possesses a
highly conserved Glu-Leu-Arg (ELR) motif essential for receptor interactions. Scatchard
analysis of 125I-labeled mini-YARS binding to PMNs revealed saturable binding,
indicative of a specific receptor. This interaction is not observed in mutants with a GluLeu-Gln (ELQ) sequence suggesting that the association is dependent on an intact ELR
motif. Furthermore, this binding is susceptible to competition by increasing amounts of
the CXC-chemokine interleukin-8 (IL-8), suggesting that the IL-8 receptor type A
(CXCR1) is the likely mini-YARS receptor. These results are supported by the
observation that mini-YARS bound to cells transfected with the gene for CXCR1 but not
those with the CXCR2 gene (59). Although these studies focused on YARS signaling in
immune cells, the ELR-motif bearing CXC chemokines also exhibit pro-angiogenic
activities (60).
The angiogenic potential of mini-YARS has been investigated through a battery
of in vitro and in vivo studies. Similar to other CXC-chemokines, mini-YARS induces
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Figure 1. Mechanisms of angiogenesis by extracellularly acting ARS.
Left-Full-length tyrosyl-tRNA synthetase (YARS) is secreted from the cell by an unknown
mechanism. Outside the cell it is cleaved by polymorphonuclear leukocyte (PMN)-elastase
or other protease molecules into N- and C-terminal fragments which stimulate angiogenesis
or immune responses respectively. Right-Full-length tryptophanyl-tRNA synthetase
(WARS) or mini-WARS are generated from alternative splicing of WARS mRNA and are
subsequently secreted into the extracellular space by unknown mechanisms. Full-length
WARS is further processed by PMN-elastase or other proteases to form fragments like miniproWARS. The WARS fragments disrupt endothelial cell–cell contacts and angiogenic
signaling molecules,
angiogenic
responseseliciting
related an
to angiostatic
endothelialeffect.
cell migration and proliferation. Transwell

migration assays indicate a significant increase in the migration of endothelial cells when
mini-YARS is present in the lower chamber (60,61). Similarly, endothelial cell cultures
treated with mini-YARS show increased migration of cells to scratch sites in wound
migration assays. Together, these studies suggest that YARS invokes chemotactic
responses in endothelial cells similar to those observed with immune cells. Additionally,
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treatment of endothelial cells with mini-YARS stimulates proliferation and organization
of vessel networks according to commercial dye and tube formation assays respectively.
Interestingly, the extent of these angiogenic effects by mini-YARS is comparable to that
demonstrated by VEGF, indicating a potent response (61). These observations are
supported by several in vivo models as well. Exposure to mini-YARS increases basal
vessel formation in chorioallantoic membrane (CAM) and mouse matrigel models of
angiogenesis (60).
The pro-angiogenic responses observed for the migration, tube-formation, and
CAM assays are dependent on an intact ELR motif as mutation of any of these residues in
mini-YARS appears to inhibit these processes. Given the importance of the ELR for the
binding of mini-YARS to CXCR1, these results implicate this receptor as the mediator of
angiogenesis. While there was originally some doubt of this due to the lack of a murine
CXCR1 homolog, subsequent studies have since identified a potential rodent CXCR1
candidate (62), suggesting that this receptor pathway may still be viable in mouse
models. In addition, the similar angiogenic effects demonstrated by mini-YARS and
VEGF led investigators to examine the involvement of another receptor, VEGFR2.
Treatment with mini-YARS stimulates phosphorylation of Y1054, activating the
receptor. Because VEGF expression is not stimulated by exposure to mini-YARS, the
authors believe that signaling by the ARS activates VEGFR2 through a trans-activation
mechanism (61).
Investigation of down-stream mini-YARS signaling cascades revealed
phosphorylation of ERK, Src, and AKT which have been previously demonstrated to
initiate pro-angiogenic responses including endothelial cell migration, proliferation, and
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survival (reviewed in (63)). To further investigate the importance of ERK signaling, the
downstream kinase MEK was inhibited using the compound U0126. Interestingly, this
treatment blocks mini-YARS induced migration, suggesting that the ERK signaling
cascade is important for mini-YARS mediated angiogenesis. In addition to kinases, miniYARS activates endothelial nitric oxide synthase (eNOS) through phosphorylation of
Ser-1179, leading to increased nitric oxide (NO) production (61). Previous studies have
demonstrated significant effects by NO on vascular permeability and other angiogenic
responses, suggesting that it could be another contributing factor to YARS’s proangiogenic activity (64). Overall, the combination of these various signaling cascades
establishes a clear angiogenic mechanism for extra-cellular YARS that is characteristic of
its similarities to the CXC-chemokine family.

1.3.2 Tryptophanyl-tRNA Synthetase
Aspects of WARS secondary functions were observed as early as 1969 with the
appearance of alternatively spliced fragments in preparations from bovine pancreas
extracts (65). Later, the presence of WARS within exocrine cells provided evidence of
secretion (66). Subsequently, a truncated, alternative splice-form of WARS, termed miniWARS, was discovered. Interestingly, the structure of the WARS catalytic core closely
resembles that of YARS and the discovery of pro-angiogenic functions by fragments of
YARS indicates that WARS fragments may also possess possible biological functions
separate from aminoacylation (67). Some of the general mechanisms governing WARS’s
secondary functions appear similar to YARS; however, the two proteins elicit opposing
responses on angiogenesis. Expression of both mini-WARS and the full-length protein is
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regulated by interferon-γ (IFNγ), a cytokine that stimulates the expression of angiostatic
chemokines and suppresses the expression of the pro-angiogenic cytokine IL-8. This
correlation between the structures of WARS and YARS coupled with the biological
connection with IFNγ led to investigations of potential angiogenic effects of WARS.
Like YARS, full-length WARS has no influence on endothelial cell migration and
proliferation assays prior to the cleavage of the appended WHEP domain. This can be
accomplished through alternative splicing, as in mini-WARS, or through limited
proteolysis, such as by PMN elastase, which generates T1 and T2 WARS fragments.
However, whereas the active YARS fragments are pro-angiogenic, WARS fragments
inhibit both VEGF- and YARS-induced migration and proliferation in endothelial cells,
suggesting an angiostatic function (60,67). Similar attenuation of angiogenic responses
are observed in the CAM, mouse matrigel plug, and mouse retinal models indicating that
these effects can be recapitulated under in vivo conditions.
To better understand the inhibitory effects of WARS, the effect of the T2-WARS
fragment on downstream, angiogenic kinase cascades was investigated. The presence of
extracellular, T2-WARS inhibits the VEGF- and shear stress-mediated phosphorylation
of ERK, AKT, and eNOS (68,69). The localization of T2-WARS to the cell periphery
(68) coupled with the susceptibility of treated endothelial cells to shear induced
detachment (69) led to the hypothesis that WARS fragments interacted with cell-cell
contacts. Subsequently it was determined that knockdown of vascular endothelial
cadherin (VE-cadherin) disrupts the interaction between WARS and endothelial cells,
implicating it as the putative extracellular mediator of WARS’s non-canonical activities
(68). Molecular modeling studies suggest that the basis of this interaction was the
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insertion of Trp2 and Trp4 from the N-terminal EC1 domain of VE-cadherin into the
active site of the WARS core. This is supported by mutational analyses in which
substitution of Trp2 and Trp4 on EC1 or essential binding residues in WARS abolish the
interaction between the proteins. Interestingly, the binding of VE-cadherin to full-length
WARS is occluded by the presence of the N-terminally appended WHEP domain in fulllength WARS. The loss of this domain in WARS fragments allows VE-cadherin to access
the WARS active site, providing a mechanism for the cleavage-dependence of WARS’s
angiostatic activity (70).
As with both YARS and TARS (see below), the mechanism of WARS exocytosis
remains unknown. The fact that WARS-secretion is not affected by brefeldin A or
A23187 indicates that it is not dependent on Golgi- or calcium-dependent transport
respectively (71). The lack of a canonical export sequence led to the hypothesis that
secretion may be dependent on protein-protein interactions. Yeast two-hybrid and coimmunoprecipitation experiments revealed an interaction between WARS and p11 (also
referred to as S100A10), a protein member of the annexin II complex (71). Previously
p11 had been found to be important for the cellular retention of the TASK-1 transcription
factor (72). Similarly, the connection of this complex to WARS’s retention was
confirmed by demonstrating that knockdown of either p11 or annexin II increases the
secretion of WARS (71). Taken together, these data suggest a model in which angiostatic
signals stimulate the release of WARS from p11 allowing for its subsequent secretion
from the cell through unknown mechanisms. Once in the extra-cellular milieu WARS can
then be processed into active fragments that inhibit angiogenesis by disrupting
endothelial cell-cell contacts.
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1.4 Transcriptional and translational regulation of angiogenesis by ARSs
As part of their role in aminoacylation, ARSs possess features necessary for
interactions with nucleic acids. Although normally limited to tRNA, adaptations of this
feature can allow for interactions with other molecules bearing the necessary recognition
motifs. In particular, seryl-tRNA synthetase is able to bind to the vegfaa gene promoter
and reduce its transcription while glutamyl-prolyl-tRNA synthetase is able to bind to the
3’ UTR of VEGFA mRNA and inhibit its translation (73,74). In contrast to the intercellular communication propogated by the secreted ARSs, SARS and EPRS mediate
intracellular responses to angiogenesis through regulation of canonical angiogenic factors
at the transcriptional and translational level (Figure 2).

1.4.1 Seryl-tRNA Synthetase
The connection between SARS and angiogenesis was first noticed based on two
independent investigations of vascular deficient zebrafish mutants related to the adrasteia
(adr) gene (75) and ko095 locus (56). These mutations were associated with the dilation
of aortic arch vessels (AAV) and the presence of ectopic branching in the cranial and
intersegmental vessels (ISV). These effects appeared after 60 and 72 hours post
fertilization (hpf) for the ko095 and adr mutants respectively. Genetic mapping using
select SSLP markers subsequently identified two of the adr (76) and one of the ko095
(56) mutations within the sars gene. All three mutations correspond to single nucleotide
changes with the ko095 (56) and one of the adr mutants resulting in a premature stop
codon and the second adr mutant converting a conserved phenylalanine (Phe383) to a
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valine (76). In further corroboration of the importance of SARS in vascular development,
a third study reported circulation restriction in zebrafish containing sars retroviral
insertional mutants (77). The fact that these separately reported mutations in sars present
with similar deficiencies in vascular development supports the hypothesis that sars is the
likely source of this phenotype.
Although the above mutations fall within the catalytic core of the enzyme, the
effects on the vasculature appear to be unrelated to the canonical aminoacylation
function. Knockdown of SARS in endothelial cells using siRNA results in concentrationdependent cell death after 48 hours. This effect is attributed to loss of SARS
aminoacylation activity and, thus, is non-specific towards cell type. In contrast, SARS
knockdown in tube-formation experiments at earlier time points results in increased,
albeit disorganized, branching of the tube networks, indicating a endothelial cell-specific
function (56). These results are supported by investigations using the catalytically
inactive T429A SARS mutant. Despite its deficiency in aminoacylation injections of
T429A SARS mRNA into ko095 mutant fish completely rescues the aberrant vessel
phenotype, thereby separating the two functions (56).
To date, the mechanism through which SARS elicits angiogenesis remains to be
elucidated; however, it appears to be dependent on signaling by the VEGFA-VEGFR2
and VEGFC-VEGFR3 pathways. Inhibition of VEGFR2 and 3 with the inhibitors
SU5416 or MAZ51 respectively blocks the dilation of AAVs and ISV ectopic branches.
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Figure 2. Mechanisms of angiogenesis by intracellularly acting ARS.
(1) seryl-tRNA synthetase (SARS) is transported into the nucleus via a canonical nuclear
localization sequence (NLS) sequence and binds to the vascular endothelial growth factor A
gene (vegfaa) promoter. The binding of SARS inhibits c-Myc-mediated expression of vascular
endothelial growth factor A (VEGFA) through modification of vegfaa epigenetics. This effect
is angiostatic; (2) glutamyl-prolyl-tRNA synthetase (EPRS) is phosphorylated upon treatment
of the cell with IFNγ, releasing it from the multisynthetase complex (MSC). Phospho-EPRS
binds with L13a, GAPDH, and NSAP1 to form the interferon-γ-activated inhibitor of Similar
translation (GAIT) complex. This complex then binds to mRNA containing stem-loop, 3' UTR
GAIT elements via EPRS WHEP domains, thereby blocking their translation. As VEGFA
effects are not observed with the EGFR-specific inhibitor AF1478, indicating a VEGFcontains a GAIT element, this effect is angiostatic.

mediated response (76). Likewise, knockdown of VEGFA and VEGFC or their
respective receptors, VEGFR2 and VEGFR3, in zebrafish by morpholino injection
prevents the development of ectopic branches as well (56).
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Despite this link to the VEGF receptor family, the necessity of the VEGF ligands
for SARS-mediated angiogenesis indicates that the ARS is unlikely to be a direct
activator of VEGFR2 or 3. Investigation of mRNA expression changes in vascularrelated genes as a result of the ko095 mutation provides some clarification. Similar to
TARS, the ko095 SARS mutant induces no changes in Notch gene expression while
vegfaa shows significant increases. Interestingly, the augmented vegfaa expression is
attenuated by the injection of the aminoacylation-deficient T429A SARS mRNA,
suggesting that this effect is due to SARS’s non-canonical function. These findings led to
the conclusion that SARS mediates angiogenesis by suppressing VEGFA expression with
the dependence on the VEGFC-VEGFR3 pathway explained simply due to the fact that it
is essential for angiogenesis in general (56).
Similar to what was observed for YARS, SARSs secondary activity is found to
depend on a C-terminal, appended domain that arose during vertebrate evolution. This
domain, termed UNE-S, encompasses residues 470 to 514 and contains a functional
nuclear localization signal (NLS) (78). Interestingly, both the ko095 and adr non-sense
mutations completely abolish the presence of this domain. Similarly, while not located in
UNE-S, the vascular-deficient F383V SARS mutant does not localize to the nucleus
while the catalytically inactive, but vascular-functional, T429A SARS mutant possesses a
clear nuclear distribution. The importance of SARS localization on VEGFA mRNA
expression in zebrafish was investigated by knocking down endogenous zebrafish SARS
with anti-SARS morpholinos and complementing with mRNA for various SARS
constructs. Interestingly, F383V and Δ482-514 SARS (SARS lacking UNE-S domain)
exhibit threefold increased expression of vegfaa compared to wildtype human SARS and
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all other constructs with a functional NLS (78). These results were later recapitulated in
both endothelial cells and human embryonic kidney (HEK293) cells in which
endogenous SARS was knocked down with shRNA and replaced by WT SARS or SARS
lacking the NLS sequence (ΔNLS-SARS) (74). Similar to zebrafish studies, vegfaa
expression is increased two-fold in cells treated with SARS shRNA relative to cells
treated with control shRNA. Furthermore, SARS knockdown cells complemented with
expression of ΔNLS-SARS exhibit a four-fold increase in VEGFA mRNA levels when
compared to those complemented with wildtype SARS. As a functional consequence of
the increased VEGFA expression, complementation of sh-SARS-treated endothelial cells
with ΔNLS-SARS promotes angiogenesis in an endothelial tube-formation assay in
contrast to complementation with wildtype SARS. Together, these data suggest a model
in which nuclear SARS suppresses expression of vegfaa and downstream angiogenesis
through a system that is conserved from zebrafish to humans.
Recent investigations have presented a new mechanism for SARS-mediated
regulation of vegfaa expression (74). Affinity precipitation of purified SARS with calfthymus DNA demonstrates that the synthetase is capable of direct interactions with DNA.
Chromatin immunoprecipitation (ChIP) and DNA foot-printing analyses narrows this
interaction to the vegfaa promoter region within -62 to -38 bp from the start site. Of note,
this site overlaps with the c-Myc binding site in the vegfaa promoter, suggesting that
SARS may inhibit the pro-angiogenic activities of c-Myc. Specifically, c-Myc recruits
histone acetyltransferase (HAT) proteins to acetylate histones in the vegfaa locus,
generating transcriptionally active euchromatin (79). Direct competition between SARS
and c-Myc for binding to the vegfaa promoter was subsequently demonstrated using an
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electrophoretic mobility shift assay (74). Once bound to the DNA, SARS facilitates the
formation of heterochromatin through the recruitment of the histone deacetylase SIRT2,
thereby counteracting c-Myc-mediated acetylation and inhibiting vegfaa transcription.

1.4.2 Glutamyl-Prolyl-tRNA Synthetase
Glutamyl-prolyl-tRNA synthetase (EPRS) is unique among the ARSs due to its
bifunctional nature, a characteristic that first originated in higher eukaryotes. The enzyme
possesses a modular structure consisting of an N-terminal elongation factor 1β-like
domain, a glutamyl-tRNA synthetase catalytic domain (EARS), a linker region composed
of three tandem WHEP domains, and a C-terminal prolyl-tRNA synthetase catalytic
domain (PARS) (73). Additionally, EPRS is associated with the aminoacyl
multisynthetase complex (MSC), a heterocomplex composed of nine ARSs (D, EP, I, K,
L, M, Q, and R) and three non-catalytic scaffolding proteins (AIMP1-3). Both the
WHEP-linker region and association with the MSC contribute to EPRS’s non-canonical
functions.
The connection between EPRS and angiogenesis arose from investigations of a
phenomenon in which prolonged exposure of cells to IFNγ induces a marked reduction of
translation in specific genes. Termed the interferon-gamma-activated inhibitor of
translation (GAIT), its mechanism involves the binding of a proteinaceous complex
(termed GAIT complex) to stem-loop structures, or GAIT-elements, in the 3’untranslated region (UTR) of a specific mRNA, thereby preventing its translation (80,81).
Yeast three-hybrid and RNA-affinity purification experiments using GAIT element
sequences as bait identified the four comprising members of the GAIT complex:
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ribosomal protein L13a (L13a), EPRS, NS1-associated protein-1 (NSAP1), and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (82,83). Stimulation of cells by
IFNγ results in the phosphorylation and release of EPRS and L13a from the MSC and
large ribosomal subunit, respectively, and initiates the formation of the active GAIT
complex (83). Binding of the complex to mRNA GAIT elements is primarily mediated by
the three tandem WHEP domains in EPRS, emphasizing the ARS as a critical component
of the GAIT system (73).
The mechanism used by the GAIT complex to inhibit translation was initially
determined in studies of the ceruloplasmin (Cp) protein expression and then expanded to
transcripts associated with other proteins, including VEGF. In Cp, treatment of
monocytic cells with INFγ for more than 24 hours results in the attenuation of Cp
translation. Since the reduction of protein levels are not associated with a concurrent drop
in mRNA expression, regulation must occur at the translational level (80). Binding of the
GAIT complex to GAIT element in mRNA 3’ UTR inhibits the assembly of the 43S
ribosome, preventing the translation process (81,82,84). Using the pattern analysis
algorithm software PatSearch several other genes have since been identified with similar
predicted 3’ UTR GAIT elements, including death associated protein kinase (DAPK),
zipper-interacting protein kinase (ZIPK), C-C motif ligand factor-A (CCL22), and
VEGFA (57). In particular, the presence of GAIT elements in VEGFA mRNA suggested
the possibility that the GAIT complex could be important for the regulation of angiogenic
processes.
To better understand the possible role of the GAIT complex in angiogenesis, the
effects of IFNγ-treatment on VEGFA expression and downstream angiogenic activities
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were investigated with respect to the putative VEGF mRNA GAIT element. The
interaction between the GAIT complex and VEGFA mRNA was confirmed using
electrophoretic mobility shift assays of 32P labeled VEGF riboprobes containing the
VEGFA GAIT element. U937 monocyte lysates treated with IFNγ for 16 or 24 hours
exhibit interactions with all four components of the GAIT complex. Furthermore, the
effect of this interaction on VEGF translation was investigated using a luciferase reporter
assay. Incubation of luciferase mRNA containing the VEGFA 3’UTR GAIT element with
U937 lysate treated with IFNγ for 24 hours show a significant reduction in luciferase
activity relative to untreated lysate or mRNA lacking the GAIT element. However,
translation can be rescued regardless of IFNγ-treatment through the immunodepletion of
EPRS, confirming that the suppression was mediated by the GAIT complex. The effect of
reduced VEGF levels on angiogenesis was subsequently investigated using endothelial
cell proliferation and tube formation assays (85). Exposure of endothelial cells to
conditioned media from U937 monocytes treated with IFNγ for 8 or 12 hours exhibits a
marked increase in proliferation whereas only basal tube formation is observed with
treatments of 16 or 24 hours. Similarly, tube formation of endothelial cells cultured on
matrigel is enhanced 2.5 fold relative to basal levels in U937 conditioned media treated
for 8 hours with IFNγ while no change is observed in media treated for 16 or 24 hours.
These changes in angiogenic activities are consistent with the kinetics for GAIT complex
activation and support a role for the complex in the time-dependent attenuation of VEGFsignaling by IFNγ following the initial induction period.
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1.5 Regulation of angiogenesis by ARS-associated proteins.
1.5.1 Aminoacyl-tRNA synthetase interacting multifunctional protein 1
The aminoacyl-tRNA synthetase interacting multifunctional protein 1 (AIMP1; also
known as p43) is one of three auxiliary proteins that combines with nine ARSs to make
up the MSC heterocomplex. Isolation of the AIMP1 gene from Chinese hamster ovary
(CHO) cDNA led to the discovery that the exact sequence for EMAP II, a proinflammatory cytokine released from apoptotic cells, is contained within the C-terminal
region, suggesting that it may serve as the EMAP II precursor molecule and possess
potent signaling activity (86). As indicated above, an EMAP II-like domain is found in a
C-terminal fragment of YARS and may possess similar signaling functions. During
apoptosis, activated caspase 7 catalyzes the cleavage of the C-terminal EMAP II domain
of AIMP1 and subsequently releases it from the MSC complex (Figure 3) (87). Once
freed, EMAP II is secreted from the cell and stimulates the recruitment of macrophages
and initiates other signaling cascades associated with the regulation of inflammation and,
of particular interest, angiogenesis.
Both EMAP II and full-length AIMP1 have been observed to regulate angiogenesis
in a variety of assays. However, the nature of this regulation is not straightforward as
they exhibit both dose-dependent and biphasic characteristics (88). Low concentrations
(0.25 to 1 nM) of either EMAP II or AIMP1 induce endothelial cell migration in
transwell migration assays and AIMP1 stimulates angiogenesis in the CAM assay (the
effects of EMAP II in CAM assays remain to be investigated). Conversely,
concentrations of 10 nM and above exhibit dose-dependent inhibition in the same assay
and appear to be related to the induction of endothelial cell specific apoptosis (88).
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Figure 3. The biphasic responses of aminoacyl-tRNA synthetase interacting
multifunctional protein 1 (AIMP1) and endothelial monocyte activating polypeptide
II (EMAP II) on angiogenesis.
(1) Caspase 7 cleaves the C-terminal EMAP II peptide from AIMP1, releasing EMAP II
from the multi-synthetase complex; (2) Alternatively, AIMP1 is released by unknown
processes; (3) Both EMAP II and AIMP1 are secreted from the cell by mechanisms that
remain to be determined; (4) At low concentrations (perhaps corresponding to early
portions of the AIMP1/EMAP II signaling responses in vivo) EMAPII and AIMP1 bind
to surface receptors, activating various kinase cascades; (5) These kinase cascades induce
the expression of tumor necrosis factor α (TNFα); (6) TNFα is secreted from the cell and
mediates angiogenesis through canonical TNFα pathways; (7) At high concentrations
(perhaps corresponding to prolonged exposure in vivo), AIMP1 and EMAP II induce the
expression of the TNFα-receptor (TNFR); and (8) Over-stimulation of TNFR by TNFα
induces apoptosis through signaling by the TNFR death-domain, resulting in an antiangiogenic response.

Additional studies with EMAP II revealed similar anti-angiogenic responses in both tube
formation and rat aortic ring assays at concentrations of 20 µg/ml (0.6 µM) and greater
(89). The cause of this biphasic signaling may be linked to the varying sensitivities of
specific kinase cascades (88,90). Interestingly, full-length AIMP1 appears to be a more
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potent inducer of migration and apoptosis than the processed EMAP II peptide (88)
suggesting a role for the whole protein in signaling events.
Several lines of evidence implicate TNFα in the AIMP1 angiogenic signaling
pathway. AIMP1 elicits a striking increase in the expression of TNFα, a potent regulator
of both pro- and anti-angiogenic activities (91). In terms of pro-angiogenic activities,
TNFα increases expression of VEGF via NF-κB activation (92). Conversely, TNFα can
also induce apoptosis in endothelial cells, lending itself to an anti-angiogenic role (93).
AIMP1-stimulated secretion of TNFα initiates the downstream phosphorylation and
activation of ERK1/2, a well-known angiogenic signal. The necessity of ERK1/2
activation for AIMP1 regulation of TNFα was subsequently confirmed using the MEK
inhibitor U0126, which was shown to attenuate the induction of TNFα (91). As such, the
TNFα activation of ERK1/2 likely contributes to the initial, pro-angiogenic phase of
AIMP1 and EMAP II signaling. However, higher concentrations or sustained secretion of
AIMP1 or EMAPII enhances the surface representation of TNF receptor 1 (TNFR1) on
endothelial cells, thereby facilitating TNFα-induced apoptosis through the TNFR1 death
domain (94). Therefore, TNFα-signaling may contribute to the second, anti-angiogenic
portion of AIMP1 and EMAPII’s biphasic response.
In addition to its role in inflammatory signaling, several different studies have
revealed that EMAP II is capable of effecting canonical angiogenic pathways. Treatment
with EMAP II inhibits endothelial cell migration by disrupting interactions between
fibronectin and alpha5 beta1 integrins (95). ELISA-based assays also determined that
EMAP II directly interacts with VEGFR1 and 2 and inhibits the binding of VEGF.
Functionally, EMAP II inhibition of VEGFRs prevents the phosphorylation of
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downstream signal mediators, including AKT, ERK1/2, p38MAPK, and Raf as well as
VEGF-dependent endothelial cell migration (96). Furthermore, over expression of EMAP
II in cells increases the proteasome subunit alpha type-7 (PSMA7)-dependent
proteasomal breakdown of HIF1α even under hypoxic conditions and, consequently,
reduces hypoxia-induced tube formation in endothelial cells at concentrations of 20 µM
(97). It should be noted, however, that most of the above functions were investigated at
EMAP II concentrations that would induce the inhibitory portion of EMAP II’s biphasic
response. Therefore, under normal conditions, it is possible that these inhibitory effects
would be delayed relative to the initial induction of angiogenesis associated with VEGFand hypoxia-based signaling.

1.6 General characteristics of angiogenesis-associated aminoacyl-tRNA
synthetases
1.6.1 Aminoacyl-tRNA synthetases may connect angiogenesis to nutrient sensing.
As indicated in section 1.2.1 above, the dependence of the aminoacylation
reaction on ATP and amino acid concentrations opens opportunities for ARSs to function
as nutrient sensors within the cell. Perhaps the best example of this was demonstrated in
recent studies of leucyl-tRNA synthetase (LARS) in which LARS was found to regulate
mTOR-mediated autophagy in a leucine-dependent manner (37,38). Alternatively, the
accumulation of uncharged-tRNA due to amino acid depletion or inhibition of any ARS
can activate the GCN2-mediated amino acid starvation response, leading to translational
arrest and apoptosis (48). Since nutritionally starved cells would benefit from the
increased vasculature, the acquisition of angiogenesis-related functions by these enzymes
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would complement their roles as intracellular sensory mechanisms. While no direct
nutrient sensing has been observed in angiogenesis-related ARSs, substrate-induced
conformational changes are well documented among ARSs in general (98,99). These
changes may regulate important interactions responsible for the transport of the ARSs
and down-stream signaling events essential for their non-canonical activities and would
warrant further study.

1.6.2 Mechanistic separation of angiogenesis-associated ARSs.
Relevant ARSs use a wide variety of mechanisms in their regulation of
angiogenesis. However, these enzymes can be subdivided into two broad categories
based on the location of their actions. The first, consisting of YARS, WARS, and
AIMP1, function extracellularly and must be secreted from the cell. While little is known
of the secretion mechanisms these events are able to accommodate full-length proteins.
Since the canonical function of ARSs in translation is catalyzed in the cytoplasm, the
export of these proteins likely serves as an important regulatory step in their noncanonical functions. The identification of this system is critical to understanding these
secondary functions and their regulatory process.
Conversely, SARS and EPRS regulate angiogenesis intracellularly through
interactions with DNA or mRNA (73,74). Unlike their secreted counterparts, the
regulation methods of the intracellular-acting ARSs are better understood. EPRS interacts
with mRNA in the cytoplasm and does not require a transport mechanism. Instead,
phosphorylation initiates its dissociation from the MSC, thereby acting as a switch
between the primary and secondary functions. SARS, on the other hand, interacts with
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nuclear DNA and must undergo nuclear transport. While the processes regulating this
event are not completely known, a nuclear localization signal has been identified within
the C-terminal domain of SARS that is essential for its regulation of VEGFA
transcription. Taken together, these findings would suggest that all of the angiogenic
ARSs appear to separate their canonical and non-canonical functions by sequestration.
Therefore, undesired angiogenic activity can be limited by regulating the translocation of
the ARSs from the cytoplasm or their dissociation from a protein complex.

1.6.3 Associations of angiogenesis-related ARSs to inflammation
Except for SARS, all angiogenesis-associated ARSs possess some connection to
inflammation. Both YARS and AIMP1 are associated with the pro-inflammatory EMAP
II or ELR domains which activate receptors from the CXC-receptor (CXCR) family.
These receptors mediate chemokine signaling pathways important for the coordinated
regulation of inflammatory and angiogenic responses during wound healing (reviewed in
(100)). Consistent with other ELR containing chemokines, mini-YARS stimulates proangiogenic signaling through interactions with CXCR1 expressed by endothelial cells.
Interestingly, while all other known ELR chemokines also stimulate CXCR2, knockdown
of the receptor has no effect on angiogenesis by mini-YARS, suggesting that mini-YARS
may be specific to CXCR1 or possesses yet unknown activities associated with CXCR2.
Similarly, EMAPII, as suspected for other ELR-lacking chemokines, regulates
angiogenesis through CXCR3. Knockdown of CXCR3 inhibits EMAP II-mediated
migration by endothelial cells, a response that would be anticipated for an angiogenic
molecule. However, these results appear atypical since CXCR3 is primarily a mediator
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of angiostasis. Given EMAP II’s biphasic response, it is may be possible that EMAP II’s
angiogenic and angiostatic activities are both mediated through CXCR3 but are
differentially regulated. Additionally, the EMAP II precursor, AIMP1, regulates
production of TNFα and its receptor, TNFR, through interations with CD23. Connections
of TNFα to angiogenesis and inflammation are well established in the literature (101). Of
particular interest, TNFα exhibits a dose-response effect, stimulating angiogenesis at
lower concentrations and inhibiting it at higher (102), consistent with the biphasic
response observed for EMAP II. Given the sequence homology between EMAP II,
similar connections to TNFα may exist with the C-terminal domain of YARS and may
play an important role in YARS-mediated angiogenesis.
The non-canonical functions of WARS and EPRS appear to be regulated by
signals from inflammatory factors rather than initiating them like YARS and AIMP1.
Treatment of cells with IFNγ stimulates the secretion of WARS and releases EPRS from
the MSC, initiating translational control by the GAIT complex. In contrast to other
inflammatory signals, like TNFα, IFNγ is anti-angiogenic, consistent with its association
with WARS and EPRS signaling. Overall, the connection to inflammation underlies a
complex association of ARSs with responses to cellular stress separate from their better
known, house-keeping roles in translation.

1.6.4 The role of appended domains in ARS-mediated angiogenesis.
The angiogenesis regulatory mechanisms exhibited by the ARSs described above
are often dependent on appended domains or sequences not found in the prokaryotic
enzymes (reviewed in (103)). These features include EMAP II-domains in YARS and
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AIMP1, an ELR motif in YARS, WHEP domains in WARS and EPRS, and an NLS in
SARS. The WHEP domain is exclusive to the ARS family of enzymes and is associated
with RNA interactions. The RNA binding affinity of the WHEP domain increases with
the number of tandem repeats and is essential for the non-canonical functions associated
with EPRS (104). Conversely, the single WHEP domain of WARS does not have a
known RNA-binding function but instead regulates angiogenesis by blocking access of
N-terminal E-cadherin to the WARS active site. Interestingly, the ELR and EMAP II
domains appear to have arisen in insects, whose blood diffuses throughout the body
cavity instead of within defined vessels (105). Likewise, WHEP domains have been
observed in organisms as early as choanoflagellates, the closest unicellular ancestor to
animals (106). Therefore, it is likely that these domains developed for a separate purpose
and expanded to include angiogenesis following the development of a complex vascular
system.

1.6.5 ARSs as targets for anti-angiogenic therapy.
Given the importance of angiogenesis in the growth and metastatic progression of
several solid tumors, many of the most prominent angiogenic factors, such as VEGF,
have been investigated as potential targets for anti-metastatic therapies. Unfortunately,
the benefits of these approaches are often temporary owing to adaptive responses by the
target tissue (107). Therefore, better understanding of ARS angiogenic activities may
allow for the development of new small molecule inhibitors for use in combinatorial
cancer therapies.
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Several natural and synthetic ARS inhibitors have been reported that exhibit antimicrobial or immunosuppressant activity by inhibiting canonical functions of aminoacyltRNA synthetases (108-111). More relevant to anti-cancer treatments, disruption of an
interaction between lysyl-tRNA synthetase (KARS) and the laminin receptor by a small
molecule inhibitor was found to inhibit the metastatic progression of a mouse breast
cancer model (112). Considering that chemical intervention of KARS non-canonical
functions influenced cancer progression it would not be surprising if similar results could
be obtained through the manipulation of other angiogenesis-associated ARSs. Therefore,
these efforts can be enhanced through the better understanding of regulation and
mechanistic processes.

1.6.6 Concluding remarks for aminoacyl-tRNA synthetase functions in angiogenesis
The above observations provide clear evidence for a role of ARSs in
angiogenesis. Their very different mechanisms suggest that these functions developed
separately for each enzyme over the course of evolution. This is not completely
surprising as ARSs are among the most ancient and essential enzymes to come into
existence and have had a long evolutionary window to acquire secondary functions.
Furthermore, their connection to the nutritional and translational status of the cell makes
them prime candidates for the development of homeostatic functions, like angiogenesis,
that are essential for the survival of complex, multicellular organisms. Nonetheless,
many features of the molecular mechanisms associated with ARS-mediated angiogenesis
remain to be determined. With the exception of EPRS, little is known about the
regulatory signals separating the canonical and non-canonical functions. Notably, the lack
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of a clear secretory mechanism for the extracellularly active ARSs has confounded
investigations focused on the initiation of their angiogenesis-associated activities.
Furthermore, future drug design would benefit from improvements in knowledge of
downstream signaling pathways and structural studies of ARS-partner interactions.
Overall, the connection between ARSs and angiogenesis emphasizes the importance of
their characterization to the field of vascular biology and opens up new and exciting areas
for future research.

1.7 Threonyl-tRNA Synthetase
1.7.1 Introduction to threonyl-tRNA synthetase
Threonyl-tRNA synthetase (TARS) is an 83 kDa (human, monomer; 76 kDa E.
coli) class II ARS that catalyzes the attachment of threonine to its corresponding tRNA
for use in translation. However, like other class II ARSs, the protein is typically found as
a homodimer (6). The structure of TARS is modular with four core domains that have
been conserved from prokaryotes to eukaryotes (Figure 4A) (18). The most N-terminal of
these is the N1-domain (residues 83-144 human, 1-62 E. coli), an ubiquitin-like domain
of unknown function. This domain is adjacent to the N2 (or editing) domain (residues
145-303 human, 63-224 E. coli), which functions in the post-transfer editing of tRNAThr
aminoacylated with the false cognate serine (113). This structure is connected to the
aminoacylation (or catalytic) domain (residues 319-607 human, 240-528 E. coli) by a
large linker helix (residues 304-321 human, 225-242 E. coli).
The aminoacylation domain contains all the conserved structural elements
characteristic of class II ARSs as well as the three substrate binding sites (5,6). While
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numerous residues contribute to substrate binding, a Class II conserved arginine, R442 in
human TARS (R383 in E. coli), is perhaps the most important (Figure 4B). R442
interacts with both the α-phosphate of ATP and the carboxyl group of threonine and
stabilizes transition state for the adenylation reaction (114). Additionally, a Zn2+ is
coordinated within the active site by two histidines and a cysteine. Crystallographic
evidence suggests that this ion is important for interacting with the threonine substrate’s
hydroxyl and removing it results in loss of TARS aminoacylation activity (18). The role
of the Zn2+ atom in discrimination of amino acids with hydroxyl groups is further
supported by kinetic evidence of alanyl-tRNA synthetase (AARS) editing, which appears
to use a Zn2+ atom to preferentially bind serine (21). The most C-terminal domain is
referred to as the anti-codon binding domain (residues 614-723 human, 535-642 E. coli),
which selects and binds anticodons corresponding to the substrate tRNAThr (18).
Together, the aminoacylation and anticodon binding domains form the dimer interface. In
addition to these core domains, eukaryotic TARS species possess an unstructured, Nterminal extension (residues 1-81 in humans). While the length of this region can vary
greatly between organisms some sequence features, such as a lysine rich region, appear to
be conserved amongst most species. The function of this region, however, remains
unknown.

1.7.2 Non-canonical functions of threonyl-tRNA synthetase
Prior to the work presented herein, the connection between TARS and
angiogenesis had not been well established. However, evidence of its connection to
vascular biology was identified concurrently with studies of the TARS-specific inhibitor
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borrelidin, a naturally occurring polyketide anti-microbial, and anti-fungal compound
from Streptomyces rochei. Characterizations of borrelidin-resistant bacterial strains and
Chinese hamster ovary cells with selective amplification of tars genes established TARS
as the principal target of borrelidin (115,116). Subsequent investigations revealed that
borrelidin inhibits tube formation of rat aortic ring fragments with an IC50 of 0.4 ng/ml
(0.8 nM). This value was 15-fold lower than the IC50 for endothelial cell growth
inhibition (6 ng/ml), suggesting a specific anti-angiogenic activity for the compound
(117). Subsequent investigations of borrelidin’s effects also demonstrated that treatment
with the compound reduced the occurrence of lung metastases in B16-BL6 mouse models
of melanoma at concentrations known to inhibit angiogenesis (118). The fact that no
alternative targets to TARS can be identified coupled with the threonine-dependent
nature of some of the anti-angiogenic effects strongly implicates TARS as the mediator
of these effects.
In addition to the angiogenesis connections alluded to by borrelidin, TARS is the
target of the PL-7 autoantibody in the polymyositis and dermatomyositis autoimmune
disorders (119). In addition to TARS, auto-antibodies have been discovered against five
other ARSs which lead to similar complications. Etiological characterizations associated
these conditions with auto-reactive T-cells in muscle tissue mediated through two major
inflammatory pathways: NF-κB and TNFα signaling (120). Both of these signaling
pathways share connections with inflammation and angiogenesis through regulation of
downstream kinases or hypoxia inducible factor 1α stabilization (121,122). Of note,
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Figure 4. Basic structural components of TARS.
(A) The monomeric structure of TARS (PDB: 1QF6) with domains highlighted as follows:
N1-domain (purple), N2/editing domain (yellow), linker helix (pink), aminoacylation
domain (cyan), and anticodon-binding domain (blue). (B) Ribbon diagram of the TARS
active site (PDB:1QF6) with specific features highlighted. AMP, A76 of the tRNAThr, and
the conserved R442 are shown as stick models; the bound Zn2+ is shown as a grey sphere.
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muscle biopsies from patients in the early phases of polymyositis and dermatomyositis
have demonstrated increased expression of VEGF, possibly due to reduction in capillaries
within the affected tissue (123). In addition, these disorders have been associated with an
increased risk of several varieties of cancer (124). However, it is currently unclear as to
whether or not the secretion of TARS in angiogenesis has any connection to these
diseases or if these autoimmune disorders contribute to neovascularization in
tumorigenesis.
The ability of the TARS inhibitor, borrelidin, to disrupt angiogenesis and
metastasis strongly implicated the compound as a possible cancer therapeutic.
Additionally, the association of other ARSs with angiogenesis and the lack of any other
targets for borrelidin suggested that TARS may possess secondary functions in
aminoacylation. Despite the extensive literature on the topic angiogenesis remains a
complicated process that is incompletely understood. Further investigation of TARS and
its inhibitors will help clarify another aspect of angiogenesis and may open up new
opportunities for pharmacological manipulation of vascular biology. The data presented
herein provide evidence for a role of extracellular TARS in the stimulation of vessel
migration and maturation in both in vitro and in vivo systems. Treatment with borrelidin
or its derivatives are found to inhibit TARS’s angiogenic properties through the induction
of conformational changes within the enzyme. Contrary to previous reports these effects
are demonstrated to be separate from the toxicity exhibited by the compounds and
rectifies incorrect assumptions of inhibitor mechanism. Together these data provide a
foundation for future investigations TARS’s secondary function in angiogenesis and the
mechanism of its inhibitor, borrelidin.
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CHAPTER 2: CHARACTERIZING THE INHIBITION OF HUMAN
THREONYL-tRNA SYNTHETASE BY BORRELIDIN AND DERIVATIVES

2.1 Introduction
Borrelidin is a polyketide, macrolide antibiotic that was first discovered in isolates
from Streptomyces rocheii in 1949 and later identified in other Streptomyces species (13). It was named for its potent anti-microbial effects against the fever-inducing
spirochetes from the Borrelia genus. However, its functions have expanded greatly since
it discovery. In addition to Borrelia, borrelidin was found to inhibit pathogenic
spirochetes of genus Treponema, the malarial parasite Plasmodium falciparum, viral
replication, and pathogenic fungi (4-7). These effects have been linked to the molecule’s
specific inhibition of TARS and, through it, the overall process of translation (8).
TARS exhibits high sequence conservation between bacteria and eukaryotes.
Consequently, borrelidin has been demonstrated to inhibit functions in a variety of
organisms. Studies of borrelidin-resistant E. coli K12 strains and Chinese hamster ovary
cells reveal modified or increased expression of ThrRS, the only known target of the
compound (9,10). These observations support an interaction between TARS and
borrelidin and suggests that this interaction is maintained through bacteria to mammals.
Similarly, borrelidin-treatment was demonstrated to influence endothelial cell processes
in both human umbilical vein endothelial cells (HUVECs) and mouse models, indirectly
insinuating that borrelidin is capable of inhibiting several varieties of mammalian TARS
(11,12). However, these hypotheses remain circumstantial without support from more
direct approaches.
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The interactions between borrelidin and several bacterial ThrRSs were confirmed
in assays utilizing isolated enzymes from the representative bacterial sources E. coli, S.
solfataricus, and Halobacterium sp. Calculated values of Ki were obtained for both E.
coli and S. solfataricus and were found to be nearly identical at 3.7 nM and 4.5 nM
respectively. Conversely, representative archaeal species, M. jannaschii and A. fulgidus,
exhibited no significant inhibition by borrelidin, consistent with the observed low
sequence conservation in archaeal TARS compared to the other domains of life (13).
Despite this suggestive evidence that borrelidin is capable of inhibiting the mammalian
TARS, direct proof of the enzyme-inhibitor interaction has not been reported.
In addition to its inhibition of aminoacylation, borrelidin was found to disrupt
angiogenesis in the mouse aortic ring fragment model (12). This feature led to subsequent
investigations interested in the development of borrelidin as an anti-metastatic agent.
Unfortunately, the potential therapeutic benefits of borrelidin are limited by its acute
toxicity to living cells (14). Efforts have been made to improve the clinical usefulness of
borrelidin by generating derivative molecules with a wider therapeutic index. In order to
synthesize these derivative molecules, the complete borrelidin biosynthetic operon from
Streptomyces parvelus Tu4055 was cloned and sequenced. By selective gene mutation
and “priming” the biosynthesis of borrelidin with alternative dicarboxylic starter
compounds novel variants of borrelidin were readily achieved. While this technique
could theoretically be used to modify a variety of locations within the borrelidin
molecule, modifications to the macrolide backbone and nitrile group completely
eliminated the compound’s functionality. In contrast, modifications to the C17 pendent
group produced derivative compounds with varying affinities and properties (15,16).
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Therefore, all borrelidin derivatives used in recent studies vary exclusively at the C17
site.

Figure 5. Structures of macrolides used in this study.
Structures of borrelidin (top left), BC194 (top right), BC196 (bottom left), and BC220 (bottom
right). Carbons C1 and C17 for the macrolide component of each compound have been labeled.

Semisynthetic generation of borrelidin derivatives has produced a battery of
compounds (Figure 5). The most promising of these molecules for use in anti-angiogenic
treatments is BC194, which substitutes a cyclobutane carboxylic acid for the C17
cyclopentane carboxylic acid group of borrelidin. Surprisingly, this seemingly minor
modification has been demonstrated to reduce the toxicity of the compound by nearly
1000-fold as determined by growth inhibition of human umbilical vein endothelial cells
(HUVEC) (16). Despite this change in toxicity, however, BC194 retains potent anti55

angiogenic activity and will be discussed in greater detail within later chapters.
Additionally, the derivatives BC196 and BC220, consisting of 2-methylbutanoic acid and
cyclopentane carboxylic acid 3-ethyl piperidine ester C17 substitutions respectively,
represent lower affinity derivatives and have been included in these studies as well.
Originally, these derivatives were investigated for their high specificity against the
malarial parasite Plasmodium falciparum relative to the human host, however, they are
used here to draw structural comparisons between the other compounds (17).
In this work we demonstrate that the C17 modification of BC194 does not
significantly alter its affinity for human TARS from that of borrelidin in enzymatic
assays. However, in accordance with recent crystallographic data, BC194 is found to be
more susceptible than borrelidin to competition by threonine in biological assays. Taking
these observations into consideration with the conformational changes presented by the
structural data and the slow, tight-binding kinetics of the compound leads to the
presentation of a two-step, induced-fit model of binding. This model justifies the apparent
incongruence of the competitive structural data with the noncompetitive kinetics and will
facilitate future understanding of borrelidin and its derivatives. Finally, point mutations
are generated in human TARS in order to develop borrelidin-resistant mutants that can be
used to investigate the TARS specificity for borrelidin-related functions in biology.

2.2 Results and Discussion
2.2.1 Discussion of borrelidin’s slow, tight-binding kinetics of enzymes
Inhibitors are often described by an equilibrium dissociation constant (Ki) for the
formation of the enzyme-inhibitor complex. The true Ki value accounts for the inhibitor’s
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modality (ie. competitive, noncompetitive, etc.) and how this affinity is influenced by
changes in substrate with respect to the reactions Km. Therefore, this value is
independent of the reaction conditions. However, in absence of detailed knowledge of
inhibitor modality or kinetic constants an apparent Ki value (Kiapp) can used for relative
comparisons of inhibitor affinity so long as nearly identical conditions are maintained.
Commonly, calculations for Kiapp are based on reversible, steady-state
measurements of initial velocity (v) and must satisfy several conditions. In particular,
these methods assume that the formation and dissociation of the enzyme inhibitor
complex (EI) is fast relative to the rate of enzymatic turnover and that the concentration
of EI is negligible to the concentration of free inhibitor. However, early investigations of
borrelidin binding modality with E. coli ThrRS using intrinsic tryptophan fluorescence
exhibited kon and koff values of 5*106 s-1 and <0.1 s-1 respectively. From these data, the
lower limit of the TARS-borrelidin complex half-life can be determined by using the
following equation (Derivation found in (18)):

t1 / 2 

0.6931
k off

By fitting koff at <0.1 s-1, a half-life of at least 7 minutes is obtained, indicating that the
rapid binding assumption is not met. As a notable consequence, the degree of inhibition
for these slow-binding inhibitors appears to change over time as demonstrated in Figure
6. In absence of inhibitor and at a concentration of 10 nM E. coli TARS (Ec ThrRS;
ThrRS designates the prokaryotic enzyme), the steady-state aminoacylation reaction
proceeds in a linear fashion until it has exhausted its available substrates. Similar
isotherms would be predicted for rapid binding inhibitors except that the initial slopes
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would be reduced as a function of inhibitor concentration. In contrast, reactions
containing 20 nM borrelidin exhibit clearly visible time dependence for inhibition. In
absence of pre-incubation, the reaction rates appear similar to the uninhibited reaction at
earlier time points but level off within 10 minutes. Given that the substrate concentrations
are identical in all reactions, this plateau is directly related to inhibitor binding and not
the exhaustion of substrates. Conversely, pre-incubation of Ec ThrRS and borrelidin prior
to the addition of substrates bypasses the slow-binding step and establishes a linear
inhibition-isotherm. The fact that the rate of the pre-incubated reaction does not seem to
increase over time suggests the rate of dissociation is so slow as to appear irreversible.
Therefore, Ki values will be determined from initial velocity values of reactions preincubated with borrelidin to account for the slow-binding character of the compound.

Figure 6. Borrelidin exhibits slow-binding kinetics.
The aminoacylation activity of Ec ThrRS treated with the DMSO vehicle (Uninhibited, blue) or
borrelidin for either 30 minutes before (pre-incubation, green) or simultaneously with (No
incubation, red) the canonical substrates. Activity was determined by the production of ThrtRNAThr per active site per minute; mean ± SD, n=3.
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Initial investigations of borrelidin’s effects on Ec ThrRS revealed significant
inhibition when ThrRS and borrelidin were present at similar concentrations, indicating
that borrelidin is also a tight-binding inhibitor. This property, like slow-binding, is
accompanied by its own set of complications that must be addressed for proper kinetic
analysis. For Ec ThrRS, the Kiapp was calculated from the IC50 (the concentration of
inhibitor that inhibits 50% of enzymatic activity under the given conditions) under the
assumption of excess inhibitor and later adjusted for tight-binding character. Often the
IC50 value of weak-binding inhibitors is a sufficient approximation for Kiapp. This value
can be determined by plotting the fractional velocity (vi/v0, where vi and v0 are the initial
velocities of the inhibited and uninhibited reactions respectively) against the total
concentration of inhibitor in the reaction ([I]T) and fitting the resulting data to the
following Langmuir isotherm equation (19,20):

vi

v0

1
[I ]
1 T
IC50

However, the derivation of this equation depends on the assumption that [I]T is in great
excess of the total enzyme concentration ([E]T). That is to say [I]T >> [E]T. Therefore, the
concentration of inhibitor in complex with enzyme is negligible compared to the free
inhibitor concentration ([I]f) and [I]T can be used as a close approximation for [I]f (ie. [I]T
≈ [I]f). In contrast, borrelidin significantly reduces Ec ThrRS activity at nearly equimolar
concentrations to the enzyme, indicating that bound borrelidin represents a significant
proportion of the total concentration. To address this concern, early borrelidin studies
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converted IC50 into Kiapp values using an equation that accounts for borrelidin’s tightbinding properties by associating IC50, Kiapp, and [E]T using the following equation
derived by Easson and Stedman in 1933 (21):

1
IC50  K iapp  [ E ]T
2

While this method could also be used for the determination of Kiapp with human TARS,
the work presented in this dissertation utilized the more robust Morrison quadratic
equation developed in 1969 (22,23).

[ E ]T  [ I ]T  K i  ([ E ]T  [ I ]T  K i ) 2  4[ E ]T [ I ]T
vi
 1
v0
2[ E ]T

Unlike the IC50 method, the Morrison equation requires no assumptions related to the
depletion of inhibitor concentration due to complex formation with the enzyme and can
directly calculate Kiapp from a plot of fractional velocity versus inhibitor concentration.

2.2.2 Inhibition of human threonyl-tRNA synthetase by borrelidin and derivatives
The ability of borrelidin and related-compounds to inhibit human TARS was
investigated kinetically using in vitro enzymatic assays similar to the early methods used
with prokaryotic versions of the enzyme. These procedures utilized human tRNAThr and
TARS constructs recombinantly expressed in E. coli cells and monitored the production
of Thr-tRNAThr as a measurement of aminoacylation activity. By plotting the relative
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velocity of the inhibited reaction (vi/v0) versus the concentration of inhibitor, a curve is
obtained from which Kiapp can be determined using the Morrison quadratic equation
above. Care was taken to maintain conditions as close to those reported for E. coli ThrRS
to keep comparisons between Kiapp values as accurate as possible. These procedures were
repeated for the various derivatives of borrelidin as well. All data have been included in
Table 2.
Table 2. Kiapp values of borrelidin derivatives on TARS constructs
Construct
Borrelidin
BC194
BC196
BC220
E. coli ThrRS
3.7a
0.006b
--Human TARS
5.44
4.09
208.2
>10,000
L567V TARS
-32.2
--a
data from Ruan et al. (13)
b
data from Anand Minajigi dissertation – Note these data have been difficult to
replicate. This may be due to the use of mislabeled stock samples and should be
repeated.

Recombinant human TARS was found to be active with a rate of 3.325 ± 0.2083
min-1 (Figure 7A). Consistent with its high sequence conservation to Ec ThrRS, this
TARS construct exhibited tight-binding interactions with borrelidin. Likewise, a preincubation step between the enzyme and inhibitor was used to account for the time
dependence of the borrelidin-TARS interaction. Borrelidin inhibited TARS with a Kiapp
of 5.44 nM (Figure 7B) nearly identical to the 3.7 nM value obtained for ThrRS. Despite
its significantly reduced toxicity, BC194 also formed a comparably tight interaction with
TARS, presenting with a Kiapp of 4.09 nM (Figure 7C). Conversely, the Kiapp values for
BC196 (Figure 7D) and BC220 (Figure 7E) were significantly higher at 208.20 nM and
>10 µM respectively.
Taken together, the Kiapp values can provide some mechanistic insights on their
own. The structural variability for all the tested compounds is limited to modifications in
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Figure 7. Determination of Kiapp for borrelidin and related compounds against human
TARS.
(A) Aminoacylation activity of purified TARS as determined by formation of Thr-tRNAThr per
active site per minute; mean ± S.D.; n=3. (B-E) Plots showing the fractional initial velocity of
TARS (10 nM) as a function of borrelidin (B), BC194 (C), BC196 (D), or BC220 (E)
concentration; mean ± S.D.; n=3.
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the pendant side chain, demonstrating the importance of this group to the binding each
compound. Specifically, the two strongest binders, borrelidin and BC194, possess closed
ring structures; whereas BC196, which resembles BC194 with an open carboxylcyclobutyl ring, exhibits a significantly higher Kiapp. Most likely, this difference is due to
the higher degrees of freedom present in the open structure compared to the closed.
Conversely, while BC220 possesses a closed cyclopentyl ring like borrelidin, the
esterification of the carboxyl group severely reduces the compounds affinity for TARS.
However, it is uncertain as to whether or not this modification reduces binding through
steric interactions or through the loss of the negatively charged carboxyl group. In
contrast, the macrolide backbone is identical for all compounds and is predicted to make
the majority of the compounds’ contact with the enzyme. Therefore, the difference in
affinity due to the C17 group may not be enough to counteract the strong contributions of
the macrolide ring in borrelidin and BC194, explaining the nearly identical Kiapp values.
Conversely, the variations in the BC196 and BC220 side chains may be disruptive
enough to inhibit strong interactions with the enzyme. However, structural information
must be considered to truly understand borrelidin’s binding mode.

2.2.3 Determination of borrelidin’s mode of inhibition.
As the high resolution crystal structure of the borrelidin-Ec ThrRS complex was
not reported until recently, early investigations of borrelidin’s binding mode were limited
to kinetic and mutational data. Naturally occurring mutations that conferred borrelidin
resistance were found to correspond to a hydrophobic pocket adjacent to the Ec ThrRS
active site implicating this region as the likely borrelidin binding site (13). This was not
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completely surprising as the non-polar macrolide ring would form higher affinity
interactions with hydrophobic residues. Other studies also demonstrated that the binding
of borrelidin induced a dose-dependent quenching of an intrinsically fluorescencent
tryptophan residue (13). Previously, this fluorescence had been associated with Trp434
and Trp478 in the E. coli ThrRS (Trp512 and H556 in humans) positioned near the active
site and were quenched in response to conformational changes induced by the binding of
ATP and threonine (24). Together these data would likewise suggest that borrelidin
induces conformational changes in Ec ThrRS upon binding. More importantly, however,
the phenomenon occurred in absence of the canonical substrates and eliminated the
possibility of borrelidin binding using an uncompetitive mode. Furthermore, despite this
location near the active site, borrelidin’s inhibitory properties were unaffected by the
addition of threonine and ATP ranging in concentrations from 0.01 to 1 mM and 0.02 to
10 mM respectively, suggesting that borrelidin does not possess a competitive or mixedtype inhibition mode as well (13). Therefore, these early reports suggested that borrelidin
must bind noncompetitively. However, the true modality of borrelidin is more
complicated than originally predicated owing to recent crystallographic data of the
TARS-borrelidin complex solved by our collaborator Min Guo (25).
Recently, the structure of borrelidin co-crystallized with a fragment of human
TARS (ΔN1N2-TARS) comprising the aminoacylation and anticodon-binding domains
(residues 318-723) was solved to a resolution of 2.6 Å. The resulting structure challenges
the conclusion of a noncompetitive binding mode suggested by the kinetic data.
Consistent with the previous investigations, borrelidin was found to bind within the
hydrophobic pocket of the aminoacylation domain active site of the protein. Specifically,
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Figure 8. TARS-borrelidin binding interactions.
(A, B) Residues involved in the borrelidin-TARS interaction for the macrolide (A) and
pendent group (B) components. The borrelidin structure is shown in yellow and binding
resides are shown in magenta. Structure provided by Min Guo.

the macrolide component forms hydrophobic interactions with residues L567, S386,
H388, Y540, D564, Q562, H590, Y392, H391, and F539 (human numbering; Figure 8A).
The pendent side chain further contributes interactions with residues T560, R442, M411,
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C413, Q460, and A592 (Figure 8B). This large number of contacts likely explains the
tight-binding character of the compound. Establishing all of these interactions, however,
requires structural changes within the enzyme as demonstrated by comparison of the
borrelidin-TARS complex to other TARS structures.
The borrelidin induced conformational changes can be easily observed when
compared to the structures of earlier Ec ThrRS complexes. These Ec ThrRS structures are
either empty (apo Ec ThrRS; PDB: 1EVK) or in complex with the threonyl-adenylate
analog, threonyl sulfamoyl adenylate (PDB: 1NYQ), or AMP (PDB: 1QF6). Although
the borrelidin-TARS complex described above refers to the human enzyme, the structure
for the aminoacylation and anti-codon binding domains of the Ec ThrRS ortholog was
also solved. Both structures superimpose with an r.m.s.d (root mean square distance) of
0.644 Å.for all 279 Cα carbons, indicating that the overall folds are highly similar.
Superposition of E. coli ΔN1N2-ThrRS with the various substrate bound structures
revealed nearly identical conformations with the exception of one region adjacent to the
aminoacylation active site (Figure 9A). As demonstrated by the threonine and AMP
bound structures, substrate binding induces the closing of a specific helix and loop
(residues 492-547 for humans and 415-469 in E. coli) into the active site as has been
previously observed (26). By comparison, borrelidin binding extrudes this helix by 14°
relative to the substrate bound conformations and opens the TARS active site even more
than the apo structure. These structural changes are consistent with the earlier intrinsic
tryptophan fluorescence data for both borrelidin and substrate binding mentioned above
since Trp434 (Trp512 in humans) is located within this region. In addition to these
conformational changes, superposition of the borrelidin-ThrRS structure with the other
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complexes also revealed substantial overlap of borrelidin with all three substrate binding
pockets, suggesting that borrelidin functions as a competitive inhibitor (Figure 9B, C).
This result is surprising, since borrelidin has been previously reported as a noncompetitive inhibitor. Nonetheless, this observation can be explained.
The structural evidence suggesting that borrelidin binds in a competitive fashion
seems to contradict earlier kinetic data indicating a non-competitive binding mode (13).
However, the misinterpretation of a competitive-binding mode as non-competitive is
common with slow, tight-binding inhibitors. Several mechanisms can contribute to the
slow-binding of a compound (reviewed in (18)). In the case of small molecule inhibitors,
these scenarios typically fit one of three descriptions: 1) the binding of the compound is
inherently slow; 2) the compound binds only one isomer of an enzyme that slowly
isomerizes in solution; or 3) the compound forms a weak initial complex and
subsequently induces a slow conformational change in the enzyme for full
accommodation. The dose-dependent effect of borrelidin, ATP, or threonine on the
intrinsic tryptophan fluorescence of E. coli ThrRS as well as the observed structural
changes within TARS upon the binding of borrelidin or substrates clearly indicate that
conformational changes are induced upon substrate or compound binding (13,24).
Therefore, model three appears to be the most relevant.
This model would suggest that borrelidin and related compounds only weakly
associate with TARS upon first encounter. In this initial phase, binding occurs under
rapid equilibrium conditions and is competitive with respect to substrates. Subsequently,
the enzyme undergoes a slow isomerization into a final, tightly-bound complex. This new
conformation precludes the binding of substrate molecules and would appear to behave
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Figure 9. Borrelidin induces conformational changes in TARS and disrupts substrate
binding.
(A) Superposition of the ΔN1N2-ThrRS-borrelidin complex (yellow) with apo- (cyan;
PDB:1EVK), threonine sulfamoyl adenylate (AMS-Thr; magenta; PDB: 1NYQ), and AMP
(PDB:1QF6) Ec ThrRS structures with focus on the substrate binding helix and loop (residues
492-547 for humans and 415-469 in E. coli). (B) Superposition of the ΔN1N2-TARS-borrelidin
and Ec ThrRS-AMS-Thr (PDB: 1NYQ) complexes revealing steric clashing between borrelidin
(green) and AMS-Thr (magenta). The true space occupancy of the borrelidin side chain is
indicated by dots. (C) Superposition of the ΔN1N2-TARS-borrelidin and Ec ThrRS- A76tRNAThr (PDB: 1QF6) complexes revealing steric clashing between borrelidin (green) and A76of tRNAThr (magenta). Borrelidin’s true space occupancy is indicated by dots.
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non-competitively (27). Owing to the pre-incubation step used in the Kiapp determination
experiments described above and in previous reports, TARS-borrelidin complexes would
be predominantly in the second binding phase at the start of these reactions. Effectively,
once in this tightly-bound phase, borrelidin titrates away free TARS, resulting in an
apparent reduction of [E]T (18). Kinetically, a decrease in [E]T manifests as a lower value
for Vmax. However, [E]T is unrelated to substrate binding affinity and would not change
the value of Km for any of the substrates. Classically, inhibitors that reduce Vmax without
affecting the Km would be characterized kinetically as non-competitive. Therefore,
borrelidin appears to be a competitive inhibitor that exhibits non-competitive
characteristics.

2.2.4 Characterizing the differences in borrelidin and BC194 binding
As mentioned above, the great toxicity of borrelidin to living cells led to the
development of less toxic derivatives, the most successful of which appears to be BC194.
Previous reports clearly indicate that BC194 exhibits significantly reduced toxicity when
compared to borrelidin (16). The physiological cause of this toxicity is linked to the
initiation of amino acid starvation responses in response to the compounds’ inhibition of
TARS aminoacylation function and will be addressed in more detail in Chapter 3.
Interestingly, borrelidin toxicity can be rescued by point mutations in the TARS enzyme,
suggesting that the observed effects of the compounds are mediated exclusively through
TARS (13). This suggests two different hypotheses to account for the differences in
toxicity between borrelidin and BC194: 1) the two compounds induce distinct
conformational changes, only one of which is associated with the toxic effects; or 2) the
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compounds have altered interactions with TARS, allowing for varying degrees of
competition with the canonical substrates. Crystallographic data would eventually
confirm the second model.
Recently the structure of the human ΔN1N2-TARS fragment was co-crystallized
with BC194 and solved by out collaborator, Min Guo, to a resolution of 2.8 Å.
Superposition of the borrelidin and BC194 TARS complexes reveals nearly identical
structure (0.62 Å r.m.s.d.) over 402 Cα’s including the retention of all macrolide
interactions (Figure 10A, B). In a global structural sense, borrelidin and BC194 act to
stabilize the same conformational state for TARS, which indicates that conformational
changes are unlikely to be responsible for variance in toxicity between the two
compounds. The loss of the methylene group from BC194’s C17 cyclobutane group
lengthens the interaction between the C17 carboxylate and the amide nitrogen of Q460 by
0.9 Å relative to the corresponding interaction in the borrelidin complex (Figure 10C).
Likewise, the Van der Waals interactions between the pendant ring and A592 are
completely lost in the BC194 structure. Interestingly, examination of the Ec ThrRS
structure co-crystallized with threonine reveals that Q460 and A592 make key hydrogenbond and hydrophobic interactions with L-threonine (Figure 10D). The loss of these
interactions in BC194 may render its interaction with TARS more susceptible to
competition with threonine and permit translation to continue over wider range of
concentrations. An important prediction of these structural studies is that borrelidin and
BC194 should exhibit differential sensitivity with respect to the inhibition of overall
translation. This hypothesis was tested by comparing the formation of luciferase in a cell
free protein synthesis system at varying concentrations of borrelidin and BC194 and
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determining the Kiapp (Figure 10E, F). Borrelidin exhibited a Kiapp of 100 nM, which is
more than half the value of 209 nM recorded with BC194. Therefore, BC194 appears to
be more susceptible to competition with threonine, allowing for translation to occur over
a broader range of the compound.
The structural and biochemical differences between borrelidin and BC194
discussed above appear to be in striking contrast to its nearly identical Kiapp obtained for
both compounds in enzymatic assays (Section 2.2.2). However, the two-phase binding
model described in Section 2.2.3 provides an explanation. Once again, the formation of
the initial encounter-complex in the first phase of binding occurs under rapid equilibrium
conditions and would be readily susceptible to competition by the canonical substrates
(27). The C17 side-chain likely contributes to the formation of this initial complex and
would be highly responsive to the structural differences between borreldin and BC194.
This would also hold true with BC196 and BC220 as well since these molecules differ
even further from borrelidin than BC194. Isomerization of the enzyme then occurs,
creating a complex with an extremely low off rate that is substantially more resistant to
substrate competition. This model also accounts for reported Kiapp values since TARS is
pre-incubated with the inhibitors prior to initiating the reaction in these enzymatic assays
and would be predominantly tied up in the stable, tight-binding mode (13,17,28). Since
this tight-binding phase consists primarily of interactions with the macrolide backbone
the affinities of borrelidin and BC194 would likely be identical at this stage. Conversely,
pre-incubation is not practical in the more complex biological approaches, such as in
vitro translation or cellular based assays, due to constant availability of substrates or
translation of new TARS. Therefore, a significant population of TARS would remain in
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Figure 10. Structure of TARS-BC194 complex.
(A) Structure superimposition of TARS-BC194 and TARS-borrelidin complexes. The protein is
shown in ribbon cartoon representation, and the bound BC194 and borrelidin are shown as pink
and blue sticks, respectively. (B) Two-dimensional scheme of TARS-BC194 interactions. Hbonding residues are shown as sticks. Hydrophobic interacting residues are shown in grey. (C)
Close up view of BC194 and borrelidin binding site residues. The five shared H-bonds are
shown as black dash lines. The 2 borrelidin-specific interactions are shown as blue dash lines,
while the corresponding distances in BC194 structure are indicated in pink. (D) Close up view
of threonine binding interactions. Interactions are shown as dashed lines. (E, F) The effects of
borrrelidin and BC194 treatment on a cell-free translation system. Rabbit reticulocyte lysate
(RRL) was incubated with 0.02 mg/ml luciferase mRNA and translation of luciferase enzyme
was quantified in a luminescence assay. Serial diluted BC194 (E) and borrelidin (F) (2.5 nM 25 µM) was added to inhibit the translation of luciferase mRNA; mean ± SEM, n=3. Data in
parts (E) and (F) were kindly provided by Min Guo, Scripps, Fl.
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the rapid-equilibrium phase and be subject to competition by threonine. Under these
conditions, borrelidin’s greater affinity would facilitate the progression of the TARSborrelidin complexes to the tight-binding phase relative to the BC194-containing
complexes.

2.2.5 Development of a Borrelidin-resistant point mutation
Early studies of borrelidin inhibition identified several naturally occurring point
mutations in E. coli ThrRS that conferred varying degrees of resistance to the compound
(13). Since the majority of borrelidin-binding interactions are maintained from E. coli to
humans it seems reasonable that similar resistance-conferring mutations could be
generated in the human enzyme. Of particular interest, the successful generation of these
mutations would be useful in subsequent investigations of borrelidin’s anti-angiogenic
mechanism. At the beginning of this dissertation work TARS was not thought to have a
role in angiogenesis; as such borrelidin’s anti-angiogenic properties were thought to be
possibly mediated through secondary targets of the compound, namely the splicing
associated factor FBP21 and the cyclin dependent kinase Cdc28/Cln2 (29-31). However,
the effects for both compounds were observed in cells at low μM concentrations (0.5-5
μM for FBP21 and about 10-50 μM for Cdc/Cln2), which is well above low nM toxicity
threshold observed for the compound and seem to be unlikely candidates for the antiangiogenic effect of the compound (16). Therefore, if a point mutation in TARS were to
confer resistance to borrelidin’s effects it would confirm the TARS dependent nature of
the interaction.
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In early efforts to identify mutations that confer borrelidin resistance, libraries of
randomly mutagenized E. coli were generated and screened for colonies resistant to
borrelidin treatment. Subsequent analyses revealed that the majority of these mutations
were associated with L489M substitution in the Ec ThrRS gene (thrS). Similar
substitutions were also generated using site-directed mutagenesis in order to further
investigate the effects of mutations within the borrelidin binding site of TARS. Notably,
the conversion of L489 to Trp conferred the greatest resistance to borrelidin, increasing
the Ki value nearly 1500-fold relative to the wildtype enzyme. Using a combination of
structural and sequence alignments L489 was found to be conserved as Leu567 in the
human enzyme. Structural data indicate that this leucine residue forms Van der Waals
contacts with the C12 nitrile of the borrelidin compound in both human and E. coli
enzymes (Figure 11A), suggesting that mutations at this site should produce similar
effects related to borrelidin binding (25). Therefore, site-directed mutagenesis was used
to generate the equivalent L567W mutation as well as the more conservative L567V.
In order to verify the resistance provided by the point mutations, the Kiapp values
were determined. Initial kinetic characterizations revealed that both mutations possessed
aminoacylation activity, albeit at very different rates. L567V TARS turned over at a rate
of 4.429 min-1, close to the 3.325 min-1 observed for the wildtype enzyme (Figure 11B).
Using the same method as the wildtype TARS above, L567V TARS possessed a Kiapp of
32.2 nM for BC194 (Figure 11C), approximately 8-fold higher than the 4.09 nM obtained
for the wildtype enzyme (Table 2). Conversely, L567W TARS catalyzed aminoacylation
at a rate of 0.2970 min-1. Owing to this much slower rate, L567W TARS activity data
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Figure 11. L567V TARS exhibits a Kiapp value greater than WT TARS.
(A) Close up of the L567 and C12 nitrile interaction in the borrelidin (yellow)-human TARS
complex. (B) Aminoacylation activity of purified WT TARS (blue), L567V TARS (red), and
L567W TARS (green) as determined by formation of Thr-tRNAThr per active site per minute;
mean ± S.D.; n=3. (C) Plots showing the fractional initial velocity of WT TARS (blue) and
L567V TARS (red) (10 nM) as a function of BC194 concentration; mean ± S.D.; n=3.

were difficult to distinguish from background radioactivity counts after the addition of
BC194 and was not used for subsequent Kiapp investigations.

75

2.3 Experimental Procedures
2.3.1 Threonyl-tRNA Synthetase Preparation
N-terminal His6-tagged human TARS was expressed and purified from E. coli
RossettaTM 2(DE3)pLysS competent cells (EMD) transformed with the plasmid pET28a
hctThrRS (provided by Dieter Söll, Yale). L567V TARS was generated using identical
procedures following QuickChange (Stratagene) site-directed mutagenesis with oliodeoxynucleotide primers from Operon. Transformant cultures were grown in terrific
broth supplemented with 100 mg/ml kanamycin and 100 mg/ml chloramphenicol at 37°C
to a cell density of A600 = 0.6. Expression of HsThrRS was induced with 1 mM isopropyl
1-thio-β-D-galactoside overnight at 15°C. The bacterial pellet was lysed by sonication in
sonication buffer (20 mM potassium phosphate buffer pH 8.0, 100 mM KCl, 35 mM
imidazole, and 5 mM β-mercaptoethanol) and cleared by centrifugation at 17050 x g for
30 minutes. Nucleic acids were precipitated by the addition of protamine sulfate to a final
concentration of 0.3% followed be centrifugation. The supernatant was loaded onto a
HisTrapTM FF column (GE Healthcare) equilibrated with sonication buffer and eluted by
an imidazole gradient of 35-250 mM over 20 column volumes. TARS containing
fractions were identified by SDS-PAGE and GelCodeTM Blue (Thermo Scientific),
pooled, and dialyzed into hydroxyapatite binding buffer (100 mM potassium phosphate
buffer pH 6.8 and 5 mM β-mercaptoethanol). The sample was loaded onto a CHTTricorn hydroxyapatite column and eluted over 20 column volumes by using a gradient
of hydroxyapatite binding buffer to 500 mM potassium phosphate pH 8.0 and 5 mM βmercaptoethanol. ThrRS containing fractions were determined by SDS-PAGE, dialyzed
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into 20 mM HEPES pH 8.0, 100 mM KCl, 5 mM β-mercaptoethanol, and 40% glycerol,
and stored at -20°C. The concentration of active sites was determined as previously
described (32).
Full-length, N-terminal 6xHis-tagged E. coli ThrRS (Ec ThrRS) was expressed
and purified from IBPC 6881 E. coli cells containing the pTetthrS plasmid through
identical procedures to those used for human TARS with minor exceptions (33).
Kanamycin and chloramphenicol were replaced by 10 μg/ml tetracycline. The protein
was purified using only the HisTrapTM FF column (GE Healthcare).
For crystallization, the N-terminal His-tagged human ΔN1N2-TARS (residues
322-723) was constructed in a PET28a vector. The protein was expressed in strain BL21
(DE3) and induced with 0.2 mM IPTG for 20 h at 16 °C. The cell pellet (from 4-8 liters)
was lysed in NTA-wash buffer (500 mM NaCl, 20 mM Tris-HCl pH 8.0, 30 mM
imidazole), loaded onto a Ni-HiTrap column and washed with NTA-wash buffer. The
protein was eluted with NTA-elution buffer (500 mM NaCl, 20 mM Tris-HCl pH 8.0,
250 mM imidazole). The eluted protein was further purified by a QAE anion exchange
column with NaCl gradient. The peak fractions of the protein were then concentrated for
crystallization.

2.3.2 tRNAThr Preparation
E. coli XL-1 Blue (Stratagene) cells expressing the plasmid pUC18hcttRNAThr-TGT
(provided by Dieter Söll, Yale), coding for human tRNAThr, were cultured in LB broth
supplemented with 100 mg/ml ampicillin at 37°C to a cell density of A600 = 0.5.
Expression of tRNAThr was induced with 1 mM isopropyl 1-thio-β-D-galactoside for 14
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hours. Bacterial pellets were resuspended in 20 mM Tris pH 7.5, 20 mM MgCl2, and 10
mM β-mercaptoethanol and extracted with water saturated phenol (pH = 4.8). The
aqueous fractions were ethanol precipitated, resuspended in 10 mM HEPES and 50%
formamide, and resolved using 8M Urea/10% polyacrylamide gel electrophoresis. The
tRNA was identified by UV shadowing, electroeluted, and ethanol precipitated. The
tRNA pellet was resuspended in 10 mM HEPES and stored at -20°C. The active
concentration of tRNAThr was determined by plateau charging assay (32).

2.3.3 Slow-Tight Binding Assay
For slow-tight binding assays reaction mixtures consisted of 1 mM ATP, 2 U/µl
pyrophosphatase (New England Biosciences), 80 µM threonine, 20 µM [14C]-threonine,
and 10 µM of human tRNAThr in Buffer A. In addition untreated reactions and nonincubated borrelidin reactions contained DMSO or 10 μM borrelidin respectively, with
the concentration of DMSO normalized to the amount present in borrelidin reactions
(about 0.00001%). These reactions were initiated with the addition of 2.5 nM Ec ThrRS
and run at 37°C. For pre-incubated borrelidin reactions, 175 nM Ec ThrRS was
incubated with 700 nM borrelidin for 30 minutes on ice. The reaction was then initiated
by adding 1 μl sample of the Ec ThrRS-borrelidin to 69 μl of reaction buffer, resulting in
a 70-fold dilution. Aliquots were taken at varying time points and spotted onto
Whatmann 3MM paper filters pre-soaked in 5% trichloroacetic acid (TCA). Filters were
washed 3 times in excess TCA, once in 95% ethanol, and dried under a heating lamp. The
formation of Thr-tRNAThr was detected by scintillation counter and the activity
determined by linear regression of threonyl-tRNAThr formed per active site per unit time.
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2.3.4 Steady-State Aminoacylation Assay
The aminoacylation activities of the various TARS constructs were determined using
modifications to established steady state aminoacylation procedures (32). Briefly,
reaction mixtures consisted of 2 mM ATP, 2 U/µl pyrophosphatase (New England
Biosciences), 160 µM threonine, 40 µM [14C]-threonine, and 10 µM of human tRNAThr
in Buffer A (20 mM HEPES pH 8.0, 100 mM KCl, 10 mM MgCl2, 5 mM βmercaptoethanol). Reactions were initiated with the addition of 100 nM TARS and run at
37°C. Aliquots were taken at varying time points and spotted onto Whatmann 3MM
paper filters pre-soaked in 5% trichloroacetic acid (TCA). Filters were washed 3 times in
excess TCA, once in 95% ethanol, and dried under a heating lamp. The formation of ThrtRNAThr was detected by scintillation counter and the activity determined by linear
regression of threonyl-tRNAThr formed per active site per unit time.

2.3.5 Kiapp Determination Assays
For Kiapp determination, reaction mixtures consisting of 2 mM ATP, 10 µM tRNA, 10 nM
TARS and various concentrations of BC194 (0 - 35 nM) in Buffer A were incubated for 3
minutes at 37°C and initiated with the addition of radio-labeled threonine (20 µM [14C]threonine and 180 µM threonine). Data collection procedures were otherwise identical to
those described for steady-state aminoacylation. Values for Kiapp were obtained by
plotting fractional velocity as a function of BC194 concentration and fitting the data to
Morrison’s quadratic equation for tight binding inhibitors (18):
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2.3.6 Crystallization and Structure Determination.
Crystallization was done by the sitting drop method. To crystallize human
TARS – BC194 complex, protein solution (10 mg/ mL) was pre-mixed with 2 mM
BC194 and 5mM L-Thr at 4 °C. The protein was then crystallized by mixing 0.5 μL of
protein solution with 0.5 μL of precipitant solution, containing 0.1 M Tris pH 8.0, and
8% PEG8000. After incubation at 18 °C for 3-7 days, the crystals were flash-frozen in
liquid nitrogen for data collection with a cryo solution consisting of 0.08M calcium
acetate, 6.4% PEG4000, and 20% glycerol. Diffraction data were obtained from the Lscat 21-ID-G beamline at the Advanced Photon Source (APS, Argonne, IL).
A dataset was integrated and scaled with HKL2000 (34). The structures were
determined by molecular replacement based on the human TARS structure (pdb: 4P3N)
in program Molrep (35). After corrections for bulk solvent and overall B values, data
were refined by iterative cycles of positional refinement and TLS refinement with
PHENIX (36) and model building with COOT (37). All current models have good
geometry and no residues are in the disallowed region of the Ramachandran plot.

2.3.7 In Vitro Translation Assay
The effects of BC194 and borrelidin on cell-free protein translation were assayed
in a rabbit reticulocyte lysate (RRL) according to the manufacturer’s instructions
(Promega), with the exceptions that no extra amino acid mix was added and 0.02 mg/ml
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firefly luciferase mRNA was used in the assays. Experiments were performed in triplicate
and fit to the Gaddum/Schild EC50 shift equation in order to determine the IC50 value:

Activity  Bottom 
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CHAPTER 3: SEPARATION OF THE TOXICITIY AND ANTI-ANGIOGENIC
EFFECTS OF BORRELIDIN AND BC194

3.1 Introduction
Aminoacyl-tRNA synthetases (ARSs) attach amino acids to their corresponding
tRNA adaptors with high specificity in an essential and early reaction of protein synthesis
(1,2). In addition to this canonical function, ARSs and ARS-related proteins exhibit
diverse alternative activities including RNA splicing, translational regulation, immune
system modulation, and angiogenesis (3-7). Recent genetic evidence has served to link
ARSs to a variety of human and murine diseases associated with the brain and the
nervous system, including Charcot-Marie Tooth disease (8,9), Type III Usher Syndrome
(10), and various encephalopathies (11,12). In several cases, these associations appear to
be linked to secondary ARS functions, potentially those most closely tied to signaling.
One secondary function with particular significance for human physiology is
angiogenesis, where multiple ARS play a variety of stimulatory and inhibitory modes.
As indicated in Chapter 1, tyrosyl-tRNA and tryptophanyl-tRNA synthetase are secreted
in response to the inflammatory cytokines TNF-α and interferon γ, respectively (6,13,14).
Fragments or splice variants of these ARSs exert opposite effects, with the YARS
fragment stimulating angiogenesis and WARS inhibiting angiogenesis. While there is
evidence to suggest that the angiostatic properties of WARS depend on direct interactions
with VE-cadherin, a role for ARSs in well-established angiogenic signaling pathways,
such as those associated with vascular endothelial growth factor (VEGF), has not been
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defined. In zebrafish, a mutations in the SARS gene encoding seryl-tRNA synthetase are
associated with altered vascular development (15,16).
The class II threonyl-tRNA synthetase (TARS) is the most recent ARS for
whom an angiogenic function has been identified, and exhibits some features that are
distinct from YARS and WARS. TARS is secreted from endothelial cells in response to
TNF-α and VEGF, and potently stimulates angiogenesis in the human umbilical vein
endothelial cell (HUVEC) tube formation and chicken chorioallantoic membrane assays
(17). The recent report of a strong association between TARS expression and advancing
stage of ovarian cancer provides evidence that the pro-angiogenic function of TARS in
angiogenesis is significant, at least in a pathophysiological context (18). An open
question is whether this pro-angiogenic function is a directly linked to the canonical
aminoacylation function, or is instead an as yet undetermined secondary function.
Moreover, the role of TARS in normal vascular development in metazoans, if any,
remains to be determined.
Insights into the pro-angiogenic properties of TARS are provided by the
characterization of its potent inhibitor borrelidin. Previously, several point mutations
within the borrelidin binding site of TARS were shown to confer resistance to the
compound, with the greatest difference resulting from the substitution of L489 (E. coli
numbering) with a tryptophan (19). The crystallographic data presented in Chapter 2
provide an explanation for this dramatic change in affinity as this modification would
disrupt a key interaction with borrelidin’s essential nitrile group (20). L489 is conserved
from E. coli to humans in the form of L567 indicating that similar mutations could be
generated in the human enzyme (see Chapter 2, section 2.2.5). Interestingly, the
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substitution of L567 with valine in the human TARS enzyme was found to block the
angiogenesis inhibiting properties of BC194. These data provide strong evidence that
borrelidin and related compounds inhibit angiogenesis specifically through interaction
with TARS in in vitro assays (21).
The anti-angiogenic properties of borrelidin provide an opportunity for its use as
an anti-metastatic agent (22). However, borrelidin has yet to be exploited clinically,
owing to its cytotoxicity to normal epithelial cells at nanomolar concentrations (23).
Several derivatives of borrelidin have since been developed through the biosynthetic
engineering of bor gene cluster in attempt to alleviate this toxicity (20). Of particular
interest is the derivative BC194 (Figure 5, Chapter 2) which possesses equipotent
inhibition of TARS relative to borrelidin in enzymatic assays (Ki of 4.09 nM for
aminoacylation) and a nearly identical structure to borrelidin save for the elimination of a
single methylene group in the C17 pendent chain (21). Despite its similar properties,
BC194 exhibits greatly reduced toxicity relative to borrelidin while still maintaining
function as an anti-angiogenic compound (20).
Recent work has also demonstrated that the toxic effects are due to the induction
of the general control nonderepressible 2 kinase (GCN2) based amino acid starvation and
is mechanistically distinct from the anti-angiogenic effects (21). The reduction of
aminoacylation activity resulting from ARS inhibitors or amino acid deprivation
increases the intracellular concentration of uncharged-tRNA. These molecules then
associate with GCN2, stimulating its dimerization and auto-phosphorylation activity.
Active GCN2 then phosphorylates the guanine nucleotide cycling protein, eukaryotic
translational initiation factor 2α (eIF2α), locking it in its GDP-bound conformation
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(GDP-eIF2α) (24). Similar phosphorylation of eIF2α is also observed following the
activation of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) by ER
stress and the unfolded protein response (25,26). GDP-eIF2α inhibits translation of
mRNA by blocking Met-tRNA initiator tRNA with the exception of select transcripts
involved in stress response pathways (27). Specifically, GDP-eIF2α encourages the
translation of activating transcription factor 4 (ATF4), a transcription factor that upregulates the expression of cell survival genes, such as VEGFA, (C/EβP) homology
protein (CHOP), and other autophagy associated genes (28-30).
The differences in toxicity between BC194 and borrelidin are shown to originate
from their varying ability to elicit the amino acid starvation response, yet both
compounds exhibit equal potency in blocking angiogenesis. Characterization of the
molecular basis of this difference opens the door to potential exploitation of these
compounds in a clinical setting, such as in the therapeutic inhibition of angiogenesis.
Here, we demonstrate that the differences in toxicity between BC194 and borrelidin are
shown to originate from their varying ability to elicit the amino acid starvation response,
while their inhibition of angiogenesis occurs through a yet undetermined mechanism.
Finally, we compare the effects of borrelidin derivatives on vascular development in the
zebrafish, and provide direct evidence for the role of TARS in angiogenesis in vivo.

3.2 Results
3.2.1 Borrelidin mediated amino acid starvation elicits cell cycle arrest
Borrelidin and BC194 were previously shown to exhibit significant differences in
their toxicity to endothelial cells (20). However, the molecular basis for these effects has
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Figure 12. Borrelidin elicits toxic responses related to cell cycle progression in
endothelial cells at lower concentrations than BC194.
(A) Cell-cycle analysis of synchronized HUVECs treated with serum containing borrelidin
or BC194 using flow cytometry. (B) Percentage of cells in G2/M phase following treatment
with borrelidin or BC194. HUVEC cells were treated with 10 nM borrelidin or BC194,
harvested at 0, 8, 16, and 24 h, and stained with propidium iodide. The cells in G2/M were
determined by gating using the 16h serum control; mean ± SEM, n=3, *p<0.05 (one-way
ANOVA, Tukey Test). (C) The effects of borrelidin and BC194 on HUVEC proliferation.
Cells were exposed to the indicated concentrations of compounds for 48 h and the relative
proliferation measured using an alamarBlue® assay.

not been established. To better understand the physiological consequences of borrelidin
and BC194, we compared their effects on HUVEC cell-cycle progression using flow
cytometry (Figure 12A, B). Treatment with 10 nM borrelidin arrested cells at the G0
boundary, delaying progression into G2/M up to 24 h. In contrast, cells treated with 10
nM BC194 did not significantly deviate from serum treated controls, and entered the
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G2/M phase 16 h following serum exposure (Figure 12B). The effects of borrelidin and
BC194 on HUVEC proliferation were subsequently investigated using an alamarBlue®
based assay (Figure 12C). Reductions in cell proliferation were observed at
concentrations as low as 10 nM for borrelidin, whereas a 10-fold higher concentration of
BC194 was required for a comparable decrease in cell proliferation. These observations
suggest that a major component of borrelidin’s toxicity is its ability to block progression
through the cell cycle.
The observed differences in the ability of two compounds to induce cell cycle
arrest may arise from variations in their ability to induce amino acid starvation. The
amino acid starvation (AAS) response is typically detected as increased phosphorylation
of the translational initiation factor eIF2α, which results from activation of the GCN2
translational control kinase (31). Previously, borrelidin treatment was demonstrated to derepress expression of amino acid biosynthetic genes in yeast, a signature of GCN2
activity (32). Particularly when coupled to the unfolded protein response, amino acid
starvation leads to cell cycle arrest and, in severe cases, the initiation of apoptosis
(24,33,34). To confirm that the anti-proliferative effects of borrelidin are linked to AAS
pathways in animal cells, cultured HUVECs were exposed to increasing amounts of
borrelidin or BC194, and then lysates from these cultures were probed for the starvation
and apoptosis markers phospo-eIF2α and cleaved-caspase 3, respectively (Figure 13A,
D). The phosphorylation of eIF2α was induced at concentrations as low as 10 nM
borrelidin (Figure 13B) but at least 10-fold higher concentrations of BC194 were required
to generate an equivalent response (Figure 13E). Likewise, the appearance of cleavedcaspase 3 at 100 nM borrelidin (Figure 13C) compared to 1000 nM for BC194 (Figure
91

Figure 13. The cytotoxicity of borrelidin is linked to the induction of the amino acid
starvation response.
(A-F) HUVEC cells grown in full serum media were exposed to the indicated concentrations
of borrelidin (A-C) or BC194 (D-F). Western blots of cell extracts were analyzed using
antibodies recognizing phospo-eIF2α and cleaved-caspase 3 with β-tubulin as a loading
control. Quantification of phospho-eIF2α and cleaved-caspase 3 for borrelidin (B, C) and
BC194 (E, F) relative to β-tubulin; mean ± SEM, n≥3, *p<0.05 relative to 0 nM (one-way
ANOVA, Tukey Test). #, Owing to the high variance at 1000 nM borrelidin resulting from
extensive apoptosis and cell death, the extent of eIF2α phosphorylation could not be reliably
quantitated. (G, H) Quantification of eif2α amounts relative to β-tubulin for both borrelidinand BC194-treated cells (100 nM) in the presence of various threonine concentrations (0-10
mM); mean ± SEM, n≥3, *p<0.05 relative to 0 mM threonine (one-way ANOVA, Tukey
Test), #p<0.01 between compounds at same threonine concentration (two-way ANOVA,
Sidak Test).

13F) demonstrates the greater potency of borrelidin relative to BC194 in inducing
apoptosis. These experiments underscore the existence of a critical concentration in the
range of 10-100 nM where borrelidin elicits AAS, and BC194 does not.
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An important prediction of the structural and cell free protein synthesis studies in
Chapter 2, section 2.2.4, is that borrelidin and BC194 should exhibit differential
sensitivity with respect to the ability of threonine to rescue compound-induced amino
acid starvation. Significantly, when threonine was added at concentrations between 2.510 mM to HUVECs treated with 100 nM BC194, the phosphorylation of eIF2α was
decreased to untreated levels (Figure 13G, H). By contrast, cells treated with 100 nM
borrelidin still exhibited substantial levels of phospho-eIF2α over this same range of
threonine concentrations. Thus, the combined structural and biochemical analysis
suggests that the reduced ability of BC194 to inhibit protein synthesis attenuates its
induction of amino acid starvation in HUVECs, thereby reducing its toxicity in growth
and proliferation assays.
As an additional control to demonstrate that borrelidin induced amino acid
starvation response is directly linked to TARS inhibition, HUVECs were incubated with
a third compound, BC220, which is structurally distinguished from borrelidin by a 3ethyl piperidine group that is esterified to the cyclopentane carboxylic acid moiety
(Chapter 2, section 2.2.2). The Ki for inhibition of TARS aminoacylation by BC220 is
greater than 10 μM (35). HUVECs exposed to BC220 showed no induction of eIF2α
phosphorylation or cleavage of caspase 3 (Figure 14A-C), indicating that the lack of
physiological response is highly correlated with its failure to inhibit TARS. In summary,
the combined results with all three compounds demonstrate that the cytotoxicity of
borrelidin activation is linked to the activation of the amino acid starvation response and
resultant apoptosis, which originates from inhibition of TARS.
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Figure 14. BC220 does not induce amino acid starvation toxicity responses.
(A-C) Western blots of cell extracts exposed to BC220 at the indicated concentrations using
antibodies against phospho-eif2α and cleaved-caspase 3 (A). Thapsigargin (Th; 1 µg/ml)
was used as a positive control for amino acid starvation. Protein values for phospho-eif2α
(B) and cleaved-caspase 3 (C) were quantified relative to the β-tubulin loading control;
mean ± SEM, n≥3, *p<0.0001 relative to 0 nM (one-way ANOVA, Tukey Test).

3.2.2 Borrelidin and BC194 exhibit comparable inhibition of angiogenesis at subtoxic levels.
Previous studies indicate that borrelidin and BC194 are both potent inhibitors of
angiogenesis (20,22,36). One potential explanation of the anti-angiogenic effect is that it
is a direct consequence of the induction of the amino acid starvation response in
endothelial cells, leading to their self-destruction through apoptosis. To test this
hypothesis, we compared the ability of all three macrolides to inhibit HUVEC branching
at sub-toxic concentrations in the endothelial tube formation assay (Figure 15A, B).
Significant decreases in branch formation were observed for both borrelidin and BC194
relative to uninhibited conditions at concentrations as low as 1 nM, which is 10- and 100fold below the lowest borrelidin and BC194 concentrations demonstrated to induce eIF2α
phosphorylation. In contrast, exposure to BC220 at these same concentrations had no
effect on tube formation (Figure 15A). Borrelidin and BC194 thus exhibit comparable
potencies in inhibiting angiogenesis, despite the fact that 10-100-fold higher
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concentrations of BC194 are required to produce the levels of cellular toxicity seen with
borrelidin.

Figure 15. Borrelidin and BC194 exhibit comparable inhibition of angiogenesis at subtoxic levels in HUVEC tube formation assays.
(A) Quantification of HUVEC branching at varying concentrations of borrelidin, BC194, and
BC220. HUVECs were plated on Matrigel in full EGM-2 (2% FBS) media and exposed to the
indicated concentrations of compounds. Cells were fixed after 4-8 h and stained with Oregon
Green 488 Phalloidin. Numbers represent percentage of control (0 nM) samples, mean ±
SEM, n=3 *p<0.05 relative to 0 nM (one-way ANOVA, Tukey Test for each compounds).
(B) Representative images of HUVEC branches for section A.
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We extended these results by using the chorioallantoic membrane (CAM) assay
(Figure 16A, B), which monitors basal vessel formation in the fertilized chicken egg and
thus more closely approximates in vivo angiogenesis, relative to the simple HUVEC tube
formation assay. As shown in Figure 4A, recurring administration of borrelidin or BC194
to CAMs at concentrations of 10 nM and 1 µM over a 72 h period inhibited basal vessel
formation relative to the PBS control. Similar to the HUVEC tube formation assays,
borrelidin and BC194 exhibited comparable potencies at concentrations in the range of 110 nM. At substantially higher concentrations (100 µM), necrosis was clearly evident in
the borrelidin treated CAMs, but not those treated with BC194 (Figure 16B). These
observations demonstrate that BC194 appears to retain all of the potency of borrelidin in
the inhibition of angiogenesis, while exhibiting substantially less cytotoxicity. We

Figure 16. Borrelidin and BC194 exhibit comparable inhibition of angiogenesis at sub-toxic
levels in chorioallantoic membrane assays.
(A) The effects of borrelidin (BN) and BC194 on in vivo angiogenesis in a CAM assay. Fertilized
chicken embryos were cultured ex-ova for 10 days after which compounds at the indicated
concentrations were applied to gelform sponges on the CAM. Images were taken daily over 72 h
and quantified as the change in vascularity score over this entire period; mean ± SEM, n≥12,
*p<0.05 relative to PBS (one-way ANOVA, Tukey Test). (B) Representative images of CAM
over time for BN and BC194 at 100 µM.
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conclude that the inhibition of angiogenesis by borrelidin is therefore not dependent on
the induction of apoptosis in HUVECs, and is more likely to be linked to a TARSspecific property that is distinct from induction of the AAS.

Figure 17. Borrelidin and BC194 treatment influences cell migration and cell-cell contacts.
(A) Representative images of HUVEC cells in the donut migration assay. Upper panels- Images
of Hoechst 33342-labeled HUVEC cells 0, 5, and 24 h after removal of PDMS gasket. Lower
panels - Images of cells outside the original PDMS gasket boundary after 5 and 24 h using cell
subtraction. (B) Quantification of migrated cells exposed to 5 or 25 nM BC194 after 5 and 24 h
in the donut assay. HUVEC monolayers were cultured overnight in a 2 mm diameter, circular
gasket. The gasket was removed and the cells treated with media containing the indicated
concentrations of compound. Images were taken after 5 and 24 h and the number of cells outside
the original 2 mm diameter region were counted; mean ± SEM, n≥6, *p<0.01 relative to DMSO
of same time point (one-way ANOVA, Tukey Test). (C) Image of cells at the leading edge of the
migratory boundary after 24 h exposure to DMSO (left) or 25 nM BC194 (right).
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In a previous study, exposure of HUVEC cultures to exogenous TARS in
transwell migration assays was found to increase cell migration, an important component
in angiogenesis (17). These observations complemented an earlier study showing that
borrelidin inhibits tumor cell migration (37). To explore this observation further, the
effect of BC194 on cell migration was examined using a donut migration assay (Figure
17A-C) (38). In this assay, endothelial cells are confined by a cloning ring on a
fibronectin-coated dish, and then cells that migrate after ring removal are quantified by
image subtraction (Figure 17A). The number of migratory cells was significantly lower
in cultures treated with 5 nM BC194 for 5 h and 25 nM BC194 for either 5 or 24 h,
relative to untreated cells (Figure 17B). Interestingly, close inspection of the cells at the
leading edge of each sample reveals a marked decrease in cell-cell contacts in samples
exposed to DMSO relative to 25 nM BC194 (Figure 17C). These data suggest that the
slow migration may be, in part, due to the retention of cell-cell adhesion molecules in
BC194-treated cells. These observations demonstrate that for borrelidin and BC194, the
inhibition of angiogenesis and the inhibition of migration are correlated to each other, but
not to the ability to induce amino acid starvation and apoptosis.

3.2.3 BC194 induces specific ectopic blood vessel formation in zebrafish without the
developmental toxicity associated with borrelidin.
Close inspection of the surface vessels proximal to the borrelidin or BC194
applied to the CAM assay revealed several instances of abrupt directional changes during
vessel migration (Figure 18A). Moreover, these directional changes often came in sets of
three, potentially corresponding to three cycles of compound addition and clearance over
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the 72-hour period. An attractive hypothesis is that the macrolide compounds elicit their
anti-angiogenic effects by confounding TARS-dependent vessel guidance signals,
resulting in an irregular vascular architecture.
In order to investigate the effects of anti-TARS macrolides on vessel development
in a whole animal model, we exposed transgenic zebrafish embryos derived from the
Tg(flk: eGFP) or Tg(flk: dsRed) lines at 13-15 h post fertilization (hpf) to a range of
concentrations of borrelidin, BC194, and BC220. After 30 h of compound exposure (~48
hpf), significant changes in gross morphology were observed in embryos exposed to
borrelidin (left column) but not BC194 (middle column) or BC220 (right column) (Figure
18B). A more quantitative assessment of treatment toxicity was obtained through
measurements of body length (Figure 18C) and heart rate (Figure 18D). Significant intragroup changes were observed for fish treated with either borrelidin or BC194, but not
BC220. However, inter-group analyses revealed that reductions in heart rate and body
length were more characteristic of borrelidin-treated than BC194-treated embryos.
To assess the angiogenesis-related effects of these compounds, we screened for
aberrancies in the development of trunk inter-segmental vessels (ISVs) by fluorescence
microscopy following exposure to 5 µM concentrations of the macrolides (Figure 19A).
Significant patterning defects were observed in response to either borrelidin or BC194
treatment. Ectopic branches were readily formed in the ISVs of embryos exposed to 5
µM BC194 for 48 h (72 hpf), but not in those of borrelidin-treated embryos (Figure 19B).
By contrast, the ISVs in borrelidin-exposed fish were often truncated or incomplete at
both 48 and 72 hpf (Figure 19C). Significantly, these effects were not observed when
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Figure 18. Borrelidin and BC194 exhibit different effects on zebrafish toxicity.
(A) Representative CAM images showing rapid changes in vessel directionality, indicated
by black arrows, before and after 72 hour treatment with 1 µM borrelidin and BC194. (B)
Whole body images of ~48 hpf zebrafish embryos treated with various concentrations of
borrelidin, BC194, and BC220 for 24 h. The DMSO vehicle was standardized for each
sample. (C, D) Histograms showing the effects of borrelidin, BC194, and BC220 exposure
on zebrafish body length (C) and heart rate (D). Dechorionated embryos were incubated for
24 hours in egg water containing the indicated compounds. Body length measurements
were obtained by analysis of bright-field images using Spot v 5.1 software; mean ± SEM,
n=11, *p<0.05 relative to 0 nM (one-way ANOVA, Tukey Test). Heart rates were
determined using bright-field microscopy to count heart beats over 15 second intervals;
mean ± SEM, n=16, *p<0.05 relative to 0 nM (one-way ANOVA, Tukey Test).
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Figure 19. Exposure to Borrelidin and BC194 results in vascular defects and mispatterning.
(A) Representative confocal images (20x magnification) of zebrafish ISVs at 48 and 72 hpf.
Zebrafish embryos were incubated in egg water at 25 °C until 8-12 somites of age. The
embryos were then manually dechorionated and incubated in egg water containing the
indicated compounds at 28.5°C until the images were taken. Calibration bar represents 100
µm. (B, C) Quantification of ectopic branching (B) and aberrant patterning (C) of ISVs.
Embryos were incubated with the indicated compounds (5 µM) or DMSO until images were
taken by fluorescent microscopy at 48 and 72 hpf. Aberrant structures were then counted
within a region encompassing 5 ISVs anterior and posterior from the end of the yolk
extension; mean ± SEM, n≥8, #*p<0.0001 relative to DMSO at 48 and 72 hpf respectively
(one-way ANOVA, Tukey Test). § Borrelidin-treated fish rarely survived to 72 hpf.
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embryos were treated with either DMSO or BC220 (Figure 19A-C).
One explanation for the diminished toxicity of BC194 relative to borrelidin is
that, as seen with in animal cell culture, BC194 has a reduced ability to induce amino
acid starvation in the context of a whole animal model. To test this hypothesis,
quantitative real time PCR was performed on total RNA prepared from embryos treated
with equivalent (5 µM) concentrations of borrelidin, BC194, and BC220, and the DMSO
vehicle. The ATF4 target genes asns, gpt2, and eif4ebp1 served as AAS markers in this
experiment (24). Consistent with our model, borrelidin caused a significant increase in
the expression of the markers asns and gpt2 but not BC194 (Figure 20). This experiment
demonstrates BC194’s induction of ectopic ISV formation in the zebrafish is not a direct
consequence of the induction of the amino acid starvation response.

Figure 20. The vascular defects and mis-patterning resulting from BC194 treatment
is not due to the induction of amino acid starvation.
RT-qPCR values for the expression amino acid starvation response genes asns, gpt2, and
eif4ebp1. Dechorionated embryos (15 hpf) were incubated in egg water containing the
indicated compounds for 24 hours. Total RNA was extracted by trizol/chloroform and the
expression levels relative to actb were determined using the ΔΔCT method; mean ± SEM,
n=3, ****p<0.0001 relative to DMSO (two-way ANOVA, Tukey Test).
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In addition to faulty vessel patterning, a reduction in vessel lumen formation was
also observed in embryos treated with either 5 µM borrelidin or BC194 for 24 h (48 hpf)
and remained partially incomplete even at 72 hpf. This observation was confirmed by live
videos of blood flow in trunk vessels of 72 hpf embryos treated with BC194 or DMSO.
No restriction of blood flow was observed in ISVs of DMSO-treated fish (Video 1)
consistent with fluorescent images showing well-defined lumens (Figure 21A). In
contrast, several ISVs in embryos treated with 5 µM BC194 were non-functional in terms
of blood flow (Video 2) and appeared to correspond to vessels associated with ectopic
branches and poorly-defined lumens (Figure 21B).

Figure 21. Treatment with BC194 inhibits blood-flow through zebrafish ISVs.
(A, B) Still frame image from videos of trunk blood flow in 72 hpf zebrafish embryos (left)
and fluorescence image of blood vessels (right) treated with DMSO (A) or 5 µM BC194 (B)
for 48 h. Non-functioning lumens and ectopic branches are designated with black arrows and
asterisks respectively. See also associated Videos 1 and 2.
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3.2.4 The effects of borrelidin and derivatives on gene expression of endothelial cell
migration associated genes.
The results of the prior experiments argue that the faulty patterning and reduction
in vessel lumen formation seen with BC194 in the zebrafish originate from a TARS
function distinct from the canonical role in protein synthesis. To obtain further insights
into the role of TARS in angiogenesis, we investigated the effects of borrelidin, BC194,
and BC220 on the expression of tars, vegfaa, and the downstream Notch-reporter genes
ephrinb2a and heyL, in the zebrafish that are either known to be or hypothesized to be

Figure 22. Borrelidin and BC194 treatment affects gene expression.
(A-D) RT-qPCR values for the expression of tars (A), vegfaa (B), ephrinb2a (C), and heyL
(D) at 48 and 72 hpf. Dechorionated embryos (15 hpf) were incubated in egg water
containing the indicated compounds. Total RNA was extracted by trizol/chloroform and the
expression levels relative to actb were determined using the ΔΔCT method; mean ± SEM,
n=3, #*p<0.05 relative to DMSO at 48 and 72 hpf respectively (one-way ANOVA, Tukey
Test). § denotes that borrelidin-treated embryos rarely survived to 72 hpf and were not
included in this figure.
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related to vascular development and branching. Quantitative real time PCR (RT-qPCR)
of total embryo RNA revealed significant increases in the expression of both tars and
vegfaa (Figure 22A, B) mRNA after exposure for 24 hours with borrelidin (48 hpf) or 48
hours with BC194 (72 hpf). No changes in gene expression were observed for embryos
treated with either DMSO or BC220, consistent with our TARS-dependent nature of our
current model for borrelidin and BC194 action. Interestingly, the notch reporter genes
showed no change over any of the tested conditions (Figure 22C, D).

3.3 Discussion
Natural product and synthetic inhibitors have been identified for many ARSs, and
readily exploited to generate anti-microbial infectives (39,40), immunosuppressive agents
(24,41), and potential modulators of cancer metastasis (42). However, many natural
compounds that target ARSs have a very narrow therapeutic index, dramatically limiting
their clinical usefulness. The toxicity seen in many cases may reflect the acute sensitivity
of animal cells to the inhibition of protein synthesis, which can arrest the cell cycle and
elicit apoptosis (24,33).
Borrelidin’s pleiotropic effects on mammalian cell physiology have been
appreciated for decades, but the molecular basis of its action or that of related compounds
has been poorly understood (20). Here, a chemical and structural biology approach was
used to compare the effects of borrelidin and two different derivatives, and gain insights
into their ability to inhibit angiogenesis. Significantly, the cytotoxicity of borrelidin was
found to originate from its induction of amino acid starvation, which leads to cell cycle
arrest and apoptosis. The ability of borrelidin to induce amino acid starvation in yeast
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was reported earlier (32). In animal cells, amino acid starvation induces the expression of
the CCAAT/enhancer binding protein homology binding protein (CHOP), a transcription
factor that stimulates apoptosis after prolonged nutritional deprivation (43). Not
surprisingly, borrelidin is a potent inducer of apoptosis in acute lymphoblastic leukemia
cells (44). These studies therefore support a strong linkage between the ability of a given
aminoacyl-tRNA synthetase inhibitor to induce the amino acid starvation response and its
potency with respect to apoptosis and cell killing. Conversely, the inhibition of
angiogenesis was observed at sub-toxic concentrations for both borrelidin and BC194,
suggesting that the compounds’ inhibition of angiogenesis is mediated through a
mechanism distinct from the induction of amino acid starvation.

3.3.1 The greater toxicity exhibited by borrelidin relative to BC194 is due to its
decreased susceptibility to threonine competition.
The major structural difference between the two TARS macrolide complexes is
that significantly weaker interactions with critical residues constituting the threonine
binding pocket (45,46) were observed in the BC194 complex (Chapter 2). Despite this
structural change, BC194’s potency as an inhibitor of angiogenesis is undiminished. One
hypothesis is that the inhibition of angiogenesis depends on the ability of borrelidin and
BC194 to stabilize a TARS conformation that is distinct from unliganded and substrate
bound states (Chapter 2, Figure 9). Such a model would be consistent with the
observation that the stimulation of angiogenesis depends on the structural integrity of the
catalytic domain, and its potential to associate with additional protein partners (see
Appendix I for investigations of TARS binding partners). Initially, however, this model
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may appear contradictory, given that BC194’s weaker interaction with the TARS enzyme
would also be expected to disrupt its ability to inhibit angiogenesis as well. The
resistance conferred by L567V TARS against BC194’s anti-angiogenic effects in CAM
assays argues against a second borrelidin binding site within the TARS enzyme (21).
However, the two-part binding mechanism of borrelidin and its related compounds
presented in Chapter 2 may provide an alternative explanation.
Upon first encounter BC194 forms a weaker complex with TARS relative to
borrelidin, accounting for its increased susceptibility to threonine competition (Figure 13
G, H). However, as demonstrated by enzymatic assays (Chapter 2, section 2.2.2), the
binding affinity for the second, tighter interaction between TARS and either inhibitor is
nearly identical. As such, compound toxicity appears to be associated with the weak
encounter complex while the anti-angiogenic effects are related to the tight-binding
mode. Considering also that TARS appears to mediate angiogenesis extracellularly while
performing aminoacylation within the cell, the concentrations of threonine must be
considered in both compartments (21). Notably, intracellular concentrations of threonine
are significantly higher than those outside the cell, indicating that competition between
the amino acid and the compounds would be reduced in the regulation of angiogenesis in
comparison to aminoacylation (47). As an alternative mechanism, full incorporation of
borrelidin or BC194 into the TARS active site is characterized by a very slow off rate
(19). Moreover, despite the increased susceptibility of BC194 to threonine competition
relative to borrelidin in the compound’s initial encounter with TARS, borrelidin and
BC194 exhibit nearly identical final values for Kiapp. Therefore, both inhibitors may
eventually proceed to a tightly bound complex but the greater activation energy
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associated with BC194 binding at equimolar concentrations of threonine will reduce its
rate of complex formation relative to that of borrelidin (48). Under these circumstances,
compensatory mechanisms, such as the synthesis of new TARS, may be able to rescue
the cell from the toxicity associated with the slower-binding BC194 but not borrelidin.
However, as both compounds eventually develop a full set of interactions with the TARS
active site, they would still be able to induce the necessary changes to inhibit
angiogenesis.

3.3.2 Borrelidin compounds influence blood vessel maturation and migration in
zebrafish.
A major finding of this study is that the reduction of TARS activity via borrelidin
or BC194 administration produced phenotypes associated with incomplete vessel
development, increased ectopic branching, and decreased vessel lumens (Figure 19, 21
Videos 1, 2). This represents the first demonstration of a role for TARS as a proangiogenic factor in a whole organism model. Yet treatment with BC194 also increased
expression of TARS (Figure 22A), an observation reminiscent of the response of CHO
cells to persistent exposure to borrelidin (49). In view of the relatively high macrolide
concentrations employed (i.e. several orders of magnitude over the apparent Ki), the
increased TARS protein levels resulting from BC194 administration might effectively be
masked by the stoichiometric formation of TARS-BC194 complexes, which are
characterized by very slow off rates (19). Alternatively, the disruption in TARS levels
resulting from BC194 treatment could alter a TARS-dependent concentration gradient
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that is necessary for proper guidance and patterning of the developing vasculature
(17,50,51).
Along these lines, endothelial cells treated with BC194 showed a higher degree of
cell-cell contacts relative to controls, even at the leading edge of a migratory boundary
(Figure 17C). Weakened cell-cell contacts have been proposed to be an important
component of angiogenesis (52). Inhibition of tyrosine phosphorylation on VE-cadherin,
which alters cell-cell interactions, decreases VEGF-mediated migration and angiogenesis
in cell culture (53). Furthermore, certain models of lumenogenesis involve the strictly
regulated disruption of contacts between endothelial cells of the developing vessel (54).
Borrelidin and related macrolide compounds may act to disrupt TARS-mediated
regulation of cell-adhesion proteins, thereby preventing both migration and proper
vascular development (37). The availability of specific inhibitory compounds and TARS
variants that ablate its angiogenic function should prove to be valuable tools to critically
test this hypothesis. The actions of borrelidin and BC194 can be ablated by single residue
substitutions in the E. coli ThrRS (19), and TARS active sites (17), respectively (17,19),
arguing against the previous suggestion that borrelidin binding to other secondary targets
is physiologically significant in the inhibition of angiogenesis (36). Structural analysis of
the ThrRS-borrelidin complex (see Chapter 2, section 2.2.3) suggests that the inhibition
mechanisms of borrelidin and BC194 involve occlusion of the binding sites for one or
more of the canonical aminoacylation substrates (55). Borrelidin is a slow tight binding
inhibitor that competes with amino acid substrate binding, accounting for the potent
stimulation of amino acid starvation (19).
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Unfortunately, the above observations do not provide a direct mechanism through
which TARS and borrelidin-based compounds influence angiogenesis. Early reports
suggested that apoptosis of endothelial cells could contribute to the reduction in
angiogenesis (56). While the impact of this phenomenon cannot be completely ruled out,
it is complicated by a lack of specificity to a single cell type (23,57). Furthermore, the
above data clearly indicate that anti-angiogenic effects of the compounds are observable
at concentrations that do not induce amino acid starvation, suggesting that another
mechanism is required to explain the relationship between TARS and borrelidin in
angiogenesis.

3.4 Experimental Procedures
3.4.1 Cell Culture and Reagents
Human umbilical endothelial cells (HUVECs) were maintained in Clonetics
EGM®-2 complete media (Lonza) and used between passages 5 to 8. Borrelidin and
BC194 were obtained from Biotica (now Isomerase Therapeutics Ltd (Cambridge, UK)).

3.4.2 Flow Cytometry
HUVECs were plated onto 10 cm dishes and serum starved in 0.5% FBS EGM®2 media for 24 h. Cells were pre-treated with 10 nM borrelidin or BC194 for 6 h. To
assess the serum-induced cell cycle entry, full serum media (EGM®-2 complete media)
was added at staggered times, such that all samples were collected simultaneously for the
8 h, 16 h and 24 h time points. Cells were trypsinized, washed and fixed in 80% ethanol,
washed in 2% BSA and then incubated with a solution containing 10 μg/ml propidium
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iodide (PI) and 250 μg/ml RNAse A for 16 h as in (58). Analysis of the PI signal (620
nm) was performed on an EPICS XL four-color analytical flow cytometer coupled with
EXPO32 ADC software.

3.4.3 Endothelial Cell Proliferation Assay
The MTT-based alamarBlue® (Invitrogen) reagent was used to assess cell
proliferation (59). HUVECs were seeded in a 96-well dish (1x103 cells/well) and grown
for 48 h in EGM®-2 media. Cells were incubated with borrelidin or BC194 (0.1-1000
nM) as indicated; media alone served as the control. After 48 h in culture, 10 µl/well
premixed alamarBlue® was added and after 3 h at 37ºC the amount of reduced
alamarBlue® was quantified by fluorescence (excitation at 530 nm, emission at 590 nm)
on a microplate reader (Synergy™ HT, BioTek). Values were graphed as % Control
compared with media alone.

3.4.4 Western Blotting
HUVEC cells were seeded into 6-well dishes and incubated at 37 °C in EGM-2
media with 2% FBS. When cells had reached 95-100% confluence the media was
exchanged and the cultures were incubated with various concentrations of borrelidin,
BC194, BC220, and DMSO for 24 h. For threonine rescue experiments, 2.5 to 10 mM
threonine was also added to the cultures. Cell monolayers were washed with PBS and
harvested using CellLyticTM M cell lysis reagent (Sigma) supplemented with complete
Mini protease inhibitor tablets (Roche) according to the manufacturer’s instructions. For
the thapsigargin control, the media was exchanged at the same time as for the borrelidin
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compounds, but 1 µg/ml thapsigargin (Sigma) was not added until 1 h before harvesting.
Lysate protein concentrations were determined using Quick StartTM Bradford Reagent
(Bio-Rad) and stored at -80 °C until used. Lysates were resolved by 10% SDS-PAGE and
transferred to nitrocellulose membranes for Western blot analysis. Primary antibodies for
phospo-eif2α, cleaved-caspase 3, and β-tubulin were purchased from Cell Signaling and
used at 1:1000. The secondary antibody, HRP-goat-anti-rabbit IgG (Santa Cruz), was
used at 1:5000. Bands were detected by X-ray film or the VersaDoc 4000 MP (BioRad)
using Pierce ECL blotting substrate or Supersignal West Femto reagent (Pierce) as
needed. Densitometric values were determined using ImageJ software lane analysis tools
(http://imagej.nih.gov/ij/; W. Rasband, NIH).

3.4.5 In vitro Tube Formation Assay
Tube formation assays were performed as previously described (17,60). Briefly
HUVEC cells were cultured until 95-100% confluent and seeded in to 48-well plates
coated with MatrigelTM (BD Biosciences). Cells were incubated at 37 °C in EGM®-2
media (Lonza) with 2% FBS and various concentrations of borrelidin, BC194, or BC220
for 4 to 8 h. Cells were fixed with 10% neutral buffered formalin, stained with Oregon
Green 488 phalloidin (Molecular Probes), and imaged via fluorescence microscopy. Tube
structures were quantified using the Simple Neurite Tracer plug-in on ImageJ software
(NIH).

3.4.6 Chick Chorioallantoic Membrane Assay
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CAM assays were performed as previously described (17). Briefly, embryos from
fertilized chicken eggs (Sunrise Farms, Catskill, NY) were cultured ex-ova in 10 cm2
tissue culture dishes at 37°C until developmental day 10. Surgical sponges (Surgifoam)
approximately 1 mm3 were then arranged within the outer third of the membrane
avoiding major vessels. Compounds in 10 µl volumes were applied directly to the
sponges at 24 h intervals over the course of 72 h. Images were taken daily using a Leica
MZ6 stereomicroscope and scored using modified Intensity Scoring described previously
(61).

3.4.7 Cell Migration Assay
The donut cell migration assay was performed as previously described (38).
Briefly, polydimethylsiloxane (PDMS) donut-shaped gaskets were placed on fibronectin
(BD Biosciences) -coated glass coverslips to form a 2mm-diameter culture well into
which 8x103 HUVECs were seeded and allowed to adhere overnight. After removal of
the gaskets, the circular HUVEC monolayers were washed twice with complete media to
remove non-adherent cells, nuclei were labeled by incubation with Hoechst 33342 for 15
min, and the monolayers were re-fed with complete media containing vehicle (DMSO) or
BC194 at the indicated concentrations. Images of the circular monolayers were acquired
after re-feeding and at the indicated times and image pairs were analyzed using a custom
ImageJ macro to calculate the number of cells at each time point that have migrated
beyond the original monolayer.

3.4.8 Zebrafish Handling and Treatments
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This project utilized the transgenic lines Tg(flk1:eGFP) and Tg(flk1:dsRed) in
which eGFP and dsRed expression respectively are controlled by the flk1 promoter. The
Tg(flk1:eGFP) or Tg(flk1:dsRed) fish lines exhibit endothelial specific fluorescence
starting at 48 and 72 hpf respectively. Due to its earlier expression the Tg(flk1:eGFP) line
was used for all 48 hpf fluorescence images; all other applications used the
Tg(flk1:dsRed) line. Zebrafish were bred and maintained in accordance with approved
University of Vermont IACUC standards for vertebrate animals and staged as previously
described (62). Fertilized embryos were transferred to glass dishes and allowed to
develop at 25°C until 8 to 12 somites in age. The fish were manually dechorionated and
transferred to 24 well dishes containing 1 ml of egg water treated with 0.003% 1-phenyl
2-thiourea to inhibit pigment, and various concentrations of borrelidin, BC194, BC220,
or DMSO (vehicle control) and incubated at 28.5 °C for downstream analyses. In all
conditions DMSO was standardized to match the highest concentration for each
compound. Dead and dying embryos were removed and the media exchanged for fresh
egg water and compounds every 24 h.

3.4.9 Quantitative Assessment of Toxicity
Heart rate and body length data were acquired after the first 24 h of compound
exposure using the Tg(flk1:dsRed) line and bright field microscopy. Heart rates were
counted over 15 sec and converted to beats per min. For body length, images were taken
using a Spot camera attached to a Nikon SMZ800 dissecting microscope at a 3X
objective and analyzed with Spot v 5.1 software.
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3.4.10 Confocal Imaging
Embryos were live imaged with a 20x objective using step sizes of 2 µm after
mounting in 0.5% low melt agarose on glass bottom dishes (Mat-Tek) on a Nikon Eclipse
Ti inverted microscope. Stacks were subjected to a kalman stack filter in ImageJ and are
presented as maximum intensity projections. Images were processed with Adobe
Photoshop for brightness and contrast. For quantification of ISV ectopic branches,
images were taken using an Olympus IX71 inverted fluorescence microscope. Abnormal
branches and vessel defects associated with ISVs were counted within a region
encompassing five ISVs anterior and posterior to the end of the yolk extension.

3.4.11 Live-Imaging of Zebrafish Blood Flow
Zebrafish embryos (72 hpf) of the Tg(flk:dsRed) line were treated for 48 hours
with DMSO or 5 µM BC194 as described above. Fluorescence images were acquired on
a Nikon TE2000-PFS epifluorescence microscope through a 20X Plan-Fluor objective
using wavelength-appropriate filters (Chroma Technologies) with a Clara CCD camera
(Andor, Inc.). Acquisition was controlled using Nikon Elements software and images
were adjusted for presentation using Elements or Fiji/ImageJ (http://imagej.nih.gov/ij/;
W. Rasband, NIH).

3.4.12 RNA Expression in Zebrafish
Following manual dechorionation embryos (~8 somites; Tg(flk:dsRed)) were
incubated for 24 or 48 h in egg water containing varying concentrations of compounds at
28.5 °C. The fish were subsequently transferred in minimum volume to 1.5 mL
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microfuge tubes and then total RNA was obtained using Trizol:chloroform (Invitrogen).
First strand cDNA was synthesized using Superscript II RT-PCR technology (Invitrogen)
according to manufacturer’s instructions. RT-qPCR was performed using an ABI prism
7700 Sequence Detection System (Applied Biosystems) and TaqMan® Assay primer
pairs (Applied Biosystems) for tars, vegfaa, heyL, ephrinb2a, and act1a. Relative mRNA
expression was determined using a comparative CT (ΔΔCT) method with act1b as an
endogenous control.

3.4.13 Statistical Analysis
All experiments were repeated at least 3 times; n values are reported in the
corresponding figure legend. Values are presented as means ± SEM. Data were analyzed
by one- or two-way ANOVA and Tukey or Sidak test as indicated using GraphPad Prism
v6 software. Significance was defined as P < 0.05.
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CHAPTER 4: INVESTIGATING THE MECHANISMS OF THREONYL-tRNA
SYNTHETASE’S ANGIOGENIC FUNCTIONS

4.1. Introduction
Angiogenesis is a multifaceted process critical to the formation and metastatic
progression of many human cancers (1). Many of the most prominent angiogenic factors,
such as vascular endothelial growth factor (VEGF), have been investigated as potential
targets for anti-metastatic therapeutics with several drugs already approved for use (2,3).
Unfortunately, the benefits of these therapies are often temporary owing to adaptive
responses by the target tissue (4). Therefore, the identification of novel angiogenic factors
and small molecule inhibitors would be beneficial for the development of new
diagnostics and combinatorial cancer therapies.
The pro-angiogenic functions of TARS were recently demonstrated through
studies led by Tamara Williams in the lab of Karen Lounsbury for which we provided
essential enzymes and compounds for testing (5). The addition of exogenous TARS was
found to stimulate human umbilical vein endothelial cell (HUVEC) tube formation and
vascular growth in chorioallantoic membrane (CAM) assays. As angiogenesis is
associated with both proliferation and migration of endothelial cells, the effect of TARS
on these two aspects were subsequently investigated. Specifically, the addition of TARS
to the lower chamber in a transwell migration assay enhanced the movement endothelial
cells from the upper level relative to media alone; however, the enzyme had no effect on
the proliferation of these cells as determined by an alamarBlue® assay. In all cases, the
angiogenesis-associated responses were subject to inhibition by subtoxic doses of the
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borrelidin derivative, BC194. Interestingly, the borrelidin-resistant TARS mutant, L567V
TARS (See Chapter 2, 2.2.5) also exhibited comparable angiogenic activity to the
wildtype enzyme but did not respond to BC194 inhibition, suggesting that the effects of
BC194 were mediated directly through the compound’s interactions with TARS. In
contrast, exposure of CAM assays to the control ARS, leucyl-tRNA synthetase (LARS),
had no effect on vessel formation, which indicates that this secondary function is not
shared by ARSs in general. Given that all of the above observations were in response to
extracellular TARS, the ability of HUVEC cultures to secrete the ARS was also
examined. Notably, the usually cytoplasmic TARS was identified in conditioned media
from endothelial cells treated with TNFα or VEGF (5). This mechanism is reminiscent of
the angiogenesis-associated ARSs tyrosyl- (YARS) and tryptophanyl- (WARS) tRNA
synthetases, which are also secreted from the cell in response to apoptotic or interferon-γ
signaling respectively (6,7). However, the exact mechanism through which extracellular
TARS regulates this process remains unclear.
Investigations of the angiogenesis-inhibitory effects of borrelidin provide some
clues to the mechanism of TARS-mediated angiogenesis. Early reports attributed
borrelidin’s inhibition of endothelial cells to the induction of apoptosis (8). However,
similar mechanisms have also been proposed for the apparent anti-tumor activities of
borrelidin observed in both breast cancer and leukemia cells (9,10). Therefore, these
apoptotic effects appear to be related to the general borrelidin toxicity responses
demonstrated in Chapter 3. Alternatively, the anti-angiogenic properties could be
specifically associated with defects in vessel patterning and maturation as demonstrated
by the zebrafish studies. The observation that the L567V point mutation is able to confer
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resistance to the compound in both aminoacylation (see Chapter 2, section 2.2.5) and
angiogenesis procedures implicates TARS as the target for macrolide induced antiangiogenic responses (5). Therefore, better understanding of TARS’s specific effect on
angiogenesis would provide opportunities for its use as a target of angiogenic based
therapies.
The data presented in Chapter 3 revealed that treatment of zebrafish with BC194
induces defects in vessel patterning that are distinct from the toxicity responses
associated with borrelidin exposure. The lack of alternative targets for borrelidin coupled
with the resistance conferred by the L567V TARS mutation in in vitro assays suggests
that the compounds mediate these effects through direct inhibition of TARS’s secondary
function (5). Knockdown of TARS in zebrafish using a splice-altering morpholino
produces similar vascular defects to borrelidin and BC194 inhibition, confirming a role
for TARS in vessel guidance in the developing zebrafish embryo. However, the
mechanisms that control these effects remain a mystery. Using various point and
truncation mutations, TARS’s stimulation of angiogenesis is shown to be independent of
its aminoacylation function but requires a full-length protein. Finally, mutations that
mimic borrelidin-induced conformational changes are shown to eliminate TARS’s
angiogenic potential and strongly implicate the importance of protein-protein interactions
in this secondary function.

4.2 Results
4.2.1 Knockdown of threonyl-tRNA synthetase expression in zebrafish morphants
produces a vascular phenotype
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Figure 23. Depletion of TARS elicits intermediate toxicity relative to borrelidin and
BC194 inhibtion.
(A) RT-PCR to validate the reduction of TARS levels by morpholino injection. Whole fish
mRNA (72 hpf) was trizol/chloroform extracted and mRNA sequences amplified by RT-PCR
with gene specific primers. The TARS (338 bp) and EF1α control amplicons were run on
1.5% agarose to show differences in relative intensities between uninjected controls (UIC)
and morphant fish. (B) Whole body images of UIC and TARS morphant fish at 48 and 72
hpf.

The zebrafish data from Chapter 3 clearly demonstrate distinct toxicity and antiangiogenic effects in response to borrelidin and BC194 treatment. Furthermore, the
angiogenesis specific results appear to be related to the induction of abnormal vessel
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Figure 24. TARS is involved in vascular development in the zebrafish.
(A) Representative confocal images (20x magnification) of control and TARS morphant
zebrafish ISVs at 48 and 72 hpf. Embryos were injected with a TARS morpholino (1.5
µM) at the one to four cell stage. Fish were manually dechorionated at 24 hpf and
imaged at 48 and 72 hpf. Arrows and asterisks denote the location of ectopic branches
and missing/incomplete vessels respectively. (B, C) Quantification of ectopic branching
(B) and missing/incomplete ISVs (C) from control and morphant zebrafish within a
region encompassing five ISVs anterior and posterior to the yolk extension ; mean ±
SEM, n≥29, #*p<0.0001 relative to uninjected controls at 48 and 72 hpf respectively
(one-way ANOVA, Tukey Test).

patterning. However, the mechanism behind these patterning defects remains to be
determined. Specifically, TARS has been shown to be the target of borrelidin in in vitro
assays but has not been proven to be responsible for the effects in zebrafish (5). To
confirm that the vessel patterning effects of borrelidin and BC194 in zebrafish in Chapter
3 are a direct consequence of action on TARS, the levels of functional TARS were
reduced using a splice altering, antisense morpholino oligonucleotide (MO) (Figure 23A).
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Consistent with the hypothesis that TARS was responsible for the vascular effects of the
borrelidin compounds, morphant fish developed with significantly more ectopic branches
and incomplete vessels than the uninjected controls (Figure 24A-C). The severe
morphological defects associated with borrelidin toxicity (Figure 23B) were not seen in
the TARS morphant fish, but their phenotypes exhibited characteristics that were
intermediate with respect to borrelidin and BC194 treatments. These results demonstrate
that vascular development in the zebrafish is highly sensitive to alterations in the activity
of TARS, induced either as a result of chemical inhibition or altered gene expression.
Additionally, these data provide strong evidence that the vascular effects of the borrelidin
and BC194 are mediated specifically through the inhibition of TARS.

4.2.2 Necessary components of threonyl-tRNA synthetase-mediated angiogenesis
Consistent with previous reports, Chapter 3 demonstrated a clear role of TARS
in angiogenesis (5). This function was further characterized in investigations of borrelidin
and its derivatives. Specifically, the fact that the L567V point mutation in TARS was
found to confer resistance to these compounds coupled with the recapitulation of
borrelidin and BC194 treatment effects in fish through knockdown of TARS indicates
that the effects of these compounds on angiogenesis must occur through modification of
TARS’s functions (5). Furthermore, these effects can be separated from amino acid
starvation, and would suggest that TARS functions through a more direct mechanism.
However, the specific structural features of TARS involved in angiogenesis remain to be
determined.
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Figure 25. Linear schematics of TARS protein constructs.
Linear schematics showing the TARS domains as they appear in the various protein
constructs, specifically TGS (N1) (Purple), Editing (N2) (Red), catalytic (green), and anticodon binding (ACBD) (Blue) domains. Amino acid numbers and point mutation locations
are indicated in the figure.

To better understand the features of TARS involved in its secondary function, the
angiogenic potentials of various TARS constructs (Figure 25) were investigated using
HUVEC tube-formation assays. Unless noted otherwise, the catalytic activity for all
constructs were determined by the aminoacylation assay and the resulting rates reported
in Tables 3 and 4. As a baseline the pro-angiogenic TARS and non-angiogenic LARS
were tested (Figures 26A-C). Similar to earlier reports, WT TARS significantly increased
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Figure 26. Characterizing the angiogenic potential of TARS and related protein
constructs.
(A) Quantification of HUVEC branching in response to WT TARS, R442A TARS, Ec ThrRS,
N1-TARS, ΔN1N2-TARS, and LARS exposure. HUVECs were plated on Matrigel in 10%
EGM-2 (0.2% FBS) media and exposed to 100 nM of the indicated constructs. Cells were fixed
after 4-8 h and stained with Oregon Green 488 Phalloidin. Numbers represent percentage of
control (0 nM) samples, mean ± SEM, n=3 *,**, and **** correspond to p<0.05, 0.01, and
0.0001 respectively relative to the media control (one-way ANOVA, Tukey Test). (B-D)
Activity data for WT TARS, Ec ThrRS, R442A TARS, LARS and buffer control. WT TARS
(B, D), Ec ThrRS (B) and R442A TARS (C) were determined as formation of Thr-tRNAThr per
active site per minute; LARS was determined as AMP per LARS per minute. WT TARS was
included in both graphs for comparative purposes; mean ± S.D.; n=3 (n=1 for Ec ThrRS).

tube-formation of endothelial cells relative to untreated cultures (Figure 26A).
Surprisingly, the control ARS, LARS, exhibited a minor reduction of tube formation,
although the cause of this effect remains unknown. It should also be noted that LARS
activity was determined as the rate of adenylate formation (using AMP formation as the
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readout) due to the lack of a viable tRNALeu purification protocol. Effectively this
reaction measures the rate of formation and subsequent breakdown of the leucyladenylate intermediate, which occurs slowly in absence of tRNALeu. While the acquired
rate data cannot be directly compared to the aminoacylation rate data of the other
constructs they clearly demonstrate that the negative control enzyme used in the tubeformation assays was active for aminoacylation, its primary function.

Table 3. Aminoacylation activity data for various protein constructs
Construct
WT TARS
R442A TARS
Ec ThrRS
LARS‡

Activity (min-1)
3.325 ± 0.2083
Below detectable limit
55.30 ± 5.594
0.1140 ± 0.007845

% Activity*
100
-1663
n/a

*Relative to WT TARS
‡
LARS activity was measured as AMP formation and is not directly
comparable to aminoacylation data

4.2.3 TARS-mediated angiogenesis is independent of aminoacylation activity
Chapter 3 demonstrated that the toxicity effects of borrelidin and related
compounds were the result of amino acid starvation from loss of aminoacylation activity.
Conversely, the effects of angiogenesis were observed at sub-toxic concentrations of the
drug. Together these data appear to indicate that TARS’s angiogenesis function is not
dependent on aminoacylation. However, there is still a possibility that angiogenesis is
more sensitive to a reduction of aminoacylation or that aminoacylation is one of several
contributing factors. To confirm that angiogenesis was separate from the aminoacylation
function of TARS, HUVEC tube-formation assays were performed using the R442A
TARS. Arginine 442 (R363 in E. coli) forms key stabilization interactions with the
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threonyl-adenylate and its mutations would be predicted to eliminate all aspects of TARS
aminoacylation function (11). Consistent with this hypothesis, R442A TARS exhibited
no adenylate formation (data not shown) or aminoacylation activity (Figure 26D; Table
3). Despite this lack of catalytic activity, treatment of HUVEC cells with R442A TARS
was found to significantly increase tube formation relative to the buffer control (Figure
26A). Moreover, these results were comparable to those received for WT TARS.
The angiogenic potential of R442A TARS was further supported through
investigations by Dr. Tamara Williams using the in vivo chorioallantoic membrane assay.
The addition of 1 μM R442A TARS soaked sponges to the membrane surface of chicken
embryos stimulated the growth of surface vessels towards the sponge significantly more
than PBS controls, much like has been previously observed with WT TARS (Figure 27).
Similar results were not obtained with LARS, again suggesting this effect was not a
general function of ARSs. The retention of angiogenic activity in R442A TARS clearly
demonstrates that TARS aminoacylation function is not required for angiogenesis. As a
side note, co-treatment of cells with 1 μM R442A TARS and 1 μM BC194 (a non-toxic
concentration in CAM assays) attenuated R442A TARS-mediated angiogenesis. These
data further support the findings in Chapter 3 that indicate separate inhibitory
mechanisms for borrelidin-derivatives against TARS aminoacylation and angiogenesis
activities. Therefore, these findings implicate borrelidin-mediated conformational
changes as the cause of its anti-angiogenic activity and will be further investigated in
Section 4.2.6.
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Figure 27. Characterizing the angiogenic potential of TARS and related protein
constructs in chorioallantoic membrane assays.
The effects of 1 μM R442A TARS with and without 1 μM BC194 and LARS on in vivo
angiogenesis in a CAM assay. Fertilized chicken embryos were cultured ex-ova for 10 days
after which compounds at the indicated concentrations were applied to gelform sponges on
the CAM. Images were taken daily over 72 h and quantified as the change in vascularity
score over this entire period; mean ± SEM, n≥12, ****p<0.0001 relative to PBS (one-way
ANOVA, Tukey Test). Data were kindly provided by Drs. Tamara Williams and Karen
Lounsbury.

4.2.4 TARS-mediated angiogenesis requires full-length constructs
As indicated in Chapter 1, section 1.6.4, all other ARSs possessing angiogenic
functions do so through mechanisms requiring an appended domain or sequence
(reviewed in Chapter 1). While no specific domain has been directly associated with
TARS, it does contain an N-terminal 82 amino acid extension predicted to be
unstructured followed by an N-terminal ubiquitin like domain of unknown function,
known as the TGS domain. The TGS domain structure is conserved from bacteria to
humans despite very different sequences. Conversely, the amino acid extension appears
to have originated during eukaryotic evolution and is not found in prokaryotic versions of
the enzyme. As such, it may be possible that this N-terminal region, known as the N1134

domain, is important for the TARS’s angiogenic function. Therefore, the importance of
both domains was investigated using the HUVEC tube formation assay with the isolated
N1-TARS (TGS domain and the 82 amino acid extension), the ΔN1N2-TARS (isolated
aminoacylation and anti-codon binding domains), and the Ec ThrRS constructs.
As the N-terminal 82 amino acid extension in only found in eukaryotic versions
of the enzyme, the necessity of this domain was investigated using Ec ThrRS. Like other
constructs, Ec ThrRS’s aminoacylation activity was investigated (Figure 26B).
Interestingly, treatment of HUVEC cultures with the E. coli enzyme exhibited
comparable stimulation of angiogenesis to human TARS (Figure 26A), indicating that the
N-terminal extension is not required for TARS-mediated angiogenesis (at least once
extracellular). Conversely, exposure of HUVECS to N1-TARS had no significant effect
on tube-formation relative to the negative, buffer control but was significantly lower in
comparison to full-length TARS (Figure 26A). As such these data would suggest that the
N1-domain alone is not capable of stimulating angiogenesis. This is not completely
surprising as Chapter 1 clearly demonstrated that borrelidin interacts with the TARS
catalytic domain likely implicating that this domain is essential for angiogenic function.
Therefore, the ability of ΔN1N2-TARS, which only possesses the isolated catalytic and
anticodon-binding domains, to induce angiogenesis was investigated. Interestingly,
treatment with the ΔN1N2-TARS construct produced significantly less tube structures
than both the negative control and full-length TARS (Figure 26A), suggesting that
ΔN1N2-TARS may even be inhibitory towards angiogenesis. Together, these data
suggest that the entire TARS protein is required for the extracellular stimulation of
angiogenesis with the exception of the eukaryotic, N-terminal extension.
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4.2.5 Mutants that mimic the borrelidin-bound conformation eliminate TARSangiogenic activity
The clear separation of aminoacylation and angiogenesis functions in TARS by
experiments in Chapter 3 and with R442A TARS above led to the hypothesis that the
anti-angiogenic properties of borrelidin-related compounds are due to their ability to
stabilize a non-permissive conformation of the enzyme. In support of this mechanism,
intrinsic tryptophan fluorescence studies demonstrate that the binding of borrelidin
induces conformational changes within the TARS structure (also shown in (12))
suggesting that the anti-angiogenic properties of the compound could function through
the disruption of TARS-protein interactions. Additionally, our crystallographic data (see
Chapter 2) show the extrusion of a surface helix in the TARS aminoacylation domain by
14° in both the borrelidin and BC194 bound complexes and agrees with our tube
formation and CAM data that suggest similar anti-angiogenic potential for both
compounds. To confirm the importance of this helix for TARS-mediated angiogenesis,
the point mutations Q566W TARS and A538W TARS were generated because they were
predicted by molecular modeling programs to mimic the borrelidin-bound conformation
(Figure 28A) (13). Initial activity investigations revealed that Q566W TARS possessed
aminoacylation activity greater than WT TARS (Figure 28B; Table 4) while A538W
TARS was inactive in active site titration assays and was not investigated for
aminoacylation activity. Interestingly, neither mutant increased tube formation relative to
the buffer control, suggesting that this conformational change alone is enough to inhibit
angiogenesis (Figure 28C).
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Figure 28. The effects of borrelidin-conformation mimetic mutations on TARS-mediated
angiogensis.
(A) Schematic of the borrelidin-induced conformational change in the TARS active site.
Borrelidin (BN, orange) binding opens up a region at the edge of the aminoacylation active site
consisting of residues 492-547 (designated by arrow). Similar conformational changes are
observed with Q566W and A538W mutations (positions in active site cleft designated by blue
lines). Inset is a superposition of the TARS-borrelidin structure (TARS-BN; TARS shown in
teal and BN in orange) superimposed with a computational model of the Q566W TARS (blue)
showing nearly identical structures. (B) Quantification of HUVEC branching in response to WT
TARS, Q566W TARS, and A538W TARS. HUVECs were plated on Matrigel in 10% EGM-2
(0.2% FBS) media and exposed to 100 nM of the indicated constructs. Cells were fixed after 48 h and stained with Oregon Green 488 Phalloidin. Numbers represent percentage of control (0
nM) samples, mean ± SEM, n=3 * p<0.05 and # p<0.01 relative to the buffer control and WT
TARS respectively (one-way ANOVA, Tukey Test). (C) Aminoacylation activity data for WT
TARS and Q566W TARS as determined by formation of Thr-tRNAThr per active site per
minute; mean ± S.D.; n=3. Diagrams in (A) were adapted from images kindly provided by our
collaborator Min Guo.
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Table 4. Activity data for borrelidin conformation mimetic mutations
Construct
WT TARS
Q566 TARS
A538W TARS‡

Activity (min-1)
3.325 ± 0.2083
9.151 ± 0.3729
Below detectable limit

% Activity*
100
275
--

* Relative to WT TARS
‡
As A538W TARS showed no adenylate formation in active site assays
it was not tested for aminoacylation activity.

4.3 Discussion
4.3.1 Borrelidin regulates angiogenesis in zebrafish specifically though interactions
with TARS
Early reports suggested that apoptosis of endothelial cells could contribute to the
reduction in angiogenesis (8). While the impact of this phenomenon cannot be
completely ruled out, it is complicated by a lack of specificity to a single cell type (9,10).
Furthermore, the data from Chapter 3 clearly indicate that anti-angiogenic effects are
observable at sub-toxic levels suggesting that another mechanism is required to explain
the relationship between TARS and borrelidin in angiogenesis. The actions of borrelidin
and BC194 can be blocked by single residue substitutions in the E. coli ThrRS, and
TARS active sites, respectively (5,12), arguing against the previous suggestion that
borrelidin binding to other secondary targets is physiologically significant in the
inhibition of angiogenesis (14). This observation was shown to extend into whole animal
models as demonstrated by the similar phenotypes exhibited between BC194 and
borrelidin exposure compared to the knockdown of TARS through treatment with a
TARS-specific morpholino. As such, the effects of compound treatment on zebrafish in
Chapter 3 can be attributed to the direct inhibition of TARS.
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4.3.2 Defining the TARS components required for the regulation of angiogenesis
Structural analysis of the ThrRS-borrelidin complex suggests that the inhibition
mechanisms of borrelidin and BC194 involve occlusion of the binding sites for one or
more of the canonical aminoacylation substrates. Borrelidin is a slow tight binding
inhibitor that competes with amino acid substrate binding, accounting for the potent
stimulation of toxic responses related to amino acid starvation (12). This toxicity
response, however, has been demonstrated to be completely separate from the angiogenic
specific effects. Conversely, the angiogenic effects exhibited by the various TARS
constructs help to characterize the mechanism of TARS-mediated angiogenesis. Since Ec
ThrRS was capable of stimulating angiogenesis it would seem that the N-terminal ~82
amino acid extension found only in higher organism is not required for angiogenesis.
However, it’s important to note that the tube formation assay only looks at the effects of
constructs outside of the cell and would not provide any evidence for intracellular events.
As such, the N-terminal extension maybe serve an important regulatory role or function
in the currently unknown TARS secretory mechanism that is unnecessary in E. coli. The
lack of structure in this region suggests a potential role as a protein-protein interaction
domain since intrinsically disordered regions allow for versatile interactions with
interaction partners (15,16). However, the actual function of this domain, if any, remains
to be established.
The loss of angiogenesis activity by Q566W TARS and A538W TARS clearly
demonstrates the importance of borrelidin’s conformational change to the mechanism of
the compound. Since Q566W TARS retains its aminoacylation activity it seems unlikely
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that this effect is due to large scale structural effects or local unfolding linked to the
mutant substitution. Moreover, the fact that this conformational change does not affect
the normal function of the protein raises the possibility that its inhibition of angiogenesis
is though the disruption of some currently unknown protein-protein interaction. This
concept is further supported by the R442A TARS tube formation assays since these data
emphasize that TARS’s aminoacylation function is not required for angiogenesis.
The TARS-mediated mechanism of angiogenesis can be further characterized by
the data from the N1-domain and ΔN1N2-TARS constructs. Since neither of these
constructs appear to stimulate angiogenesis, these data suggest that the full-length protein
is required. The use of ΔN1N2-TARS for crystallization further indicates that this
construct retains its three dimensional structure and has not lost its angiogenic activity
owing to partial denaturation. Interestingly, the Q566 mutation and its associated
conformational change are located within the aminoacylation domain, suggesting that this
construct retains the ability to engage in the protein-protein interactions that we
hypothesize borrelidin disrupts. Consistent with this interpretation ΔN1N2-TARS
reduced the number of tube like structures that grew in HUVEC culture, suggesting that
the truncated construct likely titrates potential interactions made by the full length
protein. Moreover, the necessity of the full length protein indicates that a second
interaction with the N-terminus is likely essential for TARS angiogenic function. As
described above, the ability of Ec ThrRS to stimulate angiogenesis suggests that this
interaction is not mediated by the N-terminal extension and is more likely to be
associated with the N1 (TGS) and N2 (Editing) domains of the protein.
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Unlike the ΔN1N2-TARS construct, the N1 domain alone did not inhibit
angiogenesis in the tube-formation assay. However, the data for this construct were
associated with a high standard error of mean (Figure 26A), which may indicate that this
domain has some influence in the assay and its involvement in angiogenesis should not
be completely ruled out. As the N1-domain does not possess a known active site, its
contribution, if any, would be limited to the formation of interactions between TARS and
other molecules. In this model TARS would be able to bridge two molecules together
through the formation of concurrent interactions (further developed in section 4.3.3).
Conversely, the N2 domain contains the editing active site and could theoretically
function in both the formation of interactions and non-canonical catalytic activities
(alternative catalytic functions of TARS are discussed in Chapter 5) (17). However,
unlike the other domains of TARS, the contributions of the isolated N2 domain on
angiogenesis have yet to be investigated.
One important caveat of these data is that neither the N1-domain nor the ΔN1N2TARS constructs contain the N2 editing domain. This apparent oversight is due to the
fact that both constructs were designed with other purposes in mind: the N1-domain was
designed for protein-protein interaction studies (see Appendix I) and the ΔN1N2-TARS
was designed for crystallization. Given the proven importance of the aminoacylation
domain to the angiogenic mechanism it would seem unlikely that a construct consisting
of both the N1 and N2 domains would have any pro-angiogenic activity. Conversely, if
the N2 domain is the site of the second interaction, then a ΔN1-TARS (containing only
the editing, aminoacylation, and anti-codon binding domains) could possibly exhibit
angiogenic activity. Due to technical difficulties in the creation of the ΔN1-TARS
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construct, however, these studies have yet to be performed. Nonetheless, the conclusion
that two interactions are necessary would become very important in directing future
investigations of this mechanism.

4.3.3 Models for TARS-mediated angiogenesis and their disruption by borrelidin
derivatives
Together, the zebrafish morpholino and TARS construct data support a
mechanism in which TARS regulates angiogenesis by stimulating proper vessel
patterning and migration independent of TARS’s aminoacylation function. This process
appears to be based on the formation of two separate protein-protein interactions, one of
which is located within the TARS catalytic domain. Possible identities for these
interactions have been investigated using mass-spectrometry approaches and the results
of these experiments can be observed in Appendix I. The methods used in those
interaction experiments, however, focused primarily on intra-cellular partners and may
not fully account for the apparent extracellular nature of TARS’s secondary function (5).
In contrast, the models presented below will focus on possible extracellular binding
partners for TARS.
One possible explanation for this two-binding site model is that extra-cellular
TARS establishes a spatially regulated gradient through interactions with the extracellular matrix. The second site is then able to mediate a contact with a cell surface
receptor involved in vessel migration and guidance. In support of this hypothesis,
interactions between TARS and fibronectin 1 (FN1), a major component of endothelial
cell ECM, have been reported in the literature. This possible mechanism of TARS142

mediated angiogenesis is currently being investigated and will be discussed with more
detail in Chapter 6.
In this model, the conformational change of Q566W TARS or treatment with
borrelidin would disrupt either TARS’s interaction with the ECM or the cellular receptor.
In the case of the ECM interaction, the TARS gradient would become more diffuse and
harder for vessels to follow. Likewise, disruption of the TARS-receptor interaction would
inhibit the perception of TARS by cells within a growing vessel. In either event, the
vessels would not receive the proper guidance cues, leading to the appearance of ectopic
vessels. This may explain the directional confusion displayed by in vivo assays, such as
the ISV patterning and CAM vessel formation, following borrelidin and BC194 treatment
since the diffuse TARS gradient would not allow for proper polarization of endothelial
cells. This explanation is also compatible with our cell-based assays since each has a
matrix component associated with the system. Previously, other angiogenesis-associated
factors, such as VEGF, may elicit different signaling depending on if they are free or
bound to the ECM. Therefore, disruption of TARS-ECM or receptor interactions could
have profound effects on the regulation and specifics of its signaling activity. Currently,
attempts to identify TARS-responsive receptors and borrelidin-susceptible interactions
are underway.
While the substantial cross-talk between receptors linked to angiogenesis makes it
difficult to verify a particular pathway, circumstantial evidence implicates the toll like
receptors (TLR) of the innate immune system as possible effectors. As mentioned in
Chapter 1, TARS is the second most common of six ARS associated with anti-synthetase
syndrome, a rare autoimmune disorder that includes polymyositis and dermatomyositis
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resulting from the production of the anti-ARS autoantibodies. Recently, the most
common ARS involved in this disorder, histidyl-tRNA synthetase (HARS), was
demonstrated to induce muscle inflammation in mice by a TLR2- and TLR4-dependent
mechanism (18). Activation of the TLRs has been shown to contribute to the process of
angiogenesis, in part, through MyD88-mediated activation of the NF-κB transcription
factor (19). This pathway up-regulates the production of TNFα and, consequently, VEGF
(20). As indicated earlier, TNFα and VEGF signaling stimulate the secretion of TARS
from endothelial cells (5). Furthermore, TLR-induced expression of IL-10 in
macrophages has been associated with the activation of STAT3, which binds to a specific
site within the promoter region of the tars gene (21). Taken together these observations
would describe a scenario in which TARS-mediated stimulation of TLRs would initiate
pro-angiogenic responses and propagate the signal through the expression and secretion
of additional TARS.
Other possible receptor identities include focal adhesion complexes and
purinergic signaling. Focal adhesion complexes are dynamic, multi-protein structures that
mediate contacts between a cell and the surrounding ECM and possess well documented
roles in migration (22). Interactions with ECM components are established by integrins
and can signal into the cell via complex associated kinases (23,24). The co-clustering of
growth factor associated receptors with integrins have also been observed and may
collaborate with integrin signaling by interacting with ECM bound ligands, in this case
TARS. Alternatively, the purinergic system responds to extracellular nucleotides and
became of interest upon the discovery of non-canonical, catalytic functions in TARS. The
binding of nucleotides to these purinergic receptors has been demonstrated to elicit
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functions associated with angiogenesis, including migration and proliferation of
endothelial cells (25-27). The catalysis of these reactions by TARS and the possible
involvement of this receptor system will be discussed thoroughly in the next chapter.

4.4 Experimental Procedures
4.4.1 Cell Culture and Reagents
Human umbilical endothelial cells (HUVECs) were maintained in Clonetics
EGM®-2 complete media (Lonza) and used between passages 5 to 8. Borrelidin and
BC194 were obtained from Biotica (now Isomerase Therapeutics Ltd (Cambridge, UK)).
The TARS morpholino was purchased from GeneTools.

4.4.2 Protein Preparation
Purification of human TARS, Ec TARS, and ΔN1N2-TARS was performed
identical to the procedures described in Chapter 2, section 2.3.1. Single amino acid
mutants were generated using identical procedures following QuickChange (Stratagene)
site-directed mutagenesis with olio-deoxynucleotide primers from Operon.
Preparation of human cytoplasmic LARS was adapted from previously
described methods (28,29). A plasmid encoding for N-terminal His6-tagged human
cytoplasmic LARS in the pPROEX hTb expression vector were transformed into E. coli
B21(DE3) codon plus competent cells (Stratagene) and cultured in terrific broth
supplemented with 100 μg/ml ampicillin 37°C to a cell density of A600 = 0.6. Expression
of LARS was induced with 1 mM isopropyl 1-thio-β-D-galactoside overnight at room
temperature. The bacterial pellet was lysed by sonication in buffer A (20 mM potassium
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phosphate buffer pH 8.0, 150 mM KCl, and 5 mM β-mercaptoethanol) and cleared by
centrifugation at 17050 x g for 30 minutes. Nucleic acids were precipitated by the
addition of protamine sulfate to a final concentration of 0.2% followed by centrifugation.
The supernatant was loaded onto a HisTrapTM FF column (GE Healthcare) in buffer A,
washed in 15 mM imidazole, and eluted by an imidazole gradient from 15 to 500 mM
over 20 column volumes. LARS containing fractions were identified by SDS-PAGE and
GelCodeTM Blue (Thermo Scientific), pooled, and dialyzed into buffer B (20 mM HEPES
pH 8.0, 50 mM KCl, 5 mM β-mercaptoethanol, and 10% glycerol). The sample was
loaded onto a HiTrap Q FF column (Amersham Pharmacia Biotech) and eluted over 20
column volumes by KCl gradient from 50 to 1000 mM. LARS containing fractions were
determined by SDS-PAGE, dialyzed into storage buffer (100 mM potassium phosphate
pH 6.8, 10 mM β-mercaptoethanol, and 50% glycerol), and stored at -20°C.

4.4.3 In Vitro Tube Formation Assay
Tube formation assays were performed as previously described (5,30). Briefly
HUVEC cells were cultured until 95-100% confluent and seeded in to 48-well plates
coated with MatrigelTM (BD Biosciences). Cells were incubated at 37 °C in 10 %
EGM®-2 media in EBM®-2 media (Lonza) (ie. 0.2% FBS and and 10% normal
supplement concentrations of EGM®-2). Various protein constructs were then added for
4 to 8 h. Cells were fixed with 10% neutral buffered formalin, stained with Oregon Green
488 phalloidin (Molecular Probes), and imaged via fluorescence microscopy. Tube
structures were quantified using the Simple Neurite Tracer plug-in on ImageJ software
(NIH).
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4.4.4 Chick Chorioallantoic Membrane Assay
CAM assays were performed as described in Chapter 3, section 3.4.6.

4.4.5 Zebrafish Handling and Treatments
This project utilized the transgenic line Tg(flk1:eGFP) in which eGFP is
expressed in 48 hpf and controlled by the flk1 promoter. Zebrafish were bred and
maintained in accordance with approved University of Vermont IACUC standards for
vertebrate animals and staged as previously described (31). An anti-TARS morpholino
(5’-TAATTTAGCCACTAACCTGATCCCA-3’) was designed targeting the splice donor
site within exon 3 of TARS mRNA. Blocking this site is predicted to join exon 2 to exon
4, introducing a frameshift and producing a stop codon five codons into exon 4. TARS
morpholinos (1.5 mM) were injected into the yolk sac of Tg(flk1:eGFP) embryos at the
one to four cell stage and incubated for 24 hours at 28.5 °C. The embryos were then
dechorionated, transferred to fish egg water containing 0.003% PTU, and replaced at 28.5
°C. The successful knockdown of functional TARS was confirmed by RT-PCR using the
following primers:
Exon 2, Forward: 5’-CAAGAATGCTGCTGGAGATG-3’
Exon 4, Reverse: 5’-CTTGTGCCTCTTCATCGTCA-3’
Imaging and aberrant vessel quantification were performed at 48 and 72 hpf as described
below.

4.4.6 Whole Fish and Confocal Imaging
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Whole body and confocal images were obtained using procedures identical to those
described in Chapter 3, sections 3.4.10 and 3.4.11.

4.4.7 Statistical Analysis
All experiments were repeated at least 3 times; n values are reported in the
corresponding figure legend. Values are presented as means ± SEM. Data were analyzed
by one- or two-way ANOVA and Tukey or Sidak test as indicated using GraphPad Prism
v6 software. Significance was defined as P < 0.05.

148

4.5 References
1.

Carmeliet, P., and Jain, R. K. (2000) Angiogenesis in cancer and other diseases.
Nature 407, 249-257

2.

Lien, S., and Lowman, H. B. (2008) Therapeutic anti-VEGF antibodies.
Handbook of experimental pharmacology, 131-150

3.

Morabito, A., De Maio, E., Di Maio, M., Normanno, N., and Perrone, F. (2006)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in
clinical trials: current status and future directions. The oncologist 11, 753-764

4.

Bergers, G., and Hanahan, D. (2008) Modes of resistance to anti-angiogenic
therapy. Nat Rev Cancer 8, 592-603

5.

Williams, T. F., Mirando, A. C., Wilkinson, B., Francklyn, C. S., and Lounsbury,
K. M. (2013) Secreted Threonyl-tRNA synthetase stimulates endothelial cell
migration and angiogenesis. Sci Rep 3, 1317

6.

Wakasugi, K., Slike, B. M., Hood, J., Ewalt, K. L., Cheresh, D. A., and
Schimmel, P. (2002) Induction of angiogenesis by a fragment of human tyrosyltRNA synthetase. J Biol Chem 277, 20124-20126

7.

Wakasugi, K., Slike, B. M., Hood, J., Otani, A., Ewalt, K. L., Friedlander, M.,
Cheresh, D. A., and Schimmel, P. (2002) A human aminoacyl-tRNA synthetase
as a regulator of angiogenesis. Proc Natl Acad Sci U S A 99, 173-177

8.

Kawamura, T., Liu, D., Towle, M. J., Kageyama, R., Tsukahara, N.,
Wakabayashi, T., and Littlefield, B. A. (2003) Anti-angiogenesis effects of
borrelidin are mediated through distinct pathways: threonyl-tRNA synthetase and
caspases are independently involved in suppression of proliferation and induction
of apoptosis in endothelial cells. J Antibiot (Tokyo) 56, 709-715

9.

Gafiuc, D., Weiss, M., Mylonas, I., and Bruning, A. (2013) Borrelidin has limited
anti-cancer effects in bcl-2 overexpressing breast cancer and leukemia cells and
reveals toxicity in non-malignant breast epithelial cells. J Appl Toxicol

10.

Habibi, D., Ogloff, N., Jalili, R. B., Yost, A., Weng, A. P., Ghahary, A., and Ong,
C. J. (2011) Borrelidin, a small molecule nitrile-containing macrolide inhibitor of
threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic
leukemia. Invest New Drugs 30, 1361-1370

11.

Torres-Larios, A., Sankaranarayanan, R., Rees, B., Dock-Bregeon, A. C., and
Moras, D. (2003) Conformational movements and cooperativity upon amino acid,
ATP and tRNA binding in threonyl-tRNA synthetase. J Mol Biol 331, 201-211
149

12.

Ruan, B., Bovee, M. L., Sacher, M., Stathopoulos, C., Poralla, K., Francklyn, C.
S., and Soll, D. (2005) A unique hydrophobic cluster near the active site
contributes to differences in borrelidin inhibition among threonyl-tRNA
synthetases. J Biol Chem 280, 571-577

13.

Fang, P., Yu, X., Jae Jeong, S., Mirando, A. C., Chen, K., Chen, X., Sunghoon,
K., Francklyn, C. S., and Guo, M. Structural basis for full-spectrum inhibition of
translational functions on a tRNA synthetase. Nature communications In press, 111

14.

Kawamura, T., Liu, D., Towle, M. J., Kageyama, R., Tsukahara, N.,
Wakabayashi, T., and Littlefield, B. A. (2003) Anti-angiogenesis effects of
borrelidin are mediated through distinct pathways: threonyl-tRNA synthetase and
caspases are independently involved in suppression of proliferation and induction
of apoptosis in endothelial cells. Journal of Antibiotics 56, 709-715

15.

Dyson, H. J., and Wright, P. E. (2002) Coupling of folding and binding for
unstructured proteins. Current opinion in structural biology 12, 54-60

16.

Dyson, H. J., and Wright, P. E. (2005) Intrinsically unstructured proteins and their
functions. Nat Rev Mol Cell Biol 6, 197-208

17.

Dock-Bregeon, A., Sankaranarayanan, R., Romby, P., Caillet, J., Springer, M.,
Rees, B., Francklyn, C. S., Ehresmann, C., and Moras, D. (2000) Transfer RNAmediated editing in threonyl-tRNA synthetase. The class II solution to the double
discrimination problem. Cell 103, 877-884

18.

Fernandez, I., Harlow, L., Zang, Y., Liu-Bryan, R., Ridgway, W. M., Clemens, P.
R., and Ascherman, D. P. (2013) Functional redundancy of MyD88-dependent
signaling pathways in a murine model of histidyl-transfer RNA synthetaseinduced myositis. J Immunol 191, 1865-1872

19.

Kawai, T., and Akira, S. (2006) TLR signaling. Cell Death Differ 13, 816-825

20.

Aggarwal, B. B. (2003) Signalling pathways of the TNF superfamily: a doubleedged sword. Nat Rev Immunol 3, 745-756

21.

Hu, X., Chen, J., Wang, L., and Ivashkiv, L. B. (2007) Crosstalk among JakSTAT, Toll-like receptor, and ITAM-dependent pathways in macrophage
activation. J Leukoc Biol 82, 237-243

22.

Sulzmaier, F. J., Jean, C., and Schlaepfer, D. D. (2014) FAK in cancer:
mechanistic findings and clinical applications. Nat Rev Cancer 14, 598-610

23.

Porter, J. C., and Hogg, N. (1998) Integrins take partners: cross-talk between
integrins and other membrane receptors. Trends Cell Biol 8, 390-396
150

24.

Somanath, P. R., Malinin, N. L., and Byzova, T. V. (2009) Cooperation between
integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 12, 177-185

25.

Burnstock, G. (2002) Purinergic signaling and vascular cell proliferation and
death. Arterioscler Thromb Vasc Biol 22, 364-373

26.

Corriden, R., and Insel, P. A. (2012) New insights regarding the regulation of
chemotaxis by nucleotides, adenosine, and their receptors. Purinergic signalling
8, 587-598

27.

Shen, J., and DiCorleto, P. E. (2008) ADP stimulates human endothelial cell
migration via P2Y1 nucleotide receptor-mediated mitogen-activated protein
kinase pathways. Circ Res 102, 448-456

28.

Pang, Y. L., and Martinis, S. A. (2009) A paradigm shift for the amino acid
editing mechanism of human cytoplasmic leucyl-tRNA synthetase. Biochemistry
48, 8958-8964

29.

Seiradake, E., Mao, W., Hernandez, V., Baker, S. J., Plattner, J. J., Alley, M. R.,
and Cusack, S. (2009) Crystal structures of the human and fungal cytosolic
Leucyl-tRNA synthetase editing domains: A structural basis for the rational
design of antifungal benzoxaboroles. J Mol Biol 390, 196-207

30.

Arnaoutova, I., and Kleinman, H. K. In vitro angiogenesis: endothelial cell tube
formation on gelled basement membrane extract. Nat Protoc 5, 628-635

31.

Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B., and Schilling, T. F.
(1995) Stages of embryonic development of the zebrafish. Dev Dyn 203, 253-310

151

CHAPTER 5: CHARACTERIZING THE NON-CANONICAL, CATALYTIC
FUNCTIONS OF HUMAN THREONYL-tRNA SYNTHETASE

5.1 Introduction
The canonical aminoacylation reaction proceeds through a two-step mechanism.
First, the amino acid is activated through condensation with ATP, forming an aminoacyladenylate intermediate. This is followed by the transfer of the activated amino acid to the
2’ or 3’-OH of the tRNA to generate charged-tRNA and AMP. Interestingly, several
ARSs have developed alterations to this core mechanism for the formation of
dinucleoside polyphosphates. Excluding glycyl-tRNA synthetase, the majority of these
reactions progress normally through adenylate formation but deviate in the transfer of
adenosine phosphate from the adenylate to a second nucleotide triphosphate (1-3). The
identity of this second nucleotide determines the identity of the dinucleotides (ie ATP 
Ap4A; GTP  Ap4G) (4).
The first reported synthesis of Ap4A by an ARS was in 1966 during
investigations with lysyl-tRNA synthetase (KARS) (5). The biological significance of
this find was debated over the next several decades, with potential roles in cellular
proliferation and signaling events. More specific to ARS secondary functions is the
connection between Ap4A synthesis and a non-canonical function of KARS in the
regulation of the micropthalmia transcription factor (MITF), an important transcription
factor in mast cells, osteoclasts, and melanocytes. Normally, MITF’s transcription factor
activity is inhibited by the suppressor protein Hint (previously known as protein kinase C
interacting protein 1; PKCI) but can be restored by the binding of diadenosine
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oligophosphates, including Ap4A (6). Immune activation of mast cells leads to the
phosphorylation and translocation of KARS into the nucleus, which binds to MITF and
begins local production of Ap4A. This increase in Ap4A releases Hint from MITF,
thereby allowing for the transcription of MITF-associated genes (7). Although this
function of Ap4A is not directly related to TARS, it does demonstrate that Ap4A
generation by ARSs is more than an accidental side reaction.
While most well-known for its role in the non-canonical function of KARS there
are reports that provide possible connections of Ap4A synthesis to secondary functions in
TARS. An early report of Ap4A synthesis by TARS published in 1989 and revealed rates
comparable, if not slightly faster, than those observed for KARS. Even more interesting,
the phosphorylation of unidentified serine residues by cAMP-dependent kinase was
shown to enhance the rate of this reaction by nearly 8-fold (1). The fact that this side
reaction is influenced by a common regulatory mechanism like phosphorylation
emphasizes the possibility that it may be involved in an important biological function.
Previously, extracellular TARS has been demonstrated to induce angiogenesis
(8). However, the mechanism behind this process remains to be determined. Interestingly,
extracellular nucleotides have been associated with angiogenesis through receptormediated signaling cascades known as purinergic signaling. This raises the possibility
that one component of the ability of TARS to stimulate angiogenesis is related to its
ability to catalyze the interconversion of nucleotides outside of the cell, including the
synthesis of Ap4A from ATP. While most extracellular nucleotides are able to elicit some
form of purinergic signaling the actual responses are specific for each nucleotide. This
specificity is achieved by the presence of numerous receptors with varying degrees of
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affinity for different nucleotide species. For Ap4A, signaling events are primarily
mediated by the P2X ligand-gated ion channel family. Activation of P2X leads to an
influx of Na+ and Ca2+ and stimulates the arterial vasoconstriction (9). Alternatively,
P2Y1 activation by ADP leads to the release of intracellular Ca2+ stores through IP3mediated pathways and stimulates the proliferation of vascular smooth muscles cells
through ERK1/2 pathways (10). In endothelial cells, ADP has been demonstrated to
induce proliferation and migration (11,12). Additionally, activation of P2Y receptors by
ADP on platelets was found to stimulate the release of VEGF and endostatin, which
suggests the possibility of synergistic effects between purinergic signaling in platelets
and endothelial cells on endothelial cell migration in vivo (13). Interestingly, Ap4A
exhibits antagonistic activities against platelet P2Y1, emphasizing a complex interplay
between various purinergic ligands.
Section 1.6.4 of Chapter 1 introduced the observation that, with the exception of
TARS, all angiogenesis-related functions of ARSs were dependent in some way on an
appended domain. However, there are domains of unknown function contained within the
TARS protein. One in particular is an N-terminal, ubiquitin like domain that is conserved
from bacteria to humans. The domain is called the TGS domain for its appearance in
TARS, GTPase, and SpoT proteins (14). The recurrence of this domain in GTPases is
particularly interesting, since proteins, such as elongation factors, often use the catalysis
of GTP to GDP to cycle between “on” and “off” states (14-16). Additionally, the protein
SpoT catalyzes the formation of guanosine 5’-(tri)diphosphate, 3’-diphosphate
((p)ppGpp), which is involved in the regulation of some bacterial genes (17,18).
Therefore, the identification of secondary guanine nucleotide activities in TARS might
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lead to the discovery of a switch between the canonical and non-canonical functions or
otherwise provide insights into their mechanisms.
The data in this chapter present several non-canonical, catalytic functions of
TARS, some of which have not been reported elsewhere. These reactions include a
cryptic GTPase function, conversion of ATP to ADP, and the formation of Ap4A. They
have been included in this dissertation work because of possible connections to the TARS
pro-angiogenic mechanism. The rates of these reactions have been investigated using
various TARS constructs in the presence and absence of borrelidin derivatives in order to
draw possible connections with TARS-mediated angiogenesis. These connections will be
further validated by investigating the involvement of the ADP and Ap4A receptors P2Y1
and P2X using specific inhibitors to these receptors. Together, the characterization of
these various aspects of TARS non-canonical functions provides context and foundation
for future investigations into their contribution to angiogenesis.

5.2 Results
5.2.1 TARS possesses GTPase activity
The conversion of GTP to GDP by TARS was monitored over time using
autoradiography and thin layer chromatography to resolve the products and substrates
(Figure 29A). Rates are reported as molecules of GDP produced per active site (or per
monomer in the case of R442A TARS) per minute, which results in units of min-1 (Table
5). With GTP as the only substrate, the base rate of GTPase activity for WT TARS was
calculated to be 0.3033 min-1 (Figure 29B). While this rate may appear slow, it should be
noted that GTPases often possess inherently low catalytic rates in the absence of GTPase
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Figure 29. Kinetic characterization of TARS GTPase activity.
(A) Representative autoradiographic images of TARS GTPase reactions under untreated
(left) and 2 mM ATP (right) conditions using [α32P]-labeled GTP as a tracer. Reaction
components were separated by thin-layer chromatography on polyethyleneimine-cellulose
in 750 mM potassium phosphate buffer, pH 3.5. (B-E) Rate of GDP formation by purified
TARS constructs under various conditions. (B) GTPase activity of 5 μM WT TARS (blue),
R442A TARS (red), or Ec ThrRS (green). (C) GTPase activity of WT TARS in the
presence of 0 μM (blue), 1 μM (red), 5 μM (green), or 10 μM (purple) tRNAThr. (D) WT
TARS GTPase activity untreated (blue), with 2 mM threonine (red), 2 mM ATP (green),
both 2 mM threonine and 2 mM ATP (adenylation, purple), or adenylation with 10 μM
tRNAThr (aminoacylation, orange). (E) WT TARS GTPase activity uninhibited (blue), 10
μM BC194 (red), or 10 μM borrelidin (green). All data are presented as mean ± S.D, n=3.
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activating proteins (GAP). Notably, Ec ThrRS exhibited no significant GTPase activity
(0.01576 min-1) suggesting that this effect is not found in bacteria. Moreover, the lack of
activity in the Ec ThrRS construct demonstrates that the observed rates for GDP
production in WT and R442A TARS were not simply the result of solution hydrolysis.

Table 5. Rates of GTPase activity by various TARS constructs
Construct
WT TARS:

Condition

Uninhibited

2 mM Threonine
2 mM ATP
Adenylation
Aminoacylation
10 μM Borrelidin
10 μM BC194
R442A TARS:
Uninhibited
Ec ThrRS:
Uninhibited
*Relative to WT TARS, uninhibited

Activity (min-1)
0.3033 ± 0.01541
0.3825 ± 0.03592
0.07097 ± 0.01488
0.03080 ± 0.01268
0.03434 ± 0.01167
0.3082 ± 0.02850
0.3067 ± 0.02155
0.2137 ± 0.01704
0.01576 ± 0.01062

% Activity*
100
126
23
10
11
102
101
70
5

Subsequently, the effects of the canonical substrates on the GTPase activity
were investigated (Figure 29C, D). The addition of 2 mM threonine provided a minor
enhancement to the rate, increasing it to 0.3825 min-1 (Figure 29C). In contrast, ATP in
any combination with other canonical substrates, significantly decreased the GTPase
activity: alone, 2 mM ATP dropped the rate to 0.07097 min-1, 2 mM ATP and 2 mM
threonine (adenylation conditions) dropped the rate to 0.03080 min-1, and 2 mM ATP
with 2 mM threonine and 10 μM tRNAThr (aminoacylation conditions) dropped the rate
to 0.03434 min-1 (Figure 29D). In contrast to the other two substrates, tRNAThr had no
effect when added alone at 1 μM, 5 μM, and 10 μM, corresponding to the rates 0.3485
min-1, 0.3231 min-1, and 0.3284 min-1 (Table 6).
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Table 6. The effects of tRNAThr on the rates of WT TARS GTPase activity
Construct
WT TARS:

Condition
0 μM tRNAThr
1 μM tRNAThr
5 μM tRNAThr
10 μM tRNAThr
*Relative to WT TARS, uninhibited

Activity (min-1)
0.3033 ± 0.01541
0.3485 ± 0.02269
0.3231 ± 0.01755
0.3284 ± 0.01779

% Activity*
100
115
107
108

Owing to the potential connection between the GTPase function and TARS’s
secondary activities in angiogenesis, the effects of borrelidin and BC194 were also tested
(Figure 29E). Both compounds were added at concentrations of 10 μM, which would
saturate the 5 μM enzyme concentration. Interestingly, neither borrelidin nor BC194 had
any effect on the rate of the GTPase reaction, exhibiting rates of 0.3067 min-1 for
borrelidin and 0.3083 min-1 for BC194 relative to 0.3033 min-1 for the uninhibited
reaction.

5.2.2 TARS-mediated catalysis of Diadenosine Tetraphospate (Ap4A)
Two mechanisms have been reported for the formation of Ap4A. Most
commonly, the reaction progresses through the canonical adenylation step of
aminoacylation, forming an aminoacyl-adenylate intermediate. However, instead of
transferring the amino acid to an awaiting tRNA molecule, the adenosine moiety is
transferred to a second nucleotide triphosphate instead, generating a dinucleotide
tetraphosphate (Figure 30A). As such, this mechanism would require that the
corresponding amino acid is present to proceed. Alternatively, glycyl-tRNA synthetase
has been observed to form Ap4A through an amino acid independent method. In this
mechanism an oxygen of the γ-phosphate of an ATP molecule initiates a nucleophilic
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attack on the α-phosphate of another nucleotide, producing Ap4A (Figure 30B). Most
often the second nucleotide in these reactions is ATP, resulting in Ap4A; however, other
combinations of nucleotides are also possible so long as at least one nucleotide is
adenosine (ie. Ap4N, where N is any nucleotide) (4). Despite the previously reported
observations of TARS Ap4A synthesis activity the mechanism through which this
reaction proceeds has yet to be determined.

Figure 30. Ap4A reaction schematics.
(A) Threonine-dependent reaction schematic requiring the formation of a threonyladenylate intermediated. (B) Threonine-independent reaction schematic with direct
formation of Ap4A from ATP.

In order to determine the mechanisms used by TARS to synthesize Ap4A, WT
TARS Ap4A synthetase reactions were monitored in the presence and absence of
threonine. The rate of Ap4A synthesis was determined using autoradiography of αlabeled ATP tracers resolved by thin layer chromatography on PEI-cellulose (Figure
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Figure 31. Kinetic characterization of TARS Ap4A synthesis activity.
(A) Representative autoradiographic images used for quantifying TARS Ap4A synthesis
under untreated or 10 μM BC194 conditions. Reactions were monitored using [α32P]labeled ATP as a tracer and each time point was spotted onto a polyethyleneiminecellulose thin-layer chromatography plate and resolved using 3M ammonium sulfate and
2% EDTA. (B-E) Rate of Ap4A synthesis by purified TARS constructs under various
conditions (B-E). (B) Ap4A formation by 5 μM WT TARS (blue), R442A TARS (red), Ec
ThrRS (green), or WT TARS in absence of threonine (purple). (C) Ap4A synthesis by WT
TARS in the presence of 0 μM (blue), 1 μM (red), 5 μM (green), or 10 μM (purple)
tRNAThr. (D) WT TARS Ap4A formation uninhibited (blue), with 10 μM BC194 (red), or
with 10 μM borrelidin (green). (E) Ap4A synthesis by WT TARS in the presence of 0 μM
(blue), 1 μM (red), 5 μM (green), or 10 μM (purple) tRNAThr and 10 μM BC194. All data
presented as mean ± SD, n=3.
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31A). Rates are presented as the number of Ap4A molecules generated per enzyme per
minute (Table 7). Where possible, the rates have been adjusted to represent the active
concentration of enzyme.
The reactions without threonine did not deviate significantly from background,
in contrast to the 0.1391 min-1 received for the threonine containing reactions (Figure
31B). These data indicated that the reaction likely proceeded though an adenylate
intermediate and that all subsequent reactions should be performed in the presence of
threonine. To confirm that the threonine was not simply required for structural purposes
threonine-containing reactions were investigated using the adenylation deficient R442A
TARS mutant. Like the reactions lacking threonine, no significant activity was observed.
Conversely, Ec ThrRS readily catalyzed the reaction at a rate of 0.5052 min-1, which is
more than three times the rate observed for the human enzyme.

Table 7. Rates of Ap4A synthesis by various TARS constructs
Construct
WT TARS:

Condition
Uninhibited
10 μM Borrelidin
10 μM BC194
No Threonine
R442A TARS:
Uninhibited
Ec ThrRS:
Uninhibited
*Relative to WT TARS, uninhibited

Activity (min-1)
0.1391 ± 0.007845
0.05652 ± 0.005461

0.09595 ± 0.002774
0.0008236 ± 0.0003371
0.001343 ± 0.0001381
0.5052 ± 0.04095

% Activity*
100
40.6
69
0.5
1
363

In addition to threonine, the effect of the tRNAThr on the reaction rate was also
investigated (Figure 31C; Table 8). The presence of uncharged tRNA would be expected
to inhibit Ap4A synthesis through the adenylate intermediate mechanism by allowing for
the resolution of the adenylate through the canonical transfer reaction and reducing its
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availability for Ap4A formation. Due to low concentrations of tRNAThr used in the
reactions (1 μM to 10 μM) relative to the enzyme concentration of 5 μM and the long
reaction duration, the presence of tRNAThr was only expected to exert minor effects, if
any, as most would be converted to aminoacylated product early in the reaction’s
progression. Surprisingly, the addition of 1 μM, 5 μM, and 10 μM of tRNAThr produced a
dose-responsive increase in Ap4A formation rates of 0.1690 min-1, 0.1793 min-1, and
0.2528 min-1 (corresponding to 21%, 29%, and 82% increases) relative to 0.1391 min-1
without tRNAThr. The reason for this increase, however, remains unknown.

Table 8. The effects of tRNAThr on the rates of WT TARS Ap4A synthesis
Construct
WT TARS:

Condition
0 μM tRNAThr
1 μM tRNAThr
5 μM tRNAThr
10 μM tRNAThr
0 μM tRNAThr; 10 μM BC194
1 μM tRNAThr; 10 μM BC194
5 μM tRNAThr; 10 μM BC194
10 μM tRNAThr; 10 μM BC194
*Relative to WT TARS, uninhibited.

Activity (min-1)
0.1391 ± 0.007845
0.1690 ± 0.008302
0.1793 ± 0.01076
0.2528 ± 0.01468
0.09595 ± 0.002774
0.08143 ± 0.004001
0.1171 ± 0.01041
0.1206 ± 0.01165

% Activity*
100
121
129
182
69
59
84
87

Previous work has demonstrated that borrelidin mediates its anti-angiogenic
effects through TARS. Since Ap4A-signaling represents a possible mechanism for
TARS-mediated angiogenesis it was important to investigate the effects of borrelidin on
rate of Ap4A synthesis. Like with the GTPase activity, borrelidin or BC194 were added
at saturating conditions (10 μM compound compared to 5 μM enzyme) (Figure 31D). The
presence of the two compounds reduced the rate of Ap4A formation to 40.5% (0.05652
min-1) and 69% (0.09595 min-1) respectively. This was not surprising as borrelidin and
BC194 are known to inhibit TARS adenylate formation (19). The effect of BC194
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inhibition on the tRNA stimulation effect was also tested (Figure 31E). Unlike with the
uninhibited reaction, the addition of 1 μM, 5 μM, and 10 μM of tRNAThr had less of an
effect on Ap4A formation with rates of 0.08143 min-1, 0.1171 min-1, 0.1206 min-1
(corresponding to a 15% decrease at 1 μM tRNAThr and a 22% and 26% increase at 5 μM
and 10 μM tRNAThr relative to the reaction treated with BC194 alone).

Table 9. Rates of Ap4G synthesis by various TARS constructs
Construct
WT TARS:

Condition
Uninhibited
10 μM BC194
No ATP
R442A TARS:
Uninhibited
Ec ThrRS:
Uninhibited
*Relative to WT TARS, uninhibited

Activity (min-1)
0.1639 ± 0.01224
0.07065 ± 0.009176
0.01278 ± 0.005864
0.01062 ± 0.004659
0.5612 ± 0.06121

% Activity*
100
43
8
6
342

In addition to Ap4A synthesis, TARS was also found to catalyze the formation
of Ap4G. Ap4G formation was monitored using the same method as Ap4A except that αphosphate labeled GTP was used as a tracer and final calculated value was not cut in half
because, unlike with Ap4A, only one labeled phosphate would be included per molecule
(Table 9). WT TARS catalyzed the formation of Ap4G at a rate of 0.1639 min-1, nearly
identical to the 0.1391 min-1 obtained for Ap4A formation (Figure 32A). As proof of the
products identity as Ap4G and not Gp4G, the reaction was run in the absence of ATP and
with the aminoacylation deficient R442A mutant, which yielded rates of 0.01278 min-1
and 0.01062 min-1 respectively. Together these data indicated that Ap4G synthesis was
dependent on the formation of the threonyl-adenylate before the adenosine moiety is
transferred to the second GTP molecule. Consistent with Ap4A formation, treatment with
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Figure 32. TARS catalyzes the synthesis of the hybrid dinucleotide tetraphosphate Ap4G.
(A) Ap4G formation by 5 μM WT TARS (blue), R442A TARS (red), Ec ThrRS (green), or WT
TARS in absence of threonine (purple). (B) WT TARS Ap4G formation uninhibited (blue) or
with 10 μM BC194 (red). All data are presented as mean ± SD, n=3.

BC194 reduced the rate of Ap4G synthesis to 0.07065 min-1, 43% of the uninhibited
reaction (Figure 32B).

5.2.3 TARS Catalyzes the Formation of ADP from ATP
The conversion of ATP to ADP by TARS was discovered accidently when a band
corresponding to ADP was identified on a thin layer chromatography plate originally
monitoring the formation of the threonyl-adenylate intermediated. While initially
dismissed as a substrate contaminant, its formation appeared to increase over the course
of the reaction, suggesting that it was a product of the reaction. Like with the GTPase and
Ap4A activities above, this find was particularly interesting due to the recognized
connection between extracellular nucleotides and the regulation of angiogenesis through
purinergic signaling. Notably, extracellular ADP is well documented to regulate
endothelial cell migration, much like TARS. Specifically, ADP activates the G-protein
coupled receptor P2Y1, which is highly expressed within endothelial cells (20).
164

Stimulation of this receptor in endothelial cells leads to the phosphorylation and
activation of several key mitogen-activated protein kinases involved in endothelial cell
migration, including ERK1/2, JNK, and p38 MAPK (12). Additionally, activation of the
P2Y1 receptor has been demonstrated to transactivate VEGFR2, providing an indirect
method for the regulation of angiogenesis (21).

Table 10. Rates of ADP formation by various TARS constructs
Construct
WT TARS:

Condition
Uninhibited
10 μM Borrelidin
10 μM BC194
No Threonine
R442A TARS:
Uninhibited
Ec ThrRS:
Uninhibited
*Relative to WT TARS, uninhibited

Activity (min-1)
0.1417 ± 0.01409
0.2777 ± 0.03141
0.2738 ± 0.02056
0.3925 ± 0.03888
0.1059 ± 0.01121
0.01330 ± 0.02283

% Activity*
100
182
193
277
75
9

ADP formation was measured from same reaction samples used for Ap4A
except that they were separated by TLC using a potassium phosphate buffer instead of the
ammonium sulfate/EDTA mix (Figure 33A). As with Ap4A, the amount of ADP at each
time point was determined as a fraction of the total nucleotides in the sample and
compared to the initial concentration of ATP added to the reaction. Rates are presented
as the number of ADP molecules generated per active site (or total enzyme concentration
for R442A) per minute (Table 10). Because the measurements of ADP were taken from
Ap4A reactions retrospectively, they are limited by the conditions used for Ap4A
synthesis. As such, nearly all measurements contain threonine.
Full kinetic investigations have been performed on WT TARS, WT ThrRS, and
the aminoacylation deficient R442A TARS (Figure 33B). Both WT and R442A TARS

165

Figure 33. Kinetic characterization of TARS ADP formation.
(A) Representative autoradiographic images used for quantifying TARS ADP formation under
untreated or 10 μM BC194 conditions. Reactions were monitored using [α32P]-labeled ATP as
a tracer and each time point was spotted onto a polyethyleneimine-cellulose thin-layer
chromatography plate and resolved using 750 mM potassium phosphate, pH 3.5 buffer. (B-E)
Rate of ADP formation by purified TARS constructs under various conditions. (B) ADP
formation activity of 5 μM WT TARS (blue), R442A TARS (red), Ec ThrRS (green), or WT
TARS in absence of threonine (purple). (C) ADP formation rates of WT TARS in the
presence of 0 μM (blue), 1 μM (red), 5 μM (green), or 10 μM (purple) tRNAThr. (D) WT
TARS ADP formation rates uninhibited (blue), 10 μM BC194 (red), or 10 μM borrelidin
(green). (E) ADP formation rates of WT TARS in the presence of 0 μM (blue), 1 μM (red), 5
μM (green), or 10 μM (purple) tRNAThr with 10 μM BC194. All data are presented as mean ±
SD, n=3.
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formed ADP from ATP, with rates of 0.1417 min-1 and 0.1059 min-1 respectively. Since
R442A TARS is unable to catalyze the first, adenylation step of aminoacylation, these
data would suggest that ADP formation is separate from the canonical reaction of the
enzyme. It may also be worthwhile to note that, due to loss of adenylation activity, the
active concentration of R442A could not be determined before these assays requiring that
the total protein concentration be used instead. Therefore, it is possible that the rates of
WT and R442A TARS would be closer if R442A TARS could be adjusted for the active
concentration. In contrast to the human constructs, Ec ThrRS exhibited no activity above
background with a rate of 0.01330 min-1, about 9% of the activity observed with the
human enzyme. Therefore, like GTPase activity, ADP formation appeared to be a human
phenomenon (although it remains to be tested in other organisms).
When the reaction was run in absence of threonine, WT TARS exhibited a rate of
0.3925 min-1, about 2.77 fold higher than the reaction with threonine (Figure 33B). While
this reaction was not completed in triplicate like the others (this reaction was not
necessary for the Ap4A studies) it does indicate that the reaction does not require
threonine and suggests that, while ADP formation is a separate reaction from
aminoacylation, it may still respond to aminoacylation substrates. Surprisingly, while
threonine appeared to negatively impact the rate of ADP formation, the opposite was true
for tRNAThr additions to the reaction (Table 11). The addition of 1 μM, 5 μM, and 10 μM
tRNAThr increased the reaction rate from 0.1417 min-1 to 0.2804 min-1, 0.4063 min-1, and
0.6561 min-1 respectively, which correspond to increases of 98%, 187%, and 363%
(Figure 33C).
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Table 11. The effects of tRNAThr on the rates of WT TARS ADP formation
Construct
WT TARS:

Condition
0 μM tRNAThr
1 μM tRNAThr
5 μM tRNAThr
10 μM tRNAThr
0 μM tRNAThr; 10 μM BC194
1 μM tRNAThr; 10 μM BC194
5 μM tRNAThr; 10 μM BC194
10 μM tRNAThr; 10 μM BC194
*Relative to WT TARS, uninhibited

Activity (min-1)
0.1417 ± 0.01409
0.2804 ± 0.008072
0.3993 ± 0.03835
0.6479 ± 0.04162
0.2738 ± 0.02056
0.3766 ± 0.03478
0.4463 ± 0.06611
0.5870 ± 0.04631

% Activity*
100
198
287
463
193
266
304
413

The connection between the ADP and angiogenesis opened the possibility of
this ADP reaction as a potential mechanism for TARS’s effects on endothelial cell
migration. Like with Ap4A, this hypothesis would also suggest that borrelidin and related
compounds would be able to inhibit angiogenesis by altering the rate of this reaction.
Therefore, the effects of Borrelidin and BC194 on this reaction were subsequently
investigated (Figure 33D). At saturating amounts (10 μM relative to the 5 μM TARS)
both compounds appeared to enhance the rate of the reaction: borrelidin increased the
rate by 82% (0.2578 min-1) and BC194 by 92% (0.2738 min-1). This is very different
from the potent inhibitory effects exhibited by the compounds against the canonical
aminoacylation reaction. The effect of tRNAThr on the BC194-treated reaction was also
investigated to check if the activity increase by tRNAThr is lost, enhanced, or unaffected
by BC194 (Figure 33E). At concentrations of 1 μM, 5 μM, and 10 μM tRNAThr the
reactions increased to 0.3766 min-1, 0.4304 min-1, and 0.5859 min-1 respectively. This
corresponds to enhancements of 38%, 57%, and 114% relative to the reaction treated
with BC194 alone and 93%, 166%, and 313% relative to the untreated reaction. Given
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the similarities in these values when compared to the untreated, WT TARS reaction, it
appears that the rate increases by BC194 are masked by those provided by the tRNA.
While kinetic rates for ADP formation have not be thoroughly investigated with
the other TARS constructs used in this work, the ability of these enzymes to catalyze this
reaction can be identified qualitatively from observations of other experiments.
Specifically, the TLC plates used in the determination of active site concentrations can be
used to assess for the absence or presence of ADP. However, due to the very different
assay conditions, direct comparisons concerning rates cannot be made. Using this method
ADP formation has been observed with the borrelidin-resistant L567V TARS, the
angiogenesis but aminoacylation active Q566W TARS, and the angiogenesis and
aminoacylation deficient A538W TARS (Data not shown).

5.2.4 Effects of purinergic inhibitors on TARS-mediated angiogenesis
Previously ADP and Ap4A have been shown to regulate angiogenesis by
stimulating the purinergic receptors P2Y1 and P2X respectively. Therefore, the effects of
purinergic signaling by TARS-generated ADP and Ap4A on angiogenesis were
investigated using an endothelial tube formation assay and inhibitors of the P2Y1 and
P2X receptors (Figure 34A, B). As previously described, the presence of TARS at 100
nM enhanced tube formation by around 50%. Interestingly, the inclusion of 10 μM of the
P2Y1 receptor inhibitor MRS2179 completely inhibited TARS-mediated angiogenesis
back to baseline levels (Figure 34A). Conversely, no significant inhibitory effects were
observed for the P2X inhibitor Ip5I (Figure 34B). However, the Ip5I treated cultures
appear to visually trend to a reduction in tube-formation and may warrant additional
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replications to see if statistical significance can be obtained. Neither MRS2179 nor Ip5I
exhibited significant effects on baseline tube formation in absence of TARS.

Figure 34. The effects of purinergic receptor inhibitors MRS2179 and Ip5I on TARSmediated angiogenesis.
(A, B) Quantification of HUVEC branching in control of 100 nM WT TARS-treated
cultures with and without MRS2179 (A) or Ip5I (B). HUVECs were plated on Matrigel in
10% EGM-2 (0.2% FBS) media and exposed to various combinations of buffer, 100 nM
TARS, and 10 μM of MRS2179 or Ip5I. Cells were fixed after 4-8 h and stained with
Oregon Green 488 Phalloidin. Numbers represent percentage of control (0 nM) samples,
mean ± SEM, n=3, ** and **** correspond to p<0.01 and 0.0001 respectively relative to
the TARS-treated sample (one-way ANOVA, Tukey Test).

5.3 Discussion
5.3.1 Correlations between non-canonical, catalytic reactions and TARS-mediated
angiogenesis
The data presented above demonstrate that TARS is capable of catalyzing
several different reactions in addition to its canonical role in aminoacylation. For
comparative purposes the various constructs and their ability to perform canonical and
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non-canonical functions are listed in Table 12. Unfortunately, no simple conclusions can
be drawn between the angiogenic potential of the various TARS constructs and their
participation in non-canonical catalytic activities. Primarily, the difficulty arises with
either R442A TARS or Ec ThrRS. Both of these constructs have been demonstrated to
stimulate angiogenic responses in endothelial tube formation assays. However, since Ec
ThrRS lacks GTPase activity and ADP formation and R442A TARS is unable to
synthesize Ap4A or Ap4G, none of these reactions can be clearly attributed to the
initiation of angiogenesis. Nonetheless, some explanations can be developed.

Table 12. The functions of various TARS constructs
Construct
WT TARS
WT ThrRS

Description

Aminoacylation
Yes
Yes

Angiogenesis
Yes
Yes

ATP to
ADP
Yes
No

GTPase

Ap4A/
Ap4G
Yes
Yes

Human enzyme
Yes
E. coli enzyme
No
Aminoacylation
R442A TARS
No
Yes
Yes
Yes
No
deficient
L567V TARS Borrelidin resistant
Yes
Yes
Yes
Yes
Yes
Most N-terminal
N1-Domain
domain; no known
No
No
Unlikely*
No
No
function
Catalytic and antiΔN1N2codon binding
Likely‡
No
Unknown Unknown
Likely#
Domain
domains only
Borrelidin
Q566W TARS
Yes
No
Yes
Likely*
Likely#
conformation mimic
Borrelidin
A538W TARS
No
No
Yes
Likely*
Unlikely#
conformation mimic
* When tested, all constructs with ATP to ADP or GTPase activity have exhibited the other as well.
‡
ΔN1N2-TARS is capable of rescuing cells from loss of WT TARS, supporting aminoacylation function.
#

So far, all constructs able to perform aminoacylation appear capable of Ap4A and Ap4G synthesis.

The discovery of GTPase activity in TARS opened up the possibility that this
reaction could function as a switch between TARS’s canonical and non-canonical
functions. Since TARS is normally found in the cytoplasm, it seems likely that the

171

GTPase would initiate this switch event intracellularly. However, TARS’s angiogenic
function requires that the protein be secreted outside the cell. Since the test substances are
added extracellularly during the tube formation assay, any potential importance of the
GTPase function would have been bypassed and, thus, would not have affected Ec
ThrRS’s ability to simulate angiogenesis.
Of the three non-canonical reactions (GTPase, Ap4A/Ap4G synthesis, and ADP
formation) the formation of ADP appears to be the strongest candidate as a mechanism
for TARS-mediated angiogenesis. First, ADP is already known to stimulate endothelial
cell migration, a function that is also attributed to TARS, through the stimulation of the
P2Y1 receptor. The fact that the P2Y1 specific inhibitor, MRS2179, appears to attenuate
TARS-mediated angiogenesis suggests that ADP purinergic signaling is important for
this process as well. Furthermore, while Ec ThrRS is unable to generate ADP, it does
catalyze the formation of Ap4A at a faster rate than human TARS. Since Ip5I did not
seem to affect TARS-mediated angiogenesis, it seems unlikely that Ap4A is instigating
its own purinergic signaling through the P2X receptor. However, Ap4A can be broken
down into two ADP molecules by extracellular proteins, providing an alternative method
of synthesizing ADP. Therefore, all angiogenic constructs appear to possess the ability to
synthesize ADP to some degree. Furthermore, the rate of this hydrolysis appears to be
slower than the breakdown of other extracellular adenosine phosphate nucleotides to
adenosine, suggesting that Ap4A may also serve to prolong the purinergic response (22).
This model, however, does not provide a clear mechanism for borrelidin and BC194’s
inhibition of angiogenesis.
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Treatment of TARS with borrelidin and BC194 appears to stimulate the
production of ADP instead of inhibiting it. One possible explanation for this may be
connected to the assay conditions used in the measurement of ADP formation. Because
ADP formation was measured retrospectively using time points from the Ap4A assays,
most of the reactions contained threonine. Interestingly, the one reaction that did not
contain threonine exhibited the fastest measured rate of ADP formation. While threonine
did not fully block the reaction it may have stabilized a less efficient conformation of the
TARS active site and slowed the reaction rate. This observation suggests that the rate
enhancement exhibited by borrelidin and BC194 may be due to their competition with
threonine in the reaction, a hypothesis that would be easily confirmed by investigating the
effects of borrelidin and BC194 on ADP formation in absence of threonine. Therefore, it
seems unlikely that borrelidin and BC194 would influence the ADP-mediated
angiogenesis through modification of the ADP formation rate.
Since borrelidin and BC194 do not actually appear to affect the rate of ADP
formation, they would have to inhibit ADP-mediated angiogenesis through a different
mechanism. Previously, the borrelidin and BC194 induced conformational changes have
been demonstrated to be important for inhibiting TARS-mediated angiogenesis as
demonstrated by the conformational mimetic mutations Q566W TARS and A538W
TARS (Chapter 4, section 4.2.6). Interestingly, both of these constructs possess the
ability to catalyze the conversion of ATP to ADP, providing further evidence that
inhibition of ADP formation cannot be responsible for borrelidin and BC194’s inhibition
of angiogenesis. As an alternative it may be that, as part of its angiogenic mechanism,
secreted TARS forms protein complexes that help localize it to specific extracellular
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regions. This spatial arrangement may bring it close to the P2Y1 receptor and, thus,
would enhance its activation. In this model, borrelidin and BC194 would then induce
conformational changes in TARS and disrupt its interaction with the protein complexes.
It is important to note, however, that this discussion of how TARS can stimulate
angiogenesis through ADP formation and its disruption by borrelidin and BC194 is only
to establish it as a possible model. Therefore, while all the acquired data would support
ADP as a possible mechanism for TARS-mediated angiogenesis, more data are needed to
affirm it.

5.3.2 Nucleotide preference in non-canonical, catalytic reactions
One trend that can be observed in Table 12 is that all enzymes that possess
GTPase activity also possess the ability to convert ATP to ADP. Furthermore, the
addition of ATP clearly inhibits the GTPase activity in all conditions. Therefore, it may
be possible that both functions compete for the same active site and, based on the rate
data, there is a preference for adenosine nucleotides. Without further data it is difficult to
say if the use of GTP in this reaction is an unintended side reaction or if it has a specific
purpose. Phosphorylation has been previously shown to enhance the rate of Ap4A
synthesis in TARS, therefore, it may be that some similar regulatory event might be able
to increase the sites affinity for GTP over ATP. Alternatively, it may be that this GTPase
activity functions as a switch between the canonical and non-canonical functions of the
TARS proteins.
While the conversion of nucleotide triphosphates to nucleotide diphosphates by
TARS appears to prefer adenosine-based molecules over those with guanosine, the
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opposite appears to be true for the synthesis of dinucleotide tetraphosphates. The
synthesis of both Ap4A and Ap4G required that ATP be present for the formation of the
threonyl-adenylate intermediated. As such, the synthesis of Ap4G should be in
competition with that of Ap4A, assuming that both reactions are occurring in the same
active site (which is reasonable given the dependence on the threonyl-adenylate). Under
these conditions the rate of Ap4G would be expected to be slower than Ap4A due to this
competition. However, Ap4G formed at rates comparable to Ap4A when ATP was the
only nucleotide present. Therefore, it appears as if the formation of Ap4G is preferred
over Ap4A. The affinity of other nucleotides for this reaction remain to be determined.

5.3.3 ADP-formation and GTPase activity as nutrient and energy sensors
As presented in Chapter 1, sections 1.2.1 and 1.6.1 a growing body of evidence
implicates the ARSs as cellular nutrient and energy sensors. As the rates of ADP
formation and GTPase activity in TARS are influenced by the levels of threonine and
ATP respectively, these reaction may also serve a similar function. In absence of
threonine, the rate of ADP generation increased 277%. The elevated levels of ADP
associated with these rates could then improve TARS’s stimulation of angiogenesis
through the P2Y1 receptor or by activating some other, yet unknown response (11,12).
Moreover, the extracellular concentrations of threonine are thought to be lower than those
inside the cell, which would further enhance ADP production following TARS secretion
(23). In contrast to ADP formation, the presence of ATP almost completely inhibits
TARS’s GTPase activity. As such, this activity would be limited to conditions of low
energy within the cell. Since GTPase activities in other proteins have been demonstrated
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to modify their functions, this property could serve to switch TARS between its canonical
and non-canonical functions in response to cellular energetic levels (15). However, it
remains to be determined if ADP, which would be abundant under low energy conditions,
has any influence on the rate of GTPase activity as well.

5.3.4 The effect of tRNAThr on ADP formation and Ap4A
The observation that tRNAThr stimulates both ADP and Ap4A formation is
interesting but its function and mechanism remain unknown. In both these reactions
threonine and ATP are present in great excess, suggesting that any tRNAThr present
should be fully charged by the first time point (this seems to be a safe assumption as
TARS is present at 5 μM and would only require two turnovers in 30 minutes to
aminoacylate 10 μM tRNAThr, the highest concentration used in any of the reactions).
Curiously, the stimulatory effect of tRNAThr on ADP formation is unaffected by the
presence of BC194 while it is reduced in Ap4A synthesis. However, this difference may
be due to BC194’s inhibition of the adenylation reaction, which would disrupt Ap4A
synthesis and compete with the positive effects of tRNAThr. Conversely, ADP formation
appears independent of aminoacylation and would be unaffected.
As a possible explanation for the positive effects of tRNAThr on ADP-formation,
the accumulation of charged-tRNAThr in the reaction may block the canonical
aminoacylation reaction through product inhibition. As the GTPase reactions above did
not include threonine, no Thr-tRNAThr was generated, consistent with the lack of tRNAinduced kinetic effects. Conversely, since threonine was demonstrated to reduce ADP
formation, product inhibition by Thr-tRNAThr may enhance ADP formation by blocking
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threonine binding to its original substrate pocket. Likewise, BC194 also blocks threonine
binding (Chapter 2, section 2.2.3) and may explain its enhancement to ADP-formation
rates as well. Because the binding of tRNAThr and BC194 are mutually exclusive and
would both depend on the exclusion of threonine to induce rate enhancements in this
model, synergistic effects would not be expected, consistent with the above results.
However, since the rate of ADP generation in absence of threonine (0.3925 min-1) is less
than that observed at 10 μM tRNAThr with or without BC194 (0.6479 and 0.5870 min-1) it
seems likely that threonine exclusion may not be the only effect.
As an alternative or complementary mechanism, the binding of Thr-tRNAThr to
one active site of a TARS dimer may alter the non-canonical activities within the same or
other monomer. Previously, pre-steady state kinetics have demonstrated that the presence
of tRNA reduces the rate of amino acid activation by Ec ThrRS (24). For another dimeric
ARS, E. coli Histidyl-tRNA synthetase (HisRS), the adenylation reaction appears to
proceed asymmetrically between the two monomers in absence of tRNA. Specifically,
these investigations reveal that the second site is able to bind ATP and amino acid only
after the first generates a bound adenylate intermediate. Even at this point, however, the
generation of the adenylate intermediate in the second site appears to occur at a much
slower rate (25). Interestingly, the addition of uncharged-tRNA appears to equalize the
rates of both sites, which suggests that tRNA may be important for coupling the reactions
in both sites (26). Therefore, it may be that product inhibition by charged-tRNA also
alters the individual activity or coupling of the active site monomers, albeit in favor of
non-canonical reactions. For ADP, the binding of charged-tRNA may induce
conformational changes within either active site that facilitates ADP-formation. In the
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case of Ap4A, the binding of charged tRNA in one site may encourage adenylate
formation in the other, which, without free-tRNA to continue with aminoacylation, is
resolved through the formation of Ap4A.

5.4 Experimental Procedures
5.4.1 Preparation of TARS Constructs and tRNAThr
The preparation of TARS constructs and tRNAThr was performed using
procedures identical to those described in Chapter 2, sections 2.3.1 and 2.3.2.

5.4.2 Ap4A, AMP, and ADP Formation assays
Ap4A synthesis was investigated using adaptations of previously reported
methods (3). Reaction mixtures consisted of 20 mM HEPES, pH 8.0, 100 mM KCl, 10
mM MgCl2, 5 mM β-mercaptoethanol, 5 mM threonine (unless otherwise noted), 2.5 U
pyrophosphatase (Roche), and 2.5, 5, or 20 µM E. coli ThrRS, wildtype human TARS, or
R442A TARS respectively. Where necessary, reactions were pre-incubated with 10 μM
BC194 or Borrelidin in DMSO or a comparable amount (0.05% V/V) of DMSO vehicle
for 15 minutes on ice prior to initiation. Reactions were then incubated at 37 °C for 3
minutes and initiated with the addition of 2 mM ATP. Aliquots were taken at varying
time points and quenched in 3 volumes of 400 mM sodium acetate, pH 4.5, and 0.1%
sodium dodecyl sulfate. Products were resolved by polyethyleneimine-cellulose TLC
plates with 3M (NH4)2SO4 and 2% EDTA as mobile phase and quantified by
phosphorimaging. The identity of Ap4A was confirmed by UV shadowing of an unlabeled standard. Ap4A production was calculated as a percentage of total counts and
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compared to the original amount of ATP present in the reaction. To account for the
incorporation of two ATP molecules per Ap4A product the final values were multiplied
by 0.5. ADP was measured using identical reactions except that products were resolved
using TLC with 750 mM potassium phosphate buffer, pH 3.5.

5.4.3 Ap4G synthesis and GTPase Assays
Ap4G and GTPase assays were performed as Ap4A synthesis above with the
following exceptions. Ap4G reactions always included 2 mM ATP and 2 mM threonine
and 10 µM BC194 where indicated in Figure 32B. For GTPase assays ATP and threonine
were not present in all reactions but were included in combination with 10 µM tRNAThr,
10 µM BC194, and 10 µM borrelidin according to Figure 29 C and D. Adenylation
conditions consisted of 2 mM ATP and 2 mM threonine and aminoacylation conditions
further included 10 μM tRNAThr. Reactions were initiated using 2 mM GTP with trace
amounts of [α-32P]-GTP. The components were resolved by TLC using the mobile phases
750 mM KH2PO4, pH 3.5 for GTPase data and 3 M (NH4)2SO4 and 2% EDTA for Ap4G.
Unlike with Ap4A, Ap4G involves only the incorporation of one labeled nucleotide and
does not require the 0.5 correction factor.

5.4.4 Cell Culture and Reagents
Human umbilical endothelial cells (HUVECS) were maintained in Clonetics EGM-2
complete media (Lonza) and used between passages 5 to 8. MRS2179 and Ip5I were
obtained from Abcam® and Sigma-Aldich® respectively.
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5.4.5 Tube Formation Assay with MRS2179 and Ip5I
Tube formation assays were performed as previously described (8,27). Briefly
HUVEC cells were cultured on 0.1% gelatin coated plates until 95-100% confluent and
then seeded in to 48-well plates coated with MatrigelTM (BD biosciences). Cells were
incubated at 37 °C in EGM®-2 media with 2% FBS and 10 μM MRS2179 or Ip5I where
necessary for 4 to 8 h. Cellular structures were fixed with 10% neutral buffered formalin,
stained with Oregon Green 488 phalloidin (Molecular Probes), and imaged via
fluorescence microscopy. Tube structures were quantified using the Simple Neurite
Tracer plug-in on ImageJ software (NIH).
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CHAPTER 6: DISCUSSION AND FUTURE PERSPECTIVES

6.1 Mechanisms of TARS-mediated angiogenesis
6.1.1 Borrelidin’s inhibition of angiogenesis is mediated through direct interactions
with TARS
Initial connections between TARS and angiogenesis were based on the antiangiogenic properties of its potent inhibitor borrelidin. The fact that TARS is the only
known target of borrelidin with a Ki value in the low nM range coupled with the
observation of angiogenesis-related activities in other ARSs opens the possibility that
TARS may possess its own secondary functions in vascular biology. This relationship
was subsequently confirmed when extracellular TARS was found to stimulate vessel
formation and endothelial cell migration in several in vitro assays but was susceptible to
inhibition by the borrelidin-derivative BC194. Moreover, BC194’s inhibition of TARSmediated angiogenesis could be attenuated through a single TARS point mutation,
L567V, which indicates that the compound functions directly through TARS.
Further investigations of borrelidin and BC194 revealed that their inhibition of
angiogenesis could be separated from toxic effects on cells and more related to their
association with TARS’s function in vessel patterning and maturation. Specifically,
treatment of zebrafish with BC194 or knockdown of TARS expression with an antiTARS morpholino was shown to induce ectopic vessel growth and poor lumen
development. The similar responses exhibited by both the inhibitors and the knockdown
of TARS expression further supports TARS as the only target of borrelidin inhibition.
Furthermore, these experiments represent the first time that TARS’s secondary function
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in angiogenesis has been investigated in the context of a whole animal model. This
connection between TARS and vessel guidance indicated that TARS is likely to form a
regulated gradient that is followed by the migrating endothelial cells. Based on these
observations a model for the induction of angiogenesis by extracellular-TARS was
generated (Figure 35).

6.1.2 Investigating the angiogenic potential of various TARS constructs in the
zebrafish model
The investigations of TARS and its inhibitors on zebrafish vascular biology
provide critical insights into the mechanisms of TARS-mediated angiogenesis. Moreover,
the successful knockdown of TARS expression by the anti-TARS morpholino offers an
opportunity to investigate the effects of the various TARS constructs on vessel patterning
in the context of a whole organism model. Following morpholino treatment cappedmRNA corresponding to the various TARS constructs characterized in Chapter 4 can be
injected into developing zebrafish embryos to complement the reduction of endogenous
TARS. Of particular interest, L567V TARS can be used to investigate the ability of this
construct to resist the effects of borrelidin treatment and provide additional confirmation
to the TARS-specific nature of these observations. Alternatively, Q566W TARS can be
injected to investigate the effect of the borrelidin-conformation mimic on zebrafish vessel
development. Since Q566W TARS retains aminoacylation function, this
complementation would be expected to produce the ectopic branching associated with the
angiogenesis specific effects of TARS without the toxicity associated with amino acid
starvation. Finally, the ΔN1N2-TARS construct can be investigated since it still possesses
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Figure 35. Proposed models for TARS-stimulation and borrelidin-inhibition of
angiogenesis.
(Left) Step by step proposal for stimulation of angiogenesis by TARS: 1) Activation of
immune cells and hypoxic responses in cancer cells stimulate the secretion of TNFα and
VEGF respectively. 2) TNFα and VEGF bind to receptors on the surface of endothelial cells.
3) Activation of unknown signaling pathways stimulates the secretion of TARS from
endothelial cells. 4) Stimulation of hypoxic cancer cells with TNFα also stimulates secretion
of TARS (1). 5) Extra-cellular TARS forms a free or ECM-bound gradient that guides the
migration of nascent vessels. (Right) Proposed mechanisms of borrelidin’s inhibition of
angiogenesis. Mechanism 1 – binding of Bor elicits a conformational change in TARS that
precludes its binding to an unknown receptor. Mechanism 2 – A borrelidin-mediated
conformational change disrupts spatial regulation of secreted TARS by blocking interactions
with the extra-cellular matrix. Mechanism 3 – Inhibition of TARS aminoacylation activity by
borrelidin results in the accumulation of uncharged-tRNA which activates GCN2-mediated
amino acid starvation responses.

aminoacylation activity (although not trans-editing function) but lacks the ability to
stimulate angiogenesis in tube-formation assays. Therefore, the two binding site model
could be investigated in the context of a whole organism.
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6.1.3 TARS interacts with endothelial cell-derived extracellular matrices
The observation of an angiogenic factor mediating two simultaneous
interactions is not uncommon. Many of these molecules, notably platelet-derived growth
factor (PDGF) and vascular endothelial growth factor (VEGF), associate with both a cell
surface receptor as well as components of the extracellular matrix (2-4). This mechanism
allows for the establishment of a spatially regulated gradient that assists in proper
signaling to growing blood vessels. Disruption of the gradient’s spatial arrangement or its
ability to interact with cellular receptors would, therefore, influence the navigation ability
of migrating cells and produce defects in vessel patterning.
PDGF released from vessels is important for guiding the migration of pericytes,
blood vessel support cells, to newly formed vasculature. The targeting of the pericytes to
these vessels is dependent on the binding of PDGF to the ECM adjacent to the
endothelial cells. Loss of ECM binding by PDGF results in the accumulation of pericytes
away from existing vessels as PDGF diffuses into the extracellular space (2).
Alternatively, remodeling of the ECM by matrix-metalloproteases (MMPs) during
angiogenesis can expose trapped soluble factors concealed within the matrix. For
instance, MMP cleavage can separate the receptor binding portion of VEGFA from the
ECM interaction domain, effectively generating a soluble VEGFA population. While
both ECM-bound and soluble VEGFA appear to be bioactive, the two forms elicit
differential effects on endothelial cells. Specifically, soluble VEGFA initiates more
proliferative functions while bound isoforms induce a more migratory state (5,6). The
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cause of this differential signaling is the direct association of the VEGFA receptor
(VEGFR2) and a class of ECM-recognizing receptors known as integrins.
Endothelial cells are sensitive to the condition of the ECM through the
heterodimeric integrins which are activated by interactions with matrix proteins like
fibronectin and vitronectin (7). Even when anchored to the ECM, VEGF remains
bioactive and induces responses distinct from soluble VEGF (4). Specifically, bound
VEGF appears to stimulate a population of VEGFR2 in complex with β1 integrin, which
subsequently relocates to multimeric focal adhesion complexes involved in endothelial
cell migration. In comparison to soluble VEGF, the cooperation between integrin and
VEGF receptors exhibits greater activation of the pro-migratory p38-mitogen-activated
protein kinase (p38-MAPK) (4). Moreover, other receptor tyrosine kinases (RTKs) than
VEGFR2 have been demonstrated to interact with integrins and underlie a complex
interaction between angiogenic signaling and the ECM that is too extensive to be
explained here in full detail (8). However, these observations do emphasize the potential
importance of TARS-ECM interactions for the mechanism of the ARS’s function in
angiogenesis.
Similar to VEGF and PDGF, observations in Chapter 4 suggest that TARS
forms two separate interactions in the process of stimulating angiogenesis. Combining the
various TARS constructs with the HUVEC tube formation assay (Chapter 4) allowed the
structural components and activities important for TARS-mediated angiogenesis to be
determined. The lack of angiogenic activity associated with the ΔN1N2-TARS truncation
(containing only the catalytic and anti-codon binding domains) demonstrates that the fulllength protein is necessary for TARS’s vascular functions. Moreover, the addition of this
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construct appeared to inhibit tube formation, suggesting that it might titrate away and
interaction between the full-length protein and its target. When considered with the loss
of secondary activity observed with the borrelidin-conformation mimic mutation Q566W
TARS, these data suggest that two simultaneous protein-protein interactions are required
for TARS-mediated angiogenesis. This hypothesis is also supported by the lack of
angiogenesis exhibited by the N1-domain alone as well. However, this experiment should
be reinvestigated using a fragment consisting of both the N1 and N2 domains so that all
domains of TARS can be fully investigated.
In this model, the first interaction, putatively between TARS and the ECM,
establishes a gradient for nascent blood vessels essential for proper patterning. The bound
TARS then makes a second interaction with a cellular surface receptor or related protein
complex to mediate the necessary intracellular signaling pathways for migration.
Borrelidin would be able to disrupt either the formation of the TARS gradient by
inhibiting the TARS-ECM interaction or the intracellular signaling by blocking the
TARS-receptor interaction. Recent preliminary data by Hannah Poulette and Karen
Lounsbury provide some support for this model. Immunofluorescence experiments reveal
that extracellular TARS readily binds to HUVEC-derived extracellular matrix (Figure
36A, B). Treatment with BC194, however, has no noticeable effect on TARS binding
(Figure 36B). Similar to in vitro angiogenesis assays, equivalent interactions are not
observed with the non-specific ARS control leucyl-tRNA synthetase (LARS) (Figure
36B) ((9) and Chapter 4), suggesting that the interaction is not general among the ARS
family.
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Figure 36. TARS interacts with endothelial cell derived fibronectin.
Endothelial cells (HUVECs) were plated on gelatin and incubated for five days to allow for
the accumulation of extracellular matrix (ECM). In some cases (B) cells were lysed using 20
mM NH4OH and 0.5% Triton-X in PBS, which leaves the ECM intact. The cultures were then
treated for one hour under the indicated conditions and LARS, TARS, fibronectin (FN1),
nuclei (DAPI) detected by immunofluorescence. (A) Images of HUVEC-derived matrix with
intact cells treated with 100 nM TARS showing FN1 (left), TARS (middle), and merged with
DAPI (right). (B) Merged images of HUVEC-derived ECM with lysed cells treated with PBS
(Control) or as indicated in the figure. Data were kindly provided by Hannah Poulette and
Karen Lounsbury.
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The above observations are not the first evidence of TARS interaction with the
ECM. Affinity-purification mass spectrometry experiments interested in focal adhesion
complexes have reported interactions by TARS with fibronectin 1 (FN1) and integrins
(10). As mentioned above, the connection between focal adhesions complexes and
endothelial cell migration has been well established and is very important to the process
of angiogenesis. The interaction between integrin receptors and FN1 is strongly
dependent on an RGDS amino acid sequence and can disrupted through exposure to the
equivalent peptide (11,12). Interestingly, treatment with the RGDS-peptide appears to
disrupt the TARS-ECM interaction as determined by immunofluorescence experiments
(Figure 35B). However, the effect is specific to regions that appear to have been directly
beneath or adjacent to cells prior to dissolution and ineffective against TARS bound to
more distantly deposited FN1. A possible explanation for this difference is the status of
the fibronectin matrix itself. Soluble FN1 is typically found in a dimeric structure.
However, in a cell and integrin-dependent process these FN1 dimers can be reorganized
into multimeric, fibrillar networks through fibrillogenesis. Interestingly, the process of
generating matrix FN1 can also expose new interaction sites in the FN1 molecules
(13,14). Since the formation of the fibrillar form is dependent on cellular-based integrins,
the RGDS peptide may disrupt normal fibrillogenesis and negatively impact the binding
of TARS to these sites (15). Therefore, TARS-mediated angiogenesis may be dependent
on specific structure attributes of the FN1 matrix. However, the exact mechanistic details
of how these various forms of FN1 affect this process remain to be determined.

6.1.4 Identification of extracellular TARS binding partners
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Chapter 4 revealed that the angiogenesis-inhibitory properties of borrelidin and
BC194 are mediated through a specific conformational change within the TARS
aminoacylation domain. This observation suggests that TARS protein-protein
interactions are important for the ARS’s angiogenic function. As described in Appendix
I, affinity purification of TARS followed by mass spectrometry analysis revealed the
major cellular interaction partners of TARS. However, these experiments focused on
interactions within cellular lysates despite the fact that TARS appears to stimulate
angiogenesis extracellularly. As such, future experiments would benefit from interaction
studies focusing on extracellular and cellular surface interactions. Specifically,
fluorescently labeled TARS constructs can be used to determine if the enzyme interacts
with the cell surface and the specific domains involved. Furthermore, putative receptors
or extracellular interaction partners could be isolated by affinity purification of TARSassociated membrane complexes and identified by mass-spectrometry using
modifications to established procedures (10). The successful identification of these
interactions partners would allow for the better understanding of TARS-mediated
angiogenesis and would facilitate subsequent investigations of downstream signaling
pathways.

6.1.5 Identification of downstream signaling
In addition to establishing a gradient through associations with the ECM, the
two interaction model assumes that a second interaction mediates endothelial cell
migration through the activation of downstream signaling pathways. Several common
pathways involved in this process have already been investigated in the lab of Karen
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Lounsbury, including ERK1/2, p38-MAPK, and NF-κB (data not shown). Unfortunately,
the results so far have been inconclusive. Treatment of HUVECs with 100 nM TARS or
10 nM BC194 have exhibited no effects on the phosphorylation of p38-MAPK and NFκB. Conversely, both treatments have been observed to induce phosphorylation of
ERK1/2 within five minutes. However, this result is often inconsistent. Therefore, other
pathways should be investigated.
Several RTKs are involved in the regulation of angiogenesis. As mentioned in
Chapter 4, section 4.3.3, TLR 2 and 4 exhibit interesting characteristics that implicate
these proteins as possible TARS receptors. While these receptors often activate NF-κB,
which does not appear to be related to TARS-mediated angiogenesis, reported
associations between TLRs and integrins can alter the TLR-signaling, much like ECMbound VEGF (4,16,17). Furthermore, connections between TLR-signaling and activation
of signal transducer and activator of transcription 3 (STAT3) signaling have been
observed (18). STAT3 is activated through phosphorylation, which allows for the
protein’s homodimerization, nuclear translocation, and subsequent upregulation of target
genes though interactions with STAT binding elements (SBE) in the DNA. Interestingly,
SBEs have been identified upstream of both VEGF and TARS (TARS site identified by
DECODE, Decipherment of DNA elements database; SABiosciences), allowing for the
induction of angiogenesis as well as a potential positive feedback mechanism (19). This
potential connection between TARS and STAT3 signaling can be easily investigated
through Western blot analysis against phospho-STAT3. Nonetheless, no direct evidence
exists for TLRs as the putative TARS receptor, indicating that other targets should also
be considered.
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The connection between growth factor receptors and angiogenesis has been wellestablished in the literature. The most important of these, of course, is the activation of
VEGFR2 by VEGFA. However, EGFR, PDGFR, and FGFR can strongly influence this
process in response to other ligands as well (20). Furthermore, many of these receptors
have reported interactions with integrins, which can alter ligand-mediated signaling or
initial ligand-independent activation (21). Despite the varying affinities of these
receptors to different ligands the down-stream signaling cascades often overlap. The
connections between several of these common factors to TARS-mediated angiogenesis,
such as ERK1/2 and p38-MAPK, have already been investigated without clear results.
However, the zebrafish data presented in Chapters 3 and 4 implicate that TARS is likely
involved in the regulation of endothelial cell migratory mechanism. One potential
candidate for further investigation is Src kinase, which is can be activated through
phosphorylation by growth factor or integrin receptor stimulation (22,23).
Phosphorylated Src is able to activate focal adhesion kinase (FAK) which can
subsequently activate a variety of responses connected to migration, invasion, survival,
and growth (24). Furthermore, Src signaling has been demonstrated to activate STAT3
(25,26). As with STAT3 above, the connection between Src and TARS-mediated
angiogenesis can be easily investigated by Western blot against phosphorylated Src.

6.2 The nucleo-cytoplasmic distribution of TARS
6.2.1 TARS possesses an N-terminal region of unknown function
In addition to TARS four other ARSs have been associated with effects on
angiogenesis (described in Chapter 1). The secondary functions of each of these is
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dependent on domains acquired over the course of evolution not associated with
aminoacylation. While no appended domain has been directly connected to TARS’s
secondary function, the N-terminal region of TARS consists of the ubiquitin-like TGS
domain (residues 83-144) and an unstructured 82 amino acid extension (residues 1-82)
of unknown function. The N-terminal extension appears to have arisen in eukaryotic cells
and can be observed in even the most ancient of protists, such as Giardia lamblia.
Conversely, the TGS domain is retained from bacteria to humans. As indicated in
Chapter 4, E. coli TARS is capable of stimulating angiogenesis in tube formation assays,
suggesting that the N-terminal extension is dispensable for TARS-mediated angiogenesis
once TARS is extracellular (the possibility of intracellular regulation for TARS’s
angiogenic function by this extension remains to be determined). Moreover, since the
ΔN1N2-TARS fragment (consisting of the catalytic and anticodon-binding domains) was
unable to induce angiogenesis, the TGS domain may be essential for mediating a second
extracellular interaction important for angiogenesis. However, additional investigations
with the N2 editing domain are required to confirm this. The possible roles for the Nterminal extension, if any, have yet to be investigated.
Structural data and sequence alignments demonstrate that prokaryotic TARS
begins at the ubiquitin-like TGS domain while the eukaryotic homologs possess an Nterminal extension that varies between species. In humans this extension consists of 82
amino acids not visible by crystallography or NMR. Additionally, analysis of this region
using Prediction of Order and Disorder by machine LEarning (POODLE) software
confirms that the first 52 amino acids of the protein are disordered (27). Regions of
intrinsic disorder are often sites of protein-protein interactions and are covered in greater
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detail in Appendix I. Therefore, it is possible that the N-terminal extensions of eukaryotic
TARS mediate interactions required for the regulation of the protein’s secondary
functions.

6.2.2 TARS’s N-terminal region possess a possible nuclear localization signal
Alignments of eukaryotic N-terminal regions reveal that the sequences of these
extensions can vary greatly among different organisms. This is not surprising, however,
as mutations in obligate disordered regions are common owing to the fact that sequence
conservation is not as critical to maintaining disordered regions as it is with ordered ones
(28). Despite this sequence variance, however, some features appear to be maintained.
Notably, animals and other eukaryotes, such as Saccharomyces cerevisiae, possess a
KKXK sequence (KKKNK in humans) which is similar to other sequences demonstrated
to function as nuclear localization signals (NLSs) in other proteins (29). Of particular
interest, an NLS is essential for SARS’s control of angiogenesis through the regulation of
VEGF expression (30). As shown in Chapter 3, pharmacological inhibition of TARS can
also regulate VEGF expression, however, there are currently no reports that the KKKNK
sequence functions as an NLS, let alone is involved in the regulation of VEGF
expression.
In support of TARS’s putative NLS, preliminary data demonstrate that TARS
possesses a variable nucleo-cytoplasmic distribution. Immunofluorescence studies reveal
the presence of punctate TARS containing structures within the nucleus in both human
umbilical vein endothelial cells (HUVEC) (Figure 37; data by Hannah Naughton) and
SKOV3 ovarian carcinoma cells (SKOV) (Karen Lounsbury and Jessica Cassavaugh,
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unpublished data). Exposure of HUVEC cell cultures to 50 ng/μl VEGF further increased
this nuclear population of TARS (Figure 37, right panels). In contrast, treatment with 10
nM BC194 induced a clear peri-nuclear localization as demonstrated by the appearance
of a halo-like appearance of TARS immediately around the nucleus (Figure 37, left
panels). In combination, the VEGF and BC194 treatments increased both the nuclear and
peri-nuclear distribution of TARS. As a possible explanation for the peri-nuclear
distribution, the induction of amino acid starvation by BC194-inhibition of TARS may
induce endoplasmic reticulum-associated degradation pathways by activating responses
similar to the unfolded protein response (9,31,32). This nuclear distribution is partially
corroborated by Western blots comparing the presence of TARS in the cytoplasm and
nucleus.
To further investigate the subcellular distribution of TARS in endothelial cells,
nuclear and cytoplasmic fractions from cultures treated with BC194 and VEGF were
obtained and the presence of TARS determined by Western blot (Figure 38A, B). While
full-length TARS was not observed in endothelial cell nuclear extracts treated with
control, BC194, VEGF, or BC194/VEGF combination conditions, a band corresponding
to a ~35 kDa fragment was observed under all conditions and appeared to increase in
BC194 and VEGF treated samples. Furthermore, the effects of BC194 and VEGF on the
appearance of the band were additive as the greatest intensity was observed in cultures
treated with both. Of particular interest, this band is the same size as would be expect for
the combined N-terminal extension, TGS-domain, and N2 editing domain (N1N2)
(Figure 38A). The TARS antibody that was used in these Western blot experiments
targets amino acids 1-98, which would fall in this region. Conversely, the antibody used
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Figure 37. BC194 and VEGF treatments influence the cellular distribution of TARS.
Immunofluorescence images of TARS (red) with DAPI nuclear stain (blue) following treatment
with DMSO vehicle control (top left), 10 nM BC194 (bottom left), 50 ng/μl VEGF (top right),
and 10 nM BC194 and 50 ng/μl VEGF (bottom right). HUVEC cell cultures were grown to near
confluency in full EGM-2 media (2% FBS) and then treated as indicated for 24 hours in 10%
EGM-2 media (0.2%). Images are shown in duplicates with and without DAPI stain for better
visualization of nuclear TARS. Areas occupied by the nucleus are outlined by dotted lines.
Images kindly provided by Hannah Naughton.
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in the immunofluorescence experiments targets the catalytic domain. Since target size is
undeterminable with immunofluorescence the exact form of TARS in the different
locations remain unknown, which makes it difficult to fully consolidate these data with
those acquired by Western blot. Nonetheless, cleavage of the TARS N-terminal domains
may be important for the enzyme’s nuclear localization and warrants further
investigation. Another similar N-terminal fragment has been previously observed in
nuclear fractions from the PC-3 prostate carcinoma cell line following treatment with 10
ng/μl TNFα (Figure 38C). Titration of the BC194 compound demonstrated a visual
increase in the appearance of a band corresponding to ~25-37 kDa within the nuclear
fraction, which is the approximate location expected for the N1N2 fragment, however,
difficulties visualizing the lamin loading control prevented accurate quantification of the
nuclear fraction. Full-length TARS was also observed in these fractions as well, but its
appearance did not correlate with treatment. A caveat of nuclear fractionation is that
components of the peri-nuclear region may also remain associated with the nucleus. As
such, it may be that some of the observed full-length TARS is an artifact of the
fractionation process.
The possible redistribution of an N-terminal TARS fragment is of particular
interest due to its interactions with the von Hippel-Lindau tumor suppressor, a master
regulator of the pro-angiogenic transcription factor 1α (HIF1α) (see Appendix I for more
information) (33). The interaction with VHL appeared to be greater with N1-TARS
relative to the full-length protein, suggesting that liberation of the N1-domain could have
downstream biological functions through modification of normal VHL function.
Specifically, the nucleo-cytoplasmic distribution of VHL is thought to contribute to the
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Figure 38. Effects of BC194, TNFα, and VEGFA on the nucleo-cytoplasmic
distribution of TARS.
(A, B) Nuclear (A) and cytoplasmic (B) fractions from HUVECs blotted for TARS and
loading controls lamin A/C (nuclear fractions) and β-tubulin (cytoplasmic fractions). Please
note the differences in molecular weights for nuclear and cytoplasmic TARS. (C) Nuclear
and cytoplasmic fractions of PC-3 prostate carcinoma cells blotted for TARS in the presence
or absence of 10 ng/μl TNFα. Full length TARS and the putative TARS truncation are
indicated. (D, E) Western blots against HA-tag (TARS), HIF1α, and β-tubulin in nuclear
and cytoplasmic lysates from HEK293 cells transfected with over-expression plasmids
encoding WT TARS (D) or L567V TARS (E) exposed to the indicated concentrations of
BC194. * indicates that the corresponding nuclear loading control (Histone 3) did not yield
an interpretable blot. Data in parts A and B were kindly provided by Hannah Naughton.
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regulation of its functions (34-36). When over-expressed in HEK293 cells, full-length
WT TARS was found to redistribute to the nucleus in a BC194 dose-dependent response
(Figure 38D). Unexpectedly, L567V TARS was also found to relocate to the nucleus
upon treatment with BC194 (Figure 38E) despite its resistance to the compound’s effects
in angiogenesis based assays (9). Possibly, this relocation may be due to a BC194activated stress response whose activation is normally involved in the nucleo-cytoplasmic
distribution of TARS or is simply an artifact associated with the over-expression system.
Interestingly, HIF1α protein levels appeared to stabilize at higher concentrations of
BC194. However, other experiments demonstrate a reduction in HIF1α levels following
BC194 treatment (see Figure 40 in Appendix I), suggesting a complex relationship
between TARS and HIF1α that warrants further investigation.
Altogether the above findings suggest that subsequent investigations related to
TARS’s nucleo-cytoplasmic distribution and intracellular fragmentation may be
beneficial for complete understanding of the ARS’s angiogenic functions. The
importance of the KKKNK sequence for angiogenic and other biological functions can be
investigated by generating mRNA for human TARS containing a deletion of this
sequence. This mRNA can then be injected into zebrafish embryos along with an antiTARS MO to see if any vascular or morphological defects occur. Furthermore, the
identity of the putative N-terminal TARS fragment found in the nuclear fractions should
be verified. This could be accomplished using affinity purification of TARS from
HUVEC cell cultures with an N-terminal biotin tag followed by SDS-PAGE separation
and mass-spectrometry identification of the resulting peptides.
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6.3 TARS secretion by exosomes
One of the most important questions that remains for the extracellularly acting
ARSs in angiogenesis, YARS, WARS, and TARS, is the mechanism through which these
proteins are secreted. The identification of these pathways will likely be critical to the
understanding the regulation of these secondary functions. For each of the three ARSs,
secretion is induced by specific signaling molecules, such as interferon γ, TNFα, or
VEGF, in cell culture experiments (9,37,38). Additionally, in all cases the cells appear to
be remain intact throughout the secretory process, indicating that secretion is not simply
the release of cellular components from dying cells. More in depth investigations of
WARS eliminated the classical golgi and Ca2+-dependent secretory pathways (39).
While this observation does not eliminate these canonical pathways as secretion
mechanisms for YARS and TARS it does indicate that other mechanisms exist that are
capable of secreting entire ARS molecules. As an alternative secretory mechanism,
TARS has been identified in exosomes, protein and RNA rich vesicles ranging in 20 to
100 nm in diameter (Figure 39) ((40,41) and David Lyden direct communication).
Exosomes form by budding into the endosomal compartment, forming multivesicular bodies and acquiring portions of the cytoplasm during the process. Fusion of the
multi-vesicular bodies with the plasma membrane releases the exosomes and their cargo
into the extracellular space. Of particular interest for TARS’s secondary function,
exosomes are associated with the establishment of the pre-metastatic niche of melanoma
to bone marrow progenitor cells (42). Similarly, TARS is associated with cancer
progression and its inhibition by borrelidin has been shown to inhibit the progression of
melanoma metastases (1,43). However, one potential caveat with the exosomal secretion
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Figure 39. Transmission electron migrographs of PC-3-derived exosomes
Electron micrographs of exosomes isolated from PC-3 conditioned media. Exosomes were
isolated using ExoQuickTM reagent.

model concerns the release of the components contained within the vesicles once outside
the cell. Interestingly, activation of P2X purinergic receptors have been shown to
stimulate the release of exosomes from dendritic cells. While not directly related to
endothelial cells, this observation reveals a connection between exosomal and purinergic
signaling events (44). More importantly, the nucleotides produced through non-canonical
catalytic functions of TARS observed in Chapter 5 can be transported out of the
exosomes more readily than the TARS protein itself, suggesting that they could mediate
TARS’s extracellular function. Nonetheless, further experimentation is required to truly
establish the role of exosomes in the secretion of angiogenesis-inducing TARS.
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6.4 Further investigation of non-canonical, catalytic functions of TARS
The identification of non-canonical, catalytic functions (ie. GTPase, ADP
formation, and Ap4A synthesis) of TARS provides an alternative mechanism through
which TARS can influence receptor-mediated angiogenic signals independent of direct
protein-protein interactions. The importance of these reactions is emphasized by the
ability of the P2Y1 specific inhibitor MRS2179 to inhibit TARS-mediated angiogenesis.
Specifically, P2Y1 responds to extracellular ADP, which is produced by all of the
angiogenic constructs tested either directly or indirectly through the breakdown of Ap4A
(45,46). Although borrelidin and BC194 did not exhibit any significant effects on these
reactions, the conformational changes associated with the binding of the compounds may
prevent interactions essential for localizing TARS near the purinergic receptors.
Previously, the binding of lysyl-tRNA synthetase to the MITF transcriptional regulator
was shown to stimulate MITF’s release from its inhibitor HINT through the local
generation of Ap4A (47). Moreover, the Ap4A production by human TARS can be
enhanced by TARS phosphorylation suggesting that these TARS secondary reactions
may serve a biological purpose (48). Despite these observations, however, the
connections between these non-canonical activities remain speculative and could benefit
from further investigations.
In order for the various nucleotide products of TARS to contribute to
angiogenesis TARS would have to be brought into close contact with the necessary
purinergic receptors. The most likely candidate receptor would be P2Y1 based on the
MRS2179 inhibition data and the connection between P2Y1 and endothelial cell
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migration (46). This putative connection between TARS and P2Y1 could be verified
through co-localization studies using immunofluorescence. Additionally, P2Y1 functions
by activating the downstream Gq signaling pathways, such as inositol 1,4,5-trisphosphate
(IP3) and diacyl glycerol (DAG). These pathways subsequently activate calcium
mobilization within the cell and protein kinase C (PKC) association with the cell
membrane (reviewed in (49)). Evidence for P2Y1 activation by TARS can be monitored
by Ca2+-responsive, UV-fluorescent dye or Western blotting of membrane fractions for
activated PKC (50,51).
In addition to establishing the connection between TARS and purinergic
receptors other investigations should focus on the reactions themselves. Based on
previous studies of other ARSs, the Ap4A reaction of TARS likely occurs within the
TARS catalytic site (52,53). The GTPase and ADP formation activities of TARS,
however, have not been previously reported and occur in absence of the essential R442
residue in the TARS aminoacylation active site. As such, these reactions could occur
within a different site of the protein, specifically the editing domain. Therefore,
characterization of these reactions would benefit from investigations of their activities in
the ΔN1N2-TARS construct. The presence of activity in this construct would suggest that
the reaction is catalyzed in the aminoacylation domain while absence, seeing as the
isolated N1-domain has already been shown to lack GTPase activity, would indicate the
editing domain. Once the proper domain has been established efforts could focus on the
generation of point mutations that inhibit these effects for subsequent testing of their
angiogenic potential through tube formation or CAM assays. Since Ap4A may also
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contribute to the generation of ADP, these mutations would have to be paired with the
R442A mutation to eliminate both ADP and Ap4A production.

6.5 TARS is associated with ovarian and prostate tumor progression
6.5.1 Angiogenesis is an essential process in tumorigenesis
The metastatic progression of many tumors is tightly coupled to their angiogenic
potential (reviewed in (54,55)). Early in the tumorigenic process the size of these tumors
is limited despite the presence of clear proliferative activities. The cause of this restriction
appears to be connected to apoptosis initiated by the hypoxic and nutrient deprived state
of the tissue. The hyperplastic nature of these tumor cells allows them to quickly grow
beyond the support of the available vasculature, limiting their access to essential nutrients
and oxygen. Eventually, however, small populations of cells within the tumor acquire the
ability to induce the growth of new capillaries within the surrounding tissue and relieve
the former constraint. This sudden increase of angiogenic potential by the tumor mass as
a whole is referred to as the “angiogenic switch”.
In addition to re-supplying the tumor tissue with nutrients and oxygen from the
blood, the angiogenic switch is also necessary for the tumor’s metastatic progression.
Newly formed blood vessels within tumor tissue are often immature and hyperpermeable,
allowing metastatic cells direct access to the blood stream (56). Furthermore, the
activation of HIF1α, a major tumor-associated inducer of angiogenesis, is known to
enhance the expression of the transcriptional repressors, such as SNAIL1, ZEB2, and
E47, which subsequently down-regulate the cellular contact proteins E-cadherin,
occludin, and claudin (57,58). Up-regulation of VEGF also disrupts pericyte coverage of
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nascent vessels through its suppression of platelet-derived growth factor (PDGF)
signaling (59). Normally, pericytes function to stabilize mature vessels through the
release of anigopoietins and PDGF. Furthermore, the activation of extracellular matrix
metalloproteinases (MMPS) facilitate the migratory nature of endothelial cells by
breaking down components of the ECM (20). Overall, these processes contribute to the
increased permeability associated with immature blood vessels in angiogenesis.
Interestingly, this same reduction in cell-cell contacts and matrix integrity that permits
new vasculature to work its way between the tissues also facilitates the epithelial to
mesenchymal transition (EMT) associated with metastatic tumors (60,61). Specifically,
the increase vessel permeability permits the invasion and dissemination of tumor cells to
distal regions of the body. Therefore, the identification of new factors involved in this
angiogenic switch would be beneficial the development of novel therapeutic techniques.

6.5.2 The intracellular levels of TARS increases with advancing stages of ovarian
and prostate cancers
The recent identification of angiogenic activity in TARS implicates the ARS as
a potential factor involved in the progression of tumor development. In support of this
hypothesis, data mined from the NIH Cancer Gene Anatomy Project (CGAP) project and
published DNA array analyses reveal that TARS is upregulated relative to other ARSs in
several types of metastatic cancer (62,63). Of particular interest, metastatic ovarian and
prostate cancers are highly angiogenic and exhibit increased expression of TARS
according to the above databases (64-66). Moreover, TARS is secreted by cells as part of
its angiogenic function, suggesting that serum levels of TARS could be developed as a
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potential diagnostic for the development and metastatic progression of ovarian and
prostate cancers.
The possibility of TARS as a diagnostic marker for prostate and ovarian cancer
have been recently investigated by the labs of Christopher Francklyn and Karen
Lounsbury respectively. In these studies the levels of TARS in patient tissue and serum
samples collected by the University of Vermont Medical Center were determined using
immunohistochemistry and ELISA procedures. The association between TARS and
ovarian cancer was recently published (9). As hypothesized, TARS staining intensity was
found to increase with advancing stages of ovarian cancer. Furthermore, this TARS
staining was found to co-localize with VEGF in tumor sites close to nascent vasculature.
However, while TARS was readily observed in all serum samples, there was no
significant differences between TARS levels in lower and high stages of the disease.
Therefore, further investigation is required if TARS is to be established as a diagnostic
marker of ovarian cancer.
Currently, diagnosis and risk assessment of prostate cancer relies heavily on the
expression of prostate serum antigen (PSA). Elevated levels of PSA in the blood
following surgical or radiation therapy, known as PSA biochemical failure, is associated
with a high risk of recurrence by the cancer and poor prognosis (67). However, the
accuracy of PSA-based diagnoses can be improved though the inclusion of other markers,
leading to the current investigations of TARS’s connection to prostate cancer. In these
studies TARS protein levels were compared to the Gleason scores of prostate cancer
samples at various stages of the disease. This Gleason score ranges from 2 to 10 and is a
measurement of a prostate tumors’s likelihood to spread as determined by tissue
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histology. Effectively, Gleason score increases as cellular morphology deviates from that
of healthy cells. Immunohistochemical staining of patient prostate samples revealed that
TARS stain intensity increased significantly as the tissue progressed from a primary
Gleason score of 3 to 4. To further investigate the use of TARS as a prognostic marker,
the Gleason scores and TARS levels were compared to the incidence of biochemical
failure in the samples. Like with TARS, increasing Gleason scores correlated with a
higher risk of PSA biochemical failure. Moreover, calculations of the ratio of the product
of TARS stain intensity and the percentage of the tumor at a particular Gleason score
over the product of the average TARS intensity and Gleason score percentage revealed a
correlation between risk of biochemical failure and elevated TARS levels in Gleason 4
and 5 tumors. Together the above data implicate TARS as a potential indicator of prostate
cancer prognostic outcome and warrants further investigation.
A possible mechanistic connection between TARS and prostate cancer was
demonstrated by Jon Ramsey when knockdown of TARS in a DU145 cancer cell line
using anti-TARS siRNA disrupted the migratory ability of these cells in a wound healing
assay. When considered with the vessel patterning defects observed with knockdown of
TARS in zebrafish (Chapter 4, section 4.2.1) these data appear to indicate a role for
TARS in cellular migration that is not limited to vascular cells. As such, the potential
roles for TARS as a diagnostic marker in prostate cancer and as a general component of
cellular migration warrant further investigation.
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6.6 Selective inhibition of the malarial parasite Plasmodium falciparum
Perhaps one of the greatest findings of this work is the mechanistic rationale
behind the attenuation of borrelidin associated toxicity responses resulting from
seemingly minor modifications to the compounds’ structures. As discussed in Chapter 3,
the difference between intracellular and extracellular threonine pools may account for the
seemingly contradictory observations that BC194 is more susceptible to threonine
competition than borrelidin but remains equally potent at inhibiting angiogenesis. A
similar mechanism may also be able to explain the high selectivity recently reported for
BC196 and BC220 towards the malarial parasite Plasmodium falciparum relative to
humans (68). The modifications associated with these derivatives likely increases their
susceptibility to threonine competition to a level that renders them ineffective at practical
concentrations for inhibiting aminoacylation in human cells. However, as part of its lifecycle the malarial parasite must infect host erythrocytes and obtain many of its amino
acids from break-down of hemoglobin (69). Interestingly, P. falciparum lacks the
traditional GCN-2 mediated amino acid starvation response and responds to nutrient
deprivation by entering a hibernatory-like state in which the organisms metabolism and
growth is significantly reduced (70). Furthermore, measurements of amino acid
concentrations in isolated samples of the related avian malarial parasite, Plasmodium
lophurae, revealed very low free levels of several amino acid species. Specifically,
threonine levels were determined to be <20 μM (71). Together, these observations
suggest that erythrocytic malarial parasites are consistently subject to low levels of free
amino acid concentrations. Therefore, the reduction in threonine competition within P.
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falciparum relative to human cells may account for the increased efficacy of BC196 and
BC220 against the malarial parasite.

6.7 Final Remarks
The findings demonstrated by this dissertation work provide clear evidence for
the role of TARS in angiogenesis both in vitro and in vivo. The ability to disrupt these
effects using TARS specific inhibitors underlies the potential use of TARS as a
therapeutic target in angiogenesis associated diseases and, recently, parasite pathogenesis.
However, like with other members of the ARS family, the efficacy of these treatments is
negatively impacted by the associated toxicity stemming from their inhibition of the
canonical aminoacylation reaction. Using a combination of biochemical, cellular, and
organismal based methods we were able to successfully separate these toxicity-related
responses from the desired effect on angiogenesis. Moreover, the application of similar
techniques may allow for the development of other ARS inhibitors previously limited by
their unintended side effects. Together, these findings unveil a novel role for TARS in
normal vascular development and provide opportunities for the selective modulation of
these effects by TARS-specific inhibitors.
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APPENDIX I: IDENTIFICATION AND CHARACTERIZATION OF
THREONYL-tRNA SYNTHETASE INTERACTION PARTNERS

A1.1 Introduction
The Q566W TARS and A538W TARS mutations demonstrate a clear
connection between borrelidin-induced conformational changes and the anti-angiogenic
effects of the compound (see Chapter 4, section 4.2.6). Structural prediction software
suggest that both mutations would shift a helix consisting of residues 492-547 into a
conformation that mimics the structure of the TARS-borrelidin complex (1). Since
neither of the TARS mutants exhibited the pro-angiogenic character of the wildtype
protein, this conformational change alone seems responsible for borrelidin’s antiangiogenic mechanism. Furthermore, Q566W TARS is still able to catalyze the canonical
aminoacylation reaction, suggesting that this conformational change is not important for
the normal function of TARS in translation. Therefore, the most likely explanation is that
borrelidin inhibits TARS-mediated angiogenesis by disrupting an interaction between
TARS and another molecule.
The modular structure of TARS consists of four major domains. Three of these,
N2, catalytic, and anticodon-binding domains, possess clear functions within the
canonical role of the protein (See Chapter 1, section 1.3.1). Furthermore, the ability of
ΔN1N2-TARS to rescue TARS inhibition (Min Guo, unpublished data) demonstrate that
TARS’s aminoacylation function requires only the catalytic and anticodon-binding
domains. In contrast, the fourth domain, known as the N1 or TGS domain, possesses an
ubiquitin-like structure and is dispensable for canonical TARS function. Likewise, the
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eukaryotic TARS N-terminal extension appears to be unstructured making it difficult to
predict its purpose. However, the association of ubiquitin-like proteins and intrinsically
disordered sequences as mediators of protein-protein interactions suggests that possibility
that these structures are important for the non-canonical functions of TARS.
Analysis of the eukaryotic TARS N-terminal 82 amino acid extension using the
Prediction of Order and Disorder by machine LEarning (POODLE) system indicates a
high probability of disorder (>50%) in amino acids 1-52 (2). The conformational
plasticity of disordered proteins provide many benefits in the formation of protein-protein
interactions. The less compact structure of these disordered regions can facilitate
interactions through an extended capture radius and increased interaction surface area
(3,4). Additionally, these regions can adopt new conformations upon complex formation
allowing for induced fit interactions with several possible binding partners (5-7).
Interestingly, around 70% of proteins involved in signaling functions are predicted to
contain unstructured regions, implicating these regions in important biological functions
(8).
Ubiquitin-like proteins (UBLs) represent a large and diverse superfamily of
proteins recognizable by their characteristic β-grasp superfold (9). Several family
members, such as the eponymous ubiquitin, SUMO, and Nedd, consist exclusively of the
ubiquitin-like fold and modify target proteins through the formation of covalent adducts.
Alternatively, other UBLs contain ubiquitin-like domains as part of their modular
structure. Despite their common fold, however, the sequence and function of UBLs can
vary greatly. These variations between UBLs alter their surface properties and
contributes to the specificity of their interactions with proteins containing ubiquitin220

binding domains (UBDs). The binding affinities between UBDs and UBLs are relatively
weak with Kd values ranging from 5-500 μM for single ubiquitin like domains but can be
augmented through the attachment of additional UBL monomers or contributions from
neighboring protein domain, allowing for both tight and transient binding events.
Furthermore, like their corresponding UBLs, UBDs consist of a broad range of sequences
and structures (10,11). Together, this great variance between ligand and binding partner
allows for the highly specific interactions critical for their wide range of cellular
functions (12). Therefore, protein-protein interactions appears to be a common
characteristic of UBLs.
The combination of a disordered region, ubiquitin-like domain, and
conformational dependent pro-angiogenic function emphasizes the importance of proteinprotein interactions in TARS’s secondary function. Unfortunately, the complexity of
angiogenesis provides a list of potential candidate interactions too numerous to
investigate individually within a reasonable amount of time. Using existing proteininteraction databases and our own affinity purification followed by mass spectrometry
experiments this list can be reduced to a manageable quantity. Based on literature
searches three candidates were elected for further investigation: the von Hippel-Lindau
tumor suppressor (VHL), eukaryotic elongation factor 1α (eEF1α), and poly (ADPribose) polymerase 1 (PARP1).

A1.2 Results
A1.2.1 Characterizing the TAR-VHL interaction
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One of the most important regulators of angiogenesis is the von Hippel Lindau
(VHL) tumor suppressor protein, a master regulator of the potent angiogenesis-inducer
hypoxia inducible factor 1α (HIF1α). HIF1α is constitutively expressed under most
conditions; however, its cellular levels are strictly controlled by the Von Hippel Lindau
E3-ligase system. During normoxia, a family of prolyl hydroxylases (PHDs) hydroxylate
prolines P402 and P564 of HIF1α (13). VHL recognizes these hydroxyl groups and
initiates the ubiquitination and eventual degradation of HIF1α. During hypoxia the
activities of the PHDs are significantly reduced, rescuing HIF1α from VHL-mediated
ubiquitination. This stabilization increases levels of HIF1α, which is transported into the
nucleus to form an active transcription factor complex with HIF1β. This complex is then
able to bind to hypoxia response elements (HRE), consequently up-regulating hypoxic
response genes related to angiogenesis, such as vascular endothelial growth factor
(VEGF), as well as genes involved in glycolysis and fermentation (14-16). This shift to
fermentative processes under aerobic conditions, classically referred to as the Warburg
effect, provides critical metabolic intermediates for macromolecule biosynthesis and
emphasizes the significance of the VHL/HIF1α pathway dysregulation in cancer
progression (17-19). Of particular interest to this work, a large scale protein-protein
interaction study has identified interactions between the VHL tumor suppressor and
TARS, suggesting that TARS’s non-canonical, angiogenic function could be related to
the regulation of VHL.
As an E3 ubiquitin ligase, VHL serves as the target recognition component for
protein complexes that catalyze the attachment of poly-ubiquitin chains to other proteins.
In the regulation of HIF1α this requires forming a complex with Rbx-1, elongin C,
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Figure 40. TARS may regulate VHL E3-ligase function.
(A) Structure of VHL (yellow) in complex with elongin C (purple) and elongin B (cyan)
(PDB: 1LQB). Inset – Superposition of TARS TGS domain (green; PDB: 1WWT) and
elongin B (cyan; PDB: 1LQB). (B) Western blot for HIF1α and TARS from cell lysates under
normoxic and hypoxic conditions at various concentrations of borrelidin or BC194. The prolyl
hydroxylase inhibitor, CoCl2, was used as a positive control for HIF1α stabilization. Data were
kindly provided by Karen Lounsbury.

elongin B, and Cullin-2 (20). Structural comparisons have revealed that one of these
partners, elongin B, shares a similar ubiquitin-like fold with the N1-domain of TARS. As
TARS has been shown to interact with VHL (21), it may be that elongin B is displaced by
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the N1 domain of TARS and the assembly of the complex is mediated through elongin C
(Figure 40A). Disruption of this interaction could then modify VHL’s ability to regulate
HIF1α and, through it angiogenesis. In support of this data from the lab of Karen
Lounsbury have shown that treatment of human embryonic kidney 293 cells (HEK293)
with 10 nM of the TARS inhibitors borrelidin or BC194 reduces the protein levels of
HIF1α under hypoxic conditions (Figure 40B), thereby establishing a connection between
TARS and VHL function. Therefore, the TARS-VHL interaction was characterized in
further detail.
Initial validation of the TARS-VHL interaction was achieved by investigating
the ability of various TARS constructs to “pull-down” VHL. Each TARS construct was
cloned into an overexpression vector containing a BirA biotinylation site and an HA
epitope and co-transfected into HEK293 cells with a plasmids encoding the biotin
transferase BirA and c-Myc-tagged VHL. The presence of BirA would catalyze the
biotinylation of the TARS construct, allowing for the protein to be affinity-purified by
streptavidin-coated beads from the cell lysates along with anything currently interacting
with it. Interactions are then identified by Western blot. To account for possible nonspecific binding to the streptavidin beads, the ability of VHL to recapitulate the TARS
pull-down experiments was also performed pulling VHL out of solution with anti-c-Myc
sepharose-conjugated beads and observing interaction partners by Western blot. Both
full length TARS (Figure 41A) and the isolated N1-domain (Figure 41B) were found to
co-immunoprecipitate with VHL, affirming the TARS-VHL interaction and supporting
the N1-domain as the specific action site. Interestingly, the bands for N1-TARS were
noticeably more intense than those for the full-length protein, suggesting that the isolated
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Figure 41. TARS interacts with VHL through its N1-domain.
(A, B) Western blots of TARS and VHL following affinity purification (AP: Biotin) of Full
length TARS (A) or N1-TARS (B) and VHL immunoprecipitation (IP: Myc).
Immunoprecipition with IgG-coated beads was used as a control for VHL immunoprecipitation
to demonstrate the specificity of the binding. (C) Western blots of TARS affinity-purified
lysates treated with various concentrations of BC194 (0.01 to 1000 nM) for full-length TARS
(IB: HA) and VHL (IB: Myc). Data in (C) were kindly provided by Joann Russo and Jason
Botten.

N1-domain forms stronger interactions with VHL. However, it may also be that the
smaller size of the N1-domain allows for its increased expression or reduces steric
hindrance with other molecules during the pull-down process and warrants further
investigation. While these data would support the hypothesis that TARS binds to VHL
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through elongin C by displacing elongin B, additional information is required to confirm
this interaction.
Borrelidin and its derivative BC194 have been previously shown to inhibit
TARS-mediated angiogenesis. Therefore, if the TARS-VHL interaction was important
for TARS’s non-canonical role in angiogenesis, borrelidin’s anti-angiogenic properties
may occur by disrupting this interaction. Since the borrelidin-binding site is located
within the TARS catalytic domain, only the full-length TARS construct was investigated
(Figure 41C). The addition of 0.01 nM, 10 nM, 100 nM, and 1000 nM of BC194 had no
effect on the ability of TARS to pull-down VHL, suggesting that the interaction is not
susceptible to inhibition by borrelidin and related compounds.
Owing to its association with tumor angiogenesis and anaerobic metabolism,
VHL is considered a tumor suppressor protein. The inhibition of alteration of normal
VHL function through point mutations in the protein have been associated with the onset
of several tumor types. Several of these mutations are located along the VHL-elongin C
interface. Therefore, it may be possible that these mutations could disrupt normal VHL
function by destabilizing its interaction with elongin C. Since elongin B binds through
elongin C it seems likely that these mutations would also disrupt the TARS-VHL
interaction if it truly binds by displacing elongin B. To test this hypothesis, three
mutations were introduced into VHL, R167A, R167W, and C162A, corresponding to the
two most-common pathogenic mutations at the VHL-elongin C interface, and
subsequently investigated for their ability to disrupt interactions between full-length
TARS (Figure 42A) and N1-TARS (Figure 42B) (22). The C162A mutation appeared to
disrupt the interactions between VHL and both the full-length TARS and N1-domain.
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Additionally, R167W also was found to inhibit the N1-domain interaction with VHL
(Likely R167W would have inhibited the VHL interaction with full-length TARS as well,
but due to a sample processing error these data were not obtained). Together, these data
support the hypothesis that TARS interacts with VHL through elongin C by displacing
elongin B with its N1-domain. However, it should be noted that these experiments were
only performed once and should be repeated for confirmation. Furthermore, a stronger
band was anticipated for the N1-TARS-WT VHL interaction than was received (see
Figure 41B), suggesting that an error may have occurred in the isolation of this sample.

Figure 42. TARS interacts with VHL by displacing elongin B.
(A, B) Western blots of TARS (IB:HA) and VHL (IB: Myc) following affinity purification
(AP: Biotin) of Full length TARS (A) or N1-TARS (B). Where indicated the wildtype myctagged VHL plasmid was substituted with plasmids encoding myc-tagged R167A, R167W,
or C162A VHL constructs.
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As an alternative method to demonstrate that TARS binds to VHL by displacing
elongin B, previous reports indicate that peptides mimicking the elongin C component of
the elongin C-VHL interface could disrupt both elongin B and C interactions with VHL.
Single amino acid alanine substitutions in the peptide, notably L158, were able to block
the effect of this compound, which indicates the importance of these residues for this
interaction (23). Unfortunately, this study was not discovered until after the above
experiments were performed and suggests that future repetitions of these experiments
could be improved using a L158A peptide.

A1.2.2 Identifying the TARS interactome through mass-spectrometry
Since the interaction between VHL and TARS appeared to be unaffected by
borrelidin, the ability of TARS to interact with other proteins partners was investigated
using mass spectrometry. Specific emphasis was placed on any interaction with ties to
angiogenesis or VHL function and were subsequently investigated by Western blot to
determine the effects of borrelidin. For these experiments HEK293 cell lysates overexpressing HA- and biotin-tagged TARS alone (condition 1) or with myc-tagged VHL
(condition 2) were affinity purified using streptavidin coated beads. Unbound proteins
were removed through successive washing and the prey proteins identified through mass
spec analysis of SDS-PAGE resolved bands. Non-specific interactions were determined
using an empty vector control and removed from subsequent analyses. High confidence
was given to any interaction with a cross-correlation value (XC) greater than 20.00.
Observed interactions are shown in Table 13.
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Table 13. Interactions for affinity purified TARS identified by mass spectrometry
Name
TARS
TARSL2
EPRS
RPS15A
RPS20; SNORD54
RPS3A; SNORD73A
eEF1A1
MARS
LARS
eEF1G
TARS2

XC
218.32
38.28
30.19
10.22
10.18
10.18
10.16
10.15
10.14
10.11
8.13

Name

XC

Sim. E2D2-2
Med8
VHL-1
VHL-3

10.13
10.10
10.10
10.10

Name

XC

SLC25A5

20.22

GAPDH

10.16

ENO1
ENO2
ENO3
HSPD1

10.15
10.15
10.15
10.15

Translation Related
Peptides Condition
Function
36
1,2
Threonyl-tRNA Synthetase (cytoplasmic)
4
1,2
Likely TARS isoform
4
2
Bifunctional aminoacyl-tRNA synthetase
1
2
40S Ribosomal protein
1
1,2
40S Ribosomal protein
1
1
40S ribosomal protein S3a
2,1
1,2
Elongation factor 1-alpha 1
1
2
Methionyl-tRNA Synthetase (cytoplasmic)
1
1
Leucyl-tRNA Synthetase (cytoplasmic)
1
1
Elongation factor 1-gamma
1
1,2
Mito TARS
Protein Degradation
# of
Condition
Function
Ions
1
2
Similar to Ubq-conjugating enzyme E2D 2
1
1
E3-ligase- Elongin B,C, cullin, rbx based
1
1
24kDa
1
1
18kDa
Mitochondrial/metabolism
# of
Condition
Function
Ions
3
2
ADP/ATP Translocase 2
Glyceraldehyde-3-phosphate
1
1
dehydrogenase
1
1
Alpha-enolase
1
1
Gamma-enolase
1
1
Beta-enolase
1
2
Mito Heat shock protein
Nuclear-cytoplasmic trafficking
# of
Condition
Function
Ions
1
1,2
Elongation factor 1-alpha 1
1
2
Nuclear pore protein

Name

XC

eEF1A1
NUP107

10.16
10.15

Name
PARP1
Isoform 3 Myosin 1C
HNRNPC
POTEE
CALD1

XC
30.16
20.18
20.18
20.14
10.18

Peptides
4
2
2
2
1

Condition
1
1
1
1
1

DHx30-1

10.17

1

1
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Function
Poly [ADP-ribose] polymerase 1
Myosin-Ic
Heterogeneous nuclear RNPs C1/C2
POTE ankyrin domain family member E
Caldesmon
Putative ATP-dependent RNA helicase
DHX30

1

DHx30-2

10.17

1

1

DHx30-3

10.17

1

1

HNRNPU
RUVBL1
NEFM
PRPH
ILF2
HSP90AB3P
CLTB
TDRD6
ALMS1

10.14
10.14
10.13
10.13
10.11
8.16
8.15
8.13
8.11

1
1
1
1
1
1
1
1
1

1
1
1
1
1
1
1
1
1

Putative ATP-dependent RNA helicase
DHX30
Putative ATP-dependent RNA helicase
DHX30
Heterogeneous nuclear ribonucleoprotein U
RuvB Like
Neurofilament medium polypeptide
Peripherin
Interleukin enhancer-binding factor 2
Putative heat shock protein HSP 90-beta-3
Clathrin light chain B
Tudor domain-containing protein 6
Alstrom syndrome protein 1

Condition 1 - Over-expressed TARS; Condition 2 - Over-expressed TARS and VHL

Several notable interactions were identified in these experiments including many
related to metabolism, protein translation, and nuclear-cytoplasmic trafficking. Although
XC values indicated low confidence, the results once again confirmed the previously
identified interactions with VHL. Furthermore, several members of the multi-synthetase
complex were observed even though TARS itself is not recognized as a component of the
complex (24). Specifically, high confidence was observed for its interaction with the
glutamyl/prolyl-tRNA synthetase (EPRS) and less confidently with leucyl-tRNA
synthetase (LARS) and methionyl-tRNA synthetase (MARS). Interestingly, both EPRS
and LARS are reported to be key components of various survival responses through
GAIT and mTOR mediated responses respectively (25,26). The significance of these
interactions is not yet apparent, but may indicate a higher degree of cross-talk between
the translational machinery than previously known. Finally, two other interactions were
also of interest: poly(ADP-ribose)polymerase1 (PARP1) and eukaryotic elongation factor
1α1 (eEF1A1).

A1.2.3 Characterizing TARS’s interaction with PARP1
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Canonically, PARP1 is viewed as a member of the DNA-damage response in eukaryotic
cells. In response to genotoxic stress PARP1 will homodimerize and catalyze the
attachment of ADP-ribose polymers to itself (27,28). The presence of this modification
recruits other factors to the damaged site to initiate the necessary repair events (29,30).
However, over the last decade the functions of PARP1 have expanded beyond DNA
repair and stability including inflammation and angiogenesis. Over ADP-ribosylation by
PARP1 can lead death associated pathways due to the depletion of ATP from the
synthesis of NAD+ (31,32). Alternatively, direct modification of inflammatory genes can
lead to their activation, such as NF-κB (33,34). While the connection between
inflammation and angiogenesis has been well established PARP1 also appears to have a
more direct connection as well. Treatment with several PARP1 inhibitors was found to
decrease angiogenesis as determined by in vitro HUVEC tube-formation and aortic ring
branching assays as well as in vivo rat matrigel plug assays (35,36). Specifically, these
inhibitors disrupted endothelial cell migration, similar to the effects observed with TARS
inhibition. Furthermore, PARP1 has been demonstrated to form protein-protein
interactions with the potent angiogenic factor HIF1α and synergistically up-regulates
genes under its control (37). The importance of this connection to TARS’s secondary
function is only made greater by the interaction with the master regulator of HIF1α,
VHL, established above. Finally, PARP1 has been associated with the non-canonical
functions of another ARS, WARS, with known angiostatic properties. PARP1 and
WARS have been shown to form a nuclear protein complex with DNA-dependent protein
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Figure 43. TARS interacts with poly(ADP-ribose) polymerase 1 (PARP1).
(A,B) Plasmids encoding HA-tagged TARS with BirA biotinylation site and BirA were
transfected into HEK cells. After 48 hours, TARS was “pulled-down” with streptavidincoated beads. (A) Western blots of TARS affinity-purified lysates analyzed using
antibodies against PARP1 (IB: PARP1) and β-tubulin (IB: Tubulin) at various
concentrations of BC194 (1-1000 nM). (B) Quantification of PARP1 relative to β-tubulin
by densitometric analysis; n=1. Without repetitions, no meaningful analysis of statistics
can be performed.

kinase following stimulation by interferon γ (IFNγ) (38). Not only does this observation
reveal a role of PARP1 in ARS secondary function but IFNγ itself is also known to
regulate the expression of WARS and other angiostatic signals, implicating a role of this
pathway in the regulation of angiogenesis as well (39). Together, these findings
emphasize PARP1 as a strong candidate to mediate the angiogenic functions of TARS.
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The TARS-PARP1 interaction identified by mass-spectrometry was subsequently
confirmed by Western blot of affinity-purified TARS lysate samples (Figure 43A).
Treatment with BC194 appeared to disrupt this interaction at concentrations of 10 nM
and 100 nM, maintaining only 73% and 3% of the interaction exhibited uninhibited
condition respectively. Interestingly, the disruption of this interaction was not observed at
higher concentrations of BC194 since the interaction returned to 61% relative to the
uninhibited conditions in lysates treated with 1000 nM. It should be noted, however, that
these data have not been repeated (Figure 43B). Additionally, the input samples,
representing the original PARP1 present in the lysate before TARS affinity-purification,
appear to vary with BC194-treatment concentrations as well. While these signals are
clearly saturated, as demonstrated by the empty space in the middle of each band, and
may not be completely accurate, it could be that the apparent reduction in TARS-PARP1
interaction is due to a reduction in PARP1 levels rather than a disruption of proteinprotein interactions. Therefore, repetitions are required to validate this result.

A1.2.4 Characterizing TARS’s interaction with eEF1A1
The protein eEF1A became a target of interest for several reasons: 1) a truncated
version of eEF1A is referred to as prostate tumor inducer (PTI) for its relation to
cancer (40); 2) eEF1A is known to interact with ubiquitin (41); 3) eEF1A1 is known
to assist in the nuclear export of VHL (42); and 4) a population of eEF1A has been
found to function as an extracellular membrane receptor (a component that is
currently lacking from the extracellular TARS-mediated angiogenesis model) (43).
All of these functions can be connected in some way to angiogenesis and, therefore,
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Figure 44. TARS interacts with eukaryotic elongation factor 1α1 (eEF1A1).
(A) Plasmids encoding HA-tagged TARS with BirA biotinylation site and BirA were
transfected into HEK cells. After 48 hours, TARS was “pulled-down” with
streptavidin-coated beads. The presence of eEF1A1 was determined by western blot of
TARS affinity-purified lysates using antibodies against eEF1A1 (IB: eEF1A1) and βtubulin (IB: Tubulin) at various concentrations of BC194 (1-1000 nM). (B) GTPase
activity of eEF1A1 (blue), TARS (red), or combined eEF1A1 and TARS (green) as
determined by formation of GDP per pmol of enzyme per minute. Human TARS or
eEF1A1 (2 μM) was incubated with [α-32P]-GTP and quenched at various time points.
Reaction products were resolved via thin-layer chromatography, and the formation of
GDP over time was quantified by phosphorimaging; mean ± SD, n≥3.

could be putatively modified through interactions with TARS. Before investigating
any of these individual effects the interaction between eEF1A1 and TARS was
verified by TARS affinity purification and Western blot methods similar to VHL
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except that a plasmid encoding for a C-terminally myc-tagged eEF1A1 constructs
was used in place of VHL. The samples appeared to confirm the TARS-eEF1A1
interaction indicated by the mass spectrometry data (Figure 44A). Exposure of these
lysates to BC194, however, had no effect over all at the concentrations investigated.
As the highest concentration, 1 μM, is well above the 4.09 nM predicted Kiapp there
should be plenty of compound available to inhibit this interaction if it were capable.
Like with the PARP1 observations, more repetitions are necessary to confirm these
results. However, effects of BC194 have been investigated at least one other time at a
concentration of 1 μM (data not shown) without any effect, suggesting BC194 does
not inhibit the eEF1A1’s interaction with TARS.
While BC194 treatment did not seem to affect the TARS-eEF1A1 interaction,
the possibility that TARS could influence the GTPase activity of the enzyme was also
investigated. Canonically, eEF1A functions to transport charged-tRNA to the ribosome
and regulates this transport using guanine nucleotide cycling (44). This GTPase activity
has also been proposed to be involved in eEF1A non-canonical activities (40,42). In
support of this mechanism, a recent report demonstrated that leucyl-tRNA synthetase
(LARS) stimulates the GTPase activity of the mTOR regulator, RagD, in response to
changes in amino acid concentrations (45). Furthermore, as established in Chapter 5,
TARS itself possesses a cryptic GTPase activity of unknown function. Therefore, we
investigated if TARS influences the guanine nucleotide cycling of eEF1A (Figure 44B).
Individually, both TARS and eEF1A1 were found to exhibit slow GTPase activity.
However, when the proteins were combined the rates were only additive, indicating that
no enhancement to eEF1A1’s GTPase activity was observed.
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Table 14. eEF1A1 and TARS GTPase activity
Condition
eEF1A1
TARS
Both

Activity (min-1)
0.1132 ± 0.02033
0.04745 ± 0.002536
0.1771 ± 0.01632

A1.3 Discussion
A1.3.1 Possible contributions of the TARS-VHL interaction to the regulation of
angiogenesis.
The connection between conformational changes in TARS and the inhibition of
angiogenesis strongly supports the role of protein-protein interactions in TARSmediated angiogenesis. Using affinity-purification and mass spectrometry several
cellular binding partners for TARS have been identified. Based on literature searches
indicating potential connections to angiogenesis three of these interactions have been
chosen for further investigation, including the E3 ligase VHL, eEF1A1, and PARP1.
The interaction between TARS and VHL opens up several opportunities through which
TARS could regulate angiogenesis. The regulation of the VHL/HIF1α pathway is notably
complicated and includes post-translational modification and transportation based
mechanisms, some of which could possibly be influenced through interactions with
TARS (15,46,47). The presence of cellular localization signals in TARS has not been
fully studied, however, some immunofluorescence and Western blot data provide some
evidence of TARS peri-nuclear and nuclear localization (See Chapter 6, section 6.2.2).
As such, complex formation with TARS may provide VHL with a sub-cellular
localization signal that leads to its sequestration from HIF1α and allows for angiogenesis
to occur. Alternatively, TARS’s interaction with VHL may alter the formation of the
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canonical VHL E3-ligase complex by disrupting the binding of elongin B, a hypothesis
supported by the disruption of TARS-VHL interaction through the introduction of
mutations along the VHL-elongin C interface shown above. The resulting loss of VHL
E3-ligase function would then, in turn, stimulate angiogenesis through HIF-mediated
upregulation of VEGFA expression. Therefore, future experiments investigating the
effects of TARS on HIFα stabilization and VHL E3-ligase activity would be beneficial.
The inability of BC194 to disrupt the interaction between TARS and VHL is not
surprising. The interaction appears to be mediated by the N1-domain, which is located
two domains away from the borrelidin binding site in the TARS catalytic domain.
Therefore, it seems unlikely that any conformational change induced by borrelidin would
be propagated to the N1-domain interaction interface. Alternatively, if TARS was
essential for bridging VHL with another protein essential in the regulation of
angiogenesis, borrelidin might be able to elicit an anti-angiogenic response through
disruption of this second TARS interaction. The loss of angiogenic potential by the
Q566W TARS, borrelidin-binding mimetic (Chapter 4, Section 4.2.6) already supports
the role of borrelidin-induced conformational changes as the mechanism of the
compound’s anti-angiogenic properties. However, no interaction has been identified that
is disrupted by this structural change.

A1.3.2 Possible contributions of the TARS-eEF1α and TARS-PARP1 interactions.
The identification of interactions with eEF1A1 and PARP1 appeared interesting owing to
a variety of different reports tying these proteins to angiogenesis. Although the
experiments need to be repeated, preliminary investigations suggest that the PARP1237

TARS interaction might be susceptible to disruption by borrelidin treatment. However,
the dose-responsive nature of this effect is complicated by prominent re-establishment of
an interaction from 100 nM to 1000 nM BC194. One possible explanation for this
observation is that 1000 nM is the lowest concentration observed to induce amino acid
starvation with BC194 (Chapter 3, section 3.2.1). Therefore, it may be possible that
amino acid starvation initiates an effect that overrides BC194’s inhibition of this
interaction. Conversely, while Western blot analyses appear to confirm the TARSeEF1A1 interaction identified in mass-spectrometry experiments, there is no clear
connection between TARS-angiogenesis and complex formation with eEF1A1.
Additionally, BC194 treatment showed no effect on eEF1A1 GTPase activity as well.
However, the recent development of a negative-control database for experiments that
couple affinity purification with mass spectrometry, referred to as the contaminant
repository for affinity purification-mass spectrometry data (CRAPome), suggests that the
promiscuity and abundance of both eEF1A1 and PARP1 leads to their frequent
appearance as non-specific interactions in whole interactome studies (48). Therefore,
subsequent investigations of these interactions may be valuable, but should be undertaken
with caution.

A1.4 Experimental Procedures
A1.4.1 Affinity and Immunoprecipitation Procedures
Culture dishes were seeded with 2x106 human embryonic kidney cells (HEK293) and
maintained in DMEM (Mediatech) supplemented with 10% fetal bovine serum (Gibco,
Carlsbad, CA), penicillin/streptomycin (Gibco), and L-glutamine (Gibco) at 37°C and 5%
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CO2 in a humidified incubator. Cells were transfected by polyethylenimine (0.05 mg/ml
per μg DNA) with plasmids (3 μg each) encoding a TARS construct with C-terminal HA
tag and BirA biotinylation site an C-terminally myc-tagged VHL or eEF1A1 as required.
Additionally, a BirA plasmid was included in all experiments using the TARS construct
to ensure biotinylation of the protein. Control experiments substituted an empty vector
plasmid for the TARS construct. Following a 48 hour incubation, cells were lysed with
1% Triton X, 0.5% NP-40, 140 mM NaCl, 25 mM Tris-HCl pH 7.6, and 1 Complete
Mini protease inhibitor tablet (Roche) per 10 ml and the entire lysate mixed with 100 μl
(1 mg) of streptavidin-coated magnetic beads (Invitrogen, Dynabeads MyOne
Streptavidin) or 60-70 μl of EZviewTM Red Anti-c-Myc Affinity Gel (Sigma-Aldrich) to
pull down TARS or VHL and eEF1A1 respectively. As a non-specific control for anti-cMyc experiments, separate lysates were treated with 60-70 μl of rabbit IgG-coated
agarose beads (Sigma-Aldrich). Unbound proteins were washed away with three
exchanges of lysis buffer. The bound proteins were eluted from the beads through boiling
and resolved on a reducing, SDS-PAGE gel for use in Western blotting or mass
spectrometry experiments.

A1.4.2 Mass spectrometry analysis of affinity purified TARS from cell lysate
Major bands from SDS-resolved TARS affinity purified samples and the empty vector
controls were detected using SilverSNAP Stain Kit II (Pierce) and excised. Fragments
were trypically digested using the in gel procedure for ProteaseMAX Surfactant
(Promega) according to the manufacturers specifications. Briefly, free cysteines were
alkylated by incubation with 55 mM iodoacetamide:50 mM NH4HCO3 followed by
239

trypsin digestion (2 ng/µl) in 0.01% ProteaseMAX surfactant:50 mM NH4HCO3.
Peptides were analyzed by electospray ionization (ESI) liquid chromatography mass
spectrometry (LC-MS). Samples were resolved over a fused-silica microcapillary
MagicC18 LC column (12cm x100 µm i.d.) using a 5-50% acetonitrile gradient in 0.1%
formic acid. Spectra were obtained using collision-induced dissociation with an LTQ
linear quadrupole ion trap-Orbitrap mass spectrometer (Thermo Electro, San Jose, CA)
and analyzed using SEQUEST (Bioworks software package, version 3.3.1; Thermo
Electron, San Jose, CA). Acquired TARS data were compared to empty vector
equivalents in order to identify non-specific interactions.
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